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Abstract 
Dissertation Advisor: Professor J. Wade Harper            Shireen Akhavan Sarraf 
 
 
Abstract 
 
 
Defining the landscape of the PARKIN- and PINK1-dependent ubiquitin-modified 
proteome in response to mitochondrial dysfunction 
 
 
Parkinson’s disease (PD) is a progressive neurological disorder resulting from loss of 
dopaminergic neurons of the substantia nigra, in part due to mitochondrial dysfunction. The E3 
ubiquitin ligase, PARKIN, and mitochondrial kinase, PINK1, found mutated in familial early onset 
recessive forms of PD play central roles in mitochondrial homeostasis, thus maintaining control 
of a diversity of cellular processes, including energy metabolism, calcium buffering, and cell 
death. Together, PARKIN and PINK1 control mitochondrial homeostasis via a signaling cascade 
in which depolarization-induced PINK1 stabilization and activation on the mitochondrial outer 
membrane (MOM) promotes recruitment of PARKIN. Consequently, the outer mitochondrial 
membrane is extensively decorated with ubiquitin, ultimately resulting in removal of the 
damaged organelles via mitophagy, the selective autophagic removal of mitochondria. While 
PARKIN has been demonstrated to ubiquitylate Porin, Mitofusin, and Miro proteins on the MOM, 
the full repertoire of PARKIN substrates – the PARKIN-dependent ubiquitylome – remains 
poorly defined. Here, large-scale quantitative diGlycine (diGly) capture proteomics was used to 
identify PARKIN-dependent ubiquitylation on lysine residues in proteins modified upon 
mitochondrial depolarization. Hundreds of ubiquitylation sites in dozens of proteins were 
identified, with strong enrichment for MOM proteins, indicating that PARKIN activity has the 
capacity to dramatically alter the ubiquitylation status of the mitochondrial proteome. 
Complementary interaction proteomics identified physical association of PARKIN with a cohort 
of MOM ubiquitylation targets, autophagy receptors, and the proteasome, interactions which 
were completely dependent upon mitochondrial damage and drastically reduced upon mutation 
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of the active site residue, C431, found mutated in PD patients. Furthermore, structural and 
evolutionary analysis of PARKIN-dependent ubiquitylation events revealed extensive 
conservation of target sites on cytoplasmic domains in vertebrate and D. melanogaster MOM 
proteins. Parallel PINK1 interaction proteomics identified numerous subunits of the translocase 
of the outer mitochondrial membrane (TOMM) and a novel interactor, CLU1, shown to regulate 
mitochondrial morphology in lower eukaryotes. Positive genetic interaction between CLU1, 
PINK1, and PARKIN suggests the potential of a newly identified node of regulation for the 
PINK1/PARKIN pathway. These studies define how PARKIN and PINK1 re-sculpt the proteome 
to support mitochondrial homeostasis, ultimately contributing toward an improved understanding 
of their role in the progression of disease.  
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CHAPTER 1 
Introduction 
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1.1 Parkinson’s Disease 
In 1871, James Parkinson published his account of “the shaking palsy,” a description of 
the disease which was eventually named for him (Parkinson, 2002). Nearly 200 years later, it 
was estimated that the number of people over the age of 50 afflicted with Parkinson’s disease 
(PD) in the world’s 10 most populous nations was between 4.1 and 4.6 million in 2005 and will 
double to between 8.7 and 9.3 million by 2030 as worldwide life expectancy and population 
increase (Dorsey et al., 2007). Second only to Alzheimer’s disease, Parkinson’s is the most 
common  neurodegenerative disorder whose social and economic burden on individuals and 
societies is increasing; the current estimate of prevalence in the US alone is 1.5 million cases 
(Hirtz et al., 2007; Thomas and Beal, 2007). Though recognized so many years ago, the causes 
of Parkinson’s disease are still largely unknown though a number of genetic and environmental 
risk factors have been identified. Understanding of the etiology of PD has been advanced over 
the last two decades through the identification of several gene mutations which have provided 
insight into the molecular pathways of the disease. 
1.2 Etiology of Parkinson’s disease 
Parkinson’s disease is a neurodegenerative disorder diagnosed clinically by the 
presence of motor symptoms including bradykinesia, hyperkinesia, rigidity, resting tremor, and 
postural instability; however, non-motoric symptoms can also occur, including autonomic, 
cognitive, and psychiatric difficulties. These motor deficiencies are attributed to the progressive 
and ultimately severe impairment or loss of dopaminergic neurons of the substantia nigra pars 
compacta (SNpc) (Thomas and Beal, 2007) (Figure 1.1a). When functioning normally, DA 
neurons produce the neurotransmitter, dopamine (DA), which is transmitted between the 
substantia nigra and the corpus striatum to coordinate smooth controlled muscle movement. 
Correspondingly, decreased levels of DA result in ineffective signaling, abnormal nerve 
functioning, and loss of the ability to properly regulate movement (Schwartz and Sabetay, 2012)  
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Figure 1.1 Overview of Parkinson’s disease. (PD). a, Left: Location of the substantia nigra in 
a horizontal cross section of the brain. Right: Difference between healthy and PD-affected 
substantia nigra. b, Dopamine levels are decreased in PD resulting in decreased signaling 
and movement disorders (adapted from http://www.science.ca/scientists). c, Normal 
substantia nigra (top panel), PD-affected substantia nigra, note extensive loss of pigmented 
neurons (middle panel), high magnification of PD neuron containing Lewy body (arrow) 
(bottom panel) (adapted from http://missinglink.ucsf.edu/lm/ids_104_neurodegenerative.htm). 
d, Risk factors for PD include environmental, genetic, and endogenous influences which can 
trigger oxidative modifications, mitochondrial dysfunction, and impaired protein degradation 
which together contribute to DA neuron cell death and the progression of neurodegeneration. 
(Figure 1.1b). It is estimated that at the onset of symptoms nearly 60% of SNpc DA neurons 
have already been lost and dopamine levels may be depleted by 80%. Though excessive loss 
of DA neurons does occur, the neurodegeneration extends to noradrenergic, serotonergic, and 
cholinergic systems as well as the cerebral cortex though it is unclear when this occurs relative 
to DA neuron injury or death, but is thought to occur in later stages of disease (Dauer and 
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Przedborski, 2003). Possibly a causal factor in the loss of DA neurons is a main pathological 
hallmark of idiopathic Parkinson’s – the presence of α-synuclein-immunoreactive inclusions in 
neuronal perikarya (Lewy bodies) and processes (Lewy neurites) (Figure 1.1c). These deposits 
are composed of insoluble aggregates of alpha-synuclein in association with other proteins, 
including ubiquitin, and are believed to represent an aggresome response which may ultimately 
be lethal to the cell (Kalia et al., 2012).  
Though there is no apparent genetic linkage in nearly 95% of cases of Parkinson’s 
disease, the cause(s) of idiopathic disease, the most common form of the illness, remain 
essentially unidentified. It is generally thought that a number of environmental factors may 
potentially contribute to the disease, particularly when genetic susceptibility may be present 
(Figure 1.1d). The environmental hypothesis proposes that PD-related neurodegeneration 
results from exposure to a dopaminergic toxin.  A clue into the pathogenesis of the disease 
emerged when the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), was 
discovered to cause a parkinsonian syndrome in intravenous drug users upon exposure to 
contaminated drug preparations (Langston et al., 1983). Follow-up studies in animals have 
shown that exposure to MPTP, a mitochondrial Complex I inhibitor, induces dopaminergic 
neurodegeneration and parkinsonism (Cannon and Greenamyre, 2011; Malkus et al., 2009). 
Similarly, rotenone and paraquat, also inhibitors of Complex I, are commonly used to model PD 
in animals. However, whether any specific toxin is truly a cause of sporadic PD is yet unproven. 
Another proposed initiator of the disease is an endogenous toxin, potentially produced by 
disturbances in the balance of normal metabolism, which then generates damaging reactive 
oxygen species (ROS) thus harming cells. Though the contribution of this premise is 
unconfirmed, polymorphisms in the xenobiotic detoxifying enzyme cytochrome P450 have been 
linked to greater risk of developing early-onset PD (Dauer and Przedborski, 2003; Sandy et al., 
1996). Despite the uncertainty associated with these hypotheses, much edifying and productive 
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research based on these studies has focused on oxidative stress, mitochondrial respiration 
defects, and aberrant protein aggregation in DA neurons (Figure 1.1d). 
1.3 Pathogenesis of Parkinson’s disease  
Though the initial causes are yet unknown, studies based on the models proposed lend 
support to two major hypotheses which may contribute to PD-associated neurodegeneration. 
First, protein misfolding and aggregation are toxic to SNpc DA neurons and second, that 
mitochondrial dysfunction causes oxidative stress, which ultimately results in cell death (Dauer 
and Przedborski, 2003) (Figure 1.1d). Clearly, these hypotheses are not mutually exclusive and 
it is quite likely that aspects of each play roles in SNpc neuron death and development of PD. 
Discovery of the overlap between these hypotheses may be the key to understanding the 
initiation and progression of the disease. For example, it has been shown that oxidative damage 
can encourage misfolding and aggregation of alpha-synuclein (Giasson et al., 2000).  
1.3.1 Misfolded proteins and aggregates 
The presence of abnormally folded proteins in brain tissue, a characteristic of a number 
of neurodegenerative diseases, though the proteins involved and the location of deposits differ, 
suggests that this common attribute may be toxic to neuronal cells. The avenues through which 
misfolded proteins may harm cells are numerous, including direct damage by distortion of 
cellular structures or interference with intracellular processes. Aggregates could also trap and 
sequester vital proteins, preventing them from carrying out crucial functions. Though logical, 
evidence shows that there is little correlation between protein inclusions and cell death 
(Cummings et al., 1999; Saudou et al., 1998). In fact, it now seems more likely that inclusions 
may be produced as a result of active sequestration of soluble misfolded proteins, created to 
keep toxic soluble misfolded proteins at bay, and thus they may not actually be a causal factor 
in disease (Cummings et al., 1999; Dauer and Przedborski, 2003). 
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Little progress was made into illuminating the molecular underpinnings of PD until efforts 
in recent years uncovered parallels between sporadic and genetic Parkinson’s. In patients with 
inherited PD, pathogenic mutations are thought to directly affect the folding of mutated proteins, 
thereby interfering with their normal functions. Furthermore, identification of single gene 
mutations in proteins involved in the ubiquitin proteasome system (UPS) has focused attention 
on the role of protein degradation, quality control, and homeostasis in the development of PD, 
thus linking the UPS to the production of misfolded proteins and development of inclusions. 
1.3.2 Ubiquitin system and 26S proteasome in neurodegeneration 
Ubiquitin conjugation is well-known for its prominent role in targeting cellular proteins to 
the 26S proteasome for degradation, allowing precise control over a variety of functions, 
including gene regulation, cell cycle progression, signaling pathways, endocytosis, and 
homeostatic turnover of proteins (Hershko and Ciechanover, 1998; Pickart and Eddins, 2004). 
The conjugation of ubiquitin to a substrate lysine requires an ATP-dependent enzymatic 
cascade carried out by E1 (ubiquitin activating), E2 (ubiquitin conjugating) and E3 (ubiquitin 
ligating) enzymes (Ciechanover et al., 1982; Hershko and Ciechanover, 1998; Hershko et al., 
1983; Pickart and Eddins, 2004) (Figure 1.2). Conjugation of ubiquitin can have a variety of 
downstream consequences, depending on the type of ubiquitin chain linkage formed, including 
endocytosis, signaling, autophagy, and proteasomal degradation.  
The 26S proteasome is a 2.4 MDa complex composed of two multisubunit 
subcomplexes: the 20S proteasome, which is the core protease, and the 19S regulatory 
particle, which can cap the 20S subunit at either end. As its name suggests, the 19S regulatory 
particle is responsible for regulating the activity of the proteasome by controlling access to the 
catalytic core. Additionally, the 19S controls recognition, deubiquitylation, and unfolding of 
substrates fated for degradation. ATP-dependent interaction of the hexameric ring-shaped  
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Figure 1.2 Ubiquitin Proteasome System. Ubiquitin conjugation occurs through an ATP-
dependent enzyme cascade (see text). Conjugation can target cellular proteins to the 26S 
proteasome for degradation or function in non-proteolytic pathways depending on the type of 
ubiquitin chain linkage.  
“base” subunit of the 19S with the 20S causes channel opening  and allows substrate access to 
the catalytic core (Finley et al., 2012; Smith et al., 2006). Proteasome-mediated degradation is a 
well-defined mechanism in which the 19S ubiquitin-binding subunits capture polyubiquitylated 
substrates leading to subsequent removal of ubiquitin chains by the proteasome‐associated 
deubiquitylating enzymes and finally unfolding and feeding of the substrate into the 20S core by 
the AAA-ATPase subunits of the 19S base (Demartino and Gillette, 2007; Finley, 2009; Pickart 
and Cohen, 2004; Tanaka and Tsurumi, 1997). Proteasomal degradation clears misfolded 
proteins from the cell in contrast to the chaperone system, which binds exposed hydrophobic 
regions of unfolded or partially folded proteins, thus shielding them from degradation or 
aggregation and allowing them more time to fold properly (Ross and Pickart, 2004). Coupled 
with the presence of misfolded or aggregated proteins found in SNpc DA neurons, the discovery 
of mutations in genes encoding enzymes in the UPS indicates the probable significance of the 
UPS in the molecular pathogenesis of PD. 
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As described earlier, though protein aggregates are found in many neurodegenerative 
diseases, they do not appear to be the cause of cell death, but are thought instead to be a 
protective response aimed at sequestering misfolded proteins that have escaped degradation 
(Huang and Figueiredo-Pereira, 2010). The requirement for unfolding prior to proteolysis 
suggests that proteins that arrive at the proteasome but cannot be unfolded have the potential 
to act as dominant inhibitors of its function, thus incapacitating the proteasome and potentially 
leading to accumulation (Bennett et al., 2005; Bennett et al., 2007). In fact, decreased 
proteasome activity is associated with aging, the major risk factor for PD, and has also been 
shown in post-mortem extracts of the substantia nigra from PD-afflicted patients (McNaught et 
al., 2004). Consistent with this hypothesis, when overexpressed in cultured cell, mutated forms 
of alpha-synuclein have been shown to inhibit proteasome activity, though it is not clear how this 
may work in disease progression. However, there is likely interplay between the accumulation of 
misfolded proteins, the UPS, damage to cellular organelles, such as the mitochondria, and the 
production of ROS. 
1.3.3 Mitochondrial dysfunction in SNpc DA neurons and Parkinson’s disease 
Over a century ago, the significance of mitochondria was recognized when they were 
described as “elementary organisms” alive inside cells carrying out vital functions (Ernster and 
Schatz, 1981). However, the symbiotic origin of mitochondria was dismissed until the 1960s with 
the discovery of mitochondrial DNA (mtDNA) which corroborated the theory that mitochondria 
were descendants of endosymbiotic bacteria (DiMauro and Schon, 2003; Pallen, 2011; Sagan, 
1967). Electron microscopy studies in the 1950s captured the ubiquitous bean-shaped 
organelles and revealed the ultrastructural features of mitochondria, including double lipid 
membranes, the intermembrane space, and the matrix (Palade, 1953) (Figure 1.3a). The 
importance of these unique structural features became evident once the major function of 
mitochondria was understood – to provide the chemical energy essential for biosynthetic and  
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Figure 1.3 Features of the mitochondria. a, Cartoon depicting structural aspects of the 
mitochondria (adapted from http://micro.magnet.fsu.edu/cells/mitochondria.html). b, 
Mitochondrial tubular network in HeLa cells. Mitochondria are visualized by staining with 
antibody targeting the mitochondrial protein, TOMM20. c, Healthy mitochondria undergo 
dynamic fusion-fission cycles resulting in exchange of membrane, membrane proteins, and 
contents. 
 
motor activities of the cell by means of the electron-transport chain and oxidative 
phosphorylation. Additionally, the mitochondria carry out numerous duties, such as pyruvate 
oxidation, the Krebs cycle, amino acid, fatty acid, and steroid metabolism,  regulation of calcium 
homeostasis, and control of apoptosis (Ernster and Schatz, 1981). 
More recent studies have shown that mitochondria are not the solitary organelles 
captured in static micrographs but rather dynamic interconnected tubular networks of organelles 
varying widely in size and shape (Figure 1.3b). Their morphology can differ based on cell type, 
cell cycle stage, localization within the cell, or can depend on any number of metabolic or 
chemical states existing in the cell or organelle itself (Detmer and Chan, 2007). Imaging studies 
performed in living cells have demonstrated that mitochondria are constantly in motion and that 
mitochondrial tubules move with their long axes aligned along cytoskeletal tracks (Hollenbeck 
and Saxton, 2005). Upon encountering each other during these movements, mitochondria may 
undergo fusion leading to the unification of the double membranes and the resultant mixing of 
both the lipid membranes and the interior contents (Figure 1.3c). This mixing can be problematic 
in the case of mitochondrial damage and cells have evolved intricate pathways in order to 
sequester or remove damaged organelles from the larger population. Mitochondria can also 
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divide by fission to produce numerous smaller organelles which can be actively transported to 
alternate subcellular locations (Detmer and Chan, 2007). Under steady state conditions, the 
cycles of fusion and fission are balanced, maintaining a healthy population of mitochondria 
within the cell. 
As stated, neurons bear a high metabolic burden compared to other cells of the body. It 
has been suggested that SNpc DA neurons, which are at greatest risk in PD, have a distinctive 
physiological phenotype that may contribute to their vulnerability. Explanations for a variety of 
cell-specific stresses have been proposed. One of these theories is that extended opening of L-
type calcium channels during autonomous pacemaking results in sustained calcium entry into 
the cytoplasm of SNpc DA neurons causing an elevated basal level of mitochondrial oxidant 
stress. It is thought that mitochondria are capable of dealing with this stress in the short term; 
however, this increased oxidant stress may eventually increase DNA damage and accelerate 
aging - a metabolically expensive strategy that taxes mitochondria and thus SNpc DA cells 
(Surmeier et al., 2010). Furthermore, since neurons in the SNpc are postmitotic, they are at risk 
of accumulating mitochondrial damage over an organism's lifetime, resulting in progressive 
mitochondrial dysfunction and ultimately increased oxidative stress, decreased calcium 
buffering capacity, decreased ATP production, and, eventually, cell death—unless quality 
control processes are enacted. 
Another characteristic of SNpc DA neurons that may put them at higher risk of oxidant 
stress is their large axonal field. It is estimated that a typical SNpc DA neuron has a mean 
axonal length of 470mm and supports approximately 370,000 synapses (Arbuthnott and 
Wickens, 2007; Matsuda et al., 2009). Consequently, it has been suggested that the increased 
need for axonal protein trafficking leads to elevated proteostatic stress, potentially leading to the 
accumulation of pathogenic aggregates, thus intertwining the UPS and mitochondrial fitness. 
Additionally, synaptic terminals are metabolically demanding subcellular locations which require 
a high density of ATP-producing mitochondria to power synaptic transmission and regulate 
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calcium homeostasis. In comparison to other neuronal cell types, SNpc DA neurons display 
lower mitochondrial density in the somatodendritic region (Liang et al., 2007). This dearth of 
mitochondria in the cell body may lead to lower spare oxidative capacity, thus loss of the ability 
to protect against reactive oxygen species, and insufficient ATP production, possibly inducing 
an energy crisis and contributing to age-related decline of the mitochondria (Nicholls, 2008; 
Surmeier et al., 2010). Furthermore, to achieve this non-uniform distribution, neurons rely 
heavily on active transport to recruit mitochondria and other organelles to synapses, which 
requires properly regulated mitochondrial dynamics and transport. 
The discovery that toxins such as MPTP and paraquat, which cause parkinsonism, block 
the electron transport chain (ETC) by inhibiting mitochondrial complex 1 was a compelling 
indication that defects in oxidative phosphorylation may play a role in the pathogenesis of PD 
(Nicklas et al., 1987). This was further corroborated by studies identifying abnormalities or 
deficiencies in complex I in PD and in vitro studies which indicated that defects in complex I 
could cause oxidative stress and mitochondrial failure in cells (Greenamyre et al., 2001; 
Janetzky et al., 1994). Furthermore, biological markers of oxidative stress and reduced staining 
for complex I have been identified in PD SNpc neurons examined post-mortemly (Dauer and 
Przedborski, 2003; Hattori et al., 1991). As a result of mitochondrial respiration, potent oxidants, 
such as superoxide radicals and hydrogen peroxide, are produced as byproducts. When 
complex I is not functional, the production of ATP decreases while that of ROS increases which 
can cause damage to cellular proteins, DNA, lipids, and thus all organelles. It is proposed that 
the mitochondrial ETC itself may be targeted by these reactive species, thus generating a cycle 
of mitochondrial damage and further production of ROS (Cohen, 2000). The presence of 
increased mitochondrial ROS production and oxidative stress is interconnected with defects in 
the UPS and protein folding. The result of this proliferation in reactive species causes damage 
to proteins, increasing unfolding, thus escalating strain on the UPS and chaperones. SNpc 
neurons may be acutely affected by this scenario since the metabolism of DA is known to 
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produce ROS and furthermore these cells contain a low anti-oxidant capacity (Exner et al., 
2012; Graham et al., 1978). Still, despite proof of mitochondrial dysfunction in PD tissue and 
animal models, until the discovery of commonalties between sporadic and genetic PD, little was 
understood of whether mitochondrial damage and increased oxidative stress were causative or 
additional symptoms of disease. 
1.4 Genetics of Parkinson’s disease 
Though they explain but a small proportion of disease, the discovery of several 
monogenic mutations causally linked to the development of PD have fostered research into 
molecular mechanisms that may be common to both genetic and idiopathic disease. 
Mitochondrial impairment, oxidative stress, and dysfunction of protein folding or degradation 
appear to play a central role in PD pathogenesis in both types of disease, induced either by 
single gene dysfunction or in the case of sporadic PD, by factors such as age or environmental 
exposure, though genetic factors are still thought to modulate sensitivity (Lim et al., 2002). 
Accumulating evidence suggests that disorder of mitochondrial quality control may play a 
fundamental role in both idiopathic and genetic PD (Dawson and Dawson, 2003; Exner et al., 
2012). Accumulation of damage to the mitochondria in neuronal cells, which bear a high 
metabolic load, may lead to loss of mitochondrial homeostasis and ultimately cell death. Of the 
fewer than twenty proteins implicated genetically in PD, 6 have roles in mitochondrial 
homeostasis, and many of the remainder, when mutated, lead to toxic aggregates that may 
indirectly affect mitochondrial health (Martin et al., 2011) (Table 1.1).  
The amount of risk of Parkinson’s that can be attributed to genetic causes is highly 
variable depending on the risk loci and population studied. For example, a very large proportion 
of risk, nearly 40%, is accounted for by mutations in leucine-rich repeat kinase 2 (LRRK2) 
G2019S and glucosecerebrosidase (GBA) in Ashkenazi Jewish populations; similarly LRRK2 
G2019S is highly implicated in Arab populations. In East Asian cohorts, approximately 10% of  
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Table 1.1 Genes and loci associated with parkinsonism
    
PARK locus Gene Inheritance 
Map 
position Clinical phenotype Pathology 
      
PARK1/4 SNCA Dominant 4q21 Parkinsonism with common 
dementia 
Lewy bodies 
PARK2 Parkin Recessive 6q25-q27 Early-onset, slowly progressing 
parkinsonism 
Lewy bodies 
PARK3 Unknown  2p13 Late-onset parkinsonism Lewy bodies 
PARK5 UCHL1  4p14 Late-onset parkinsonism Unknown 
PARK6 PINK1 Recessive 1p35-p36 Early-onset, slowly progressing 
parkinsonism 
One case with 
Lewy bodies 
PARK7 DJ-1 Recessive 1p36 Early-onset parkinsonism Unknown 
PARK8 LRRK2 Dominant 12q12 Late-onset parkinsonism Lewy bodies 
(usually) 
PARK9 ATP13A2 Recessive 1p36 Early-onset parkinsonism with 
Kufor-Rakeb syndrome 
Unknown 
PARK10 Unknown  1p32 Unclear Unknown 
PARK11 GIGFY2  2q36-q37 Late-onset parkinsonism Unknown 
PARK12 Unknown  Xq Unclear Unknown 
PARK13 Omi/HTRA2  2p13 Unclear Unknown 
PARK14 PLA2G6 Recessive 22q13.1 Parkinsonism with additional 
features 
Lewy bodies 
PARK15 FBXO7  22q12-q13 Early-onset parkinsonism Unknown 
PARK16 Unknown  1q32 Late-onset parkinsonism Unknown 
FTDP-17 MAPT Dominant 17q21.1 Dementia, sometimes 
parkinsonism 
Neurofibrillary 
tangles 
SCA2 Ataxin 2 Dominant 12q24.1 Usually ataxia, sometimes 
parkinsonism 
Unknown 
SCA3 Ataxin 3 Dominant 14q21 Usually ataxia, sometimes 
parkinsonism 
Unknown 
Gaucher’s 
locus 
GBA High-risk 
locus 
1q21 Late-onset parkinsonism 
 
 
Lewy bodies 
SPG11 Spatacsin Recessive  Usually spastic paraplegia; some 
complex parkinsonism, addl 
features 
Unknown 
Adapted from (Hardy, 2010; Martin et al., 2011) 
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PD has been associated with a number of LRRK2 mutations. In outbred European populations, 
association of LRRK2 and GBA mutations with increased risk is near 8% (Hardy, 2010). Loss-
of-function mutations or deletions in PARKIN and PTEN-induced putative kinase (PINK1) which 
explain nearly 50% of early-onset disease (before age 40), account for perhaps only 1-2% of PD 
overall ((Martin et al., 2011). Taken together, Mendelian and high risk loci identified via genome 
wide association studies (GWAS) explain perhaps 10-40% of PD risk across most populations 
that have been studied (Hardy, 2010; Martin et al., 2011).  
As more and more studies uncover genetic contributions to PD, the proportion of risk 
assigned to the environment has consistently decreased. Table 1.1 lists the loci at which 
pathogenic mutations have been linked to parkinsonism, both those conventionally termed 
“Parkinson loci,” such as PARK2, PINK1, SNCA, LRRK2, DJ-1, and FBXO7 and others, 
including UCHL1, MAPT, SCA2, SCA3, and SPG11, which can clinically present as Parkinson 
disease but are also often clinically distinct (Hardy, 2010; Martin et al., 2011). Because 
Parkinson’s disease has traditionally been defined clinically, it can be difficult to unambiguously 
distinguish. The majority of idiopathic cases exhibit Lewy bodies, though this is not the case with 
the genetic forms of disease and obviously impossible to document in living patients (Hardy, 
2010). However, a small number of cases of PD caused by PARKIN and PINK1 mutations have 
been reported to contain typical Lewy bodies, suggesting some commonality in the 
pathogeneses of the two forms of the disease (Farrer et al., 2001). Nevertheless, PARKIN- and 
PINK1-associated disease is very distinct from typical idiopathic PD, presenting with a 
prolonged and benign disease duration, profound dopamine sensitivity, and sleep benefit 
(Dawson and Dawson, 2010).  
1.5 Parkinson’s disease genes are linked to mitochondrial quality control 
As is often the case, studies of genes associated with Mendelian disease have provided 
insight into the molecular pathogenesis of PD. Deficits in mitochondrial respiration, morphology,  
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trafficking, and quality control, probably triggered by a combination of environmental factors and 
genetic susceptibility, have long been implicated in the pathogenesis of idiopathic PD. 
Dysfunction of mitochondria due to complex 1 deficiency resulting in impaired electron transfer 
in the substantia nigra as well as mutations in mitochondrial proteins and mtDNA deletions have 
all been identified in PD patients (Keane et al., 2011). In recent decades, the identification of 
numerous genes, some mitochondrial, linked to PD have highlighted the importance of 
mitochondrial quality control in the etiology of the disease. The discovery of these distinct 
genetic loci which contain pathogenic mutations associated with PD has accelerated the 
understanding of mechanisms of disease pathogenesis, which appear to be common to both 
genetic and sporadic disease. The most apparent pathways revealed include mitochondrial 
damage and quality control and the UPS (Figure 1.1d). 
PARKIN, an E3 ubiquitin ligase acts downstream of PINK1, a mitochondrial kinase, in a 
pathway which is involved in the selective elimination of damaged mitochondria, termed 
mitophagy (Narendra et al., 2008) (Figure 1.4a). Similarly, DJ-1 may move to the mitochondria 
in response to oxidative stress in order to help maintain mitochondrial function (Canet-Aviles et 
al., 2004; Cookson, 2010; McCoy and Cookson, 2011). The role of FBXO7, a component of 
another E3 ligase complex, is yet unclear, but it is thought that it may also be involved in 
mitochondrial physiology (Hardy, 2010; Paisan-Ruiz et al., 2010; Zhao et al., 2011). It is 
unresolved as to whether the proteins produced by these genes are directly involved the same 
or parallel mitochondrial maintenance pathways, but it is a striking commonality that all of these 
genes are engaged in a mitochondrial damage response. Another prominent pathway which 
appears to play a role in the development of PD involves lysosomes. Both GBA and ATP13A2 
are lysosomal enzymes found mutated in Parkinson’s (Paisan-Ruiz et al., 2010). It is tempting to 
imagine that these proteins act downstream in the elimination of damaged mitochondria via 
autophagy – thus the role for lysosomes; however, a relationship between these loci and the 
mitochondrial loci is not obvious at this point. 
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Figure 1.4 PARKIN and PINK1 in mitophagy. a, The E3 ligase, PARKIN contains a UBL 
domain, two RING domains, and an in-between-RING (IBR) domain. PARKIN associates with the 
proteasome through the UBL and with the E2, UbcH7 through RING1. PD-associated mutations 
span the entire protein and are found within each domain. A small sample of patient mutations is 
shown. b, PINK1 is a serine/threonine kinase with an N-terminal mitochondrial targeting 
sequence (MTS), transmembrane domain (TM), and C-terminal kinase domain. c, Model 
depicting PINK1 and PARKIN in mitophagy. Upon mitochondrial membrane depolarization, full-
length PINK1 accumulates at the outer mitochondrial membrane promoting PARKIN 
translocation to the mitochondria, leading to PARKIN-dependent mitochondrial ubiquitylation. 
Ubiquitylation promotes degradation of some proteins, like MFN, creating a pro-fission 
environment promoting the isolation of damaged organelles. Ubiquitylation also recruits 
autophagic machinery to the mitochondria, possibly through interaction with ubiquitin receptors, 
resulting in the ultimate removal of damaged mitochondria via autophagy.
1.6 Phosphatase and tensin (PTEN)-induced putative kinase 1 (PINK1) (PARK6) 
Mutations in PINK1, a serine, threonine kinase cause early-onset familial PD (Valente et al., 
2004). PINK1 is a 581 amino acid protein that contains an N-terminal mitochondrial targeting 
sequence, a transmembrane domain, and a highly conserved protein kinase domain, similar to 
serine/threonine kinases of the Ca2+ calmodulin family (Figure 1.4b). Nearly 30 pathogenic 
mutations in PINK1 have been identified, among them missense, non-sense, or frameshift 
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mutations, deletions or rearrangements which for the most part impair kinase activity or reduce 
the stability of the protein (Corti et al., 2011).Though it has been reported to be found in both the 
cytosol and both outer and inner mitochondrial membrane, PINK1 does contain an N-terminal 
mitochondrial targeting sequence (MTS) and staining patterns appear to be consistent with 
mitochondrial localization (Gandhi et al., 2006; Haque et al., 2008; Lin and Kang, 2008; Muqit et 
al., 2006; Narendra et al., 2010b). Only as of 2006 was PINK1 shown to be important at the 
mitochondria; knockout (KO) of the Drosophila PINK1 homolog resulted in male sterility, muscle 
degeneration, defects in mitochondrial morphology, and increased sensitivity to oxidative stress 
(Clark et al., 2006). The same study also showed mitochondrial localization of WT PINK1 and 
fragmentation of cristae upon knockout. Upon loss of PARKIN, a similar phenotype was seen, 
though PARKIN overexpression could rescue PINK1 deficiency, thus placing PARKIN 
downstream of PINK1 in the same pathway and underscoring the significance of mitochondrial 
disorder as a fundamental mechanism of PD pathogenesis (Clark et al., 2006; Park et al., 2006; 
Yang et al., 2006). Whether PINK1 and PARKIN interact directly, or if PINK1 phosphorylates 
PARKIN and/or PARKIN ubiquitylates PINK1 is a controversial issue, supported by some 
studies but refuted by others (Kim et al., 2008b; Lazarou et al., 2012; Moore, 2006; Sha et al., 
2010; Shiba et al., 2009; Um et al., 2009). 
 In the few years since it was determined that PINK1 played a vital role in maintaining 
mitochondrial well-being, numerous details of its processing and function have been discovered. 
It is proposed that under steady state conditions, PINK1 is targeted by its MTS for import via the 
TOM/TIM23 complexes into the inner mitochondrial membrane where it is cleaved by an 
intermembrane protease, presenilin-associated rhomboid like protease (PARL), and ultimately 
degraded by an MG132-senstive protease (Deas et al., 2011; Jin et al., 2010). It is not yet clear 
where this proteolysis occurs, but if in fact the proteasome is responsible, PINK1 must 
presumably be removed from the mitochondria via reverse translocation. Evidence suggests 
that perturbation of the mitochondrial membrane potential results in cleavage of the MTS on a 
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PINK1 import intermediate still associated with the TOMM complex, thus preventing import into 
the inner mitochondrial membrane and PARL-mediated processing (Narendra et al., 2010b).  
Additionally, upon mitochondrial depolarization, inner membrane proteases are thought to be 
rendered nonfunctional, resulting in PINK1 stabilization and accumulation in the outer 
mitochondrial membrane (Jin et al., 2010). PINK1 can then move laterally into the outer 
mitochondrial membrane and extend its kinase domain into the cytoplasm, which is essential for 
the recruitment of PARKIN to the mitochondria (Meissner et al., 2011; Narendra et al., 2010b). A 
recent study has shown that PINK1 is associated with the TOMM complex in depolarized 
mitochondria, potentially enabling rapid reimport of PINK1 after repolarization to terminate the 
mitophagy response (Lazarou et al., 2012). 
 Loss of PINK1 in mice increases sensitivity of DA neurons to MPTP treatment which can 
be abrogated by overexpression of PARKIN or DJ-1 (Haque et al., 2008). Correspondingly, 
PINK1 has been shown to increase cellular resistance to a diverse array of stresses and in 
addition to its role in PD, may act as tumor suppressor (Devine et al., 2011). Obviously, 
unearthing the identity of PINK1 targets is essential and a number of studies have been 
conducted to do so. TNF receptor-associated protein 1 (TRAP1), a mitochondrial chaperone of 
the Hsp90 family, and HtrA2/Omi, a mitochondria serine protease, were both identified as 
substrates and shown to play roles in mediating protection against oxidative stress (Plun-
Favreau et al., 2007; Pridgeon et al., 2007). Recently, the Rho-like GTPase, Miro, was identified 
as a PINK1 substrate after mitochondrial depolarization (Wang et al., 2011b). Miro, located in 
the outer mitochondrial membrane, binds Milton, an adaptor protein, which bridges an 
interaction with kinesin heavy chain, thus allowing mitochondria to be trafficked along 
microtubules for axonal transport (Glater et al., 2006; Guo et al., 2005). Working in rat 
hippocampal neurons or Drosophila larval neurons, Wang et al. (2011) found that PINK1 or 
PARKIN overexpression could arrest mitochondrial transport and that PINK1 may directly 
modify Miro by phosphorylation after mitochondrial depolarization, thus targeting it for 
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proteasome-mediated degradation after PARKIN-mediated ubiquitination. These observations 
support the model that PINK1 and Miro play opposing roles in mitochondrial trafficking in which 
degradation of Miro induced by PINK1 and PARKIN arrests mitochondrial movement and 
sequesters damaged mitochondria prior to elimination by mitophagy. 
Much progress has been made, yet the precise mechanism by which PINK1 is regulated 
and how it promotes PARKIN activity is incompletely understood. It is evident that PINK1 is 
essential for PARKIN recruitment to mitochondria after CCCP treatment (Narendra and Youle, 
2011). Recent reports support direct phosphorylation of PARKIN by PINK1, but the in vivo 
functional consequences of reported sites have not yet been elucidated (Kondapalli et al., 
2012). By determining interactors, regulators, and additional substrates of PINK1 in the 
presence or absence of mitochondrial depolarization, we hope to elucidate how PINK1 
regulation of Parkin occurs. Our initial analysis has uncovered a candidate PINK1 regulatory 
factor, CLU1, which has been genetically linked to the PARKIN/PINK1 pathway in Drosophila 
(Cox and Spradling, 2009).  Loss of CLU1 orthologs identified in Drosophila, Dictyostelium, and 
S.cerevisiae results in mitochondrial clustering and altered morphology (Cox and Spradling, 
2009; Fields et al., 1998; Zhu et al., 1997). To our knowledge, our findings provide the first 
evidence of direct interaction between PINK1 and CLU1 and we are investigating whether CLU1 
may control the activity, stability, or localization properties of PINK1. Furthermore, we are 
examining whether phosphorylation of candidate Parkin substrates by PINK1 promotes 
ubiquitination in vivo and in vitro. 
1.7 Role of the PARKIN E3 ligase in Parkinson’s disease and mitophagy 
1.7.1 PARKIN is mutated in autosomal recessive early-onset PD  
Parkin is commonly mutated in autosomal recessive forms of early-onset PD, often 
referred to as autosomal recessive juvenile PD (ARJPD), and accounts for a large proportion, 
nearly 50% of familial early onset PD cases (Abbas et al., 1999; Kitada et al., 1998). In addition 
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to its established role in PD, Parkin is also a putative tumor suppressor located adjacent to a 
fragile chromosome site frequently lost in a number of human cancers  (Devine et al., 2011). 
The full length protein is widely expressed in a variety of tissues, though predominantly in 
muscle and brain (Kitada et al., 1998). Pathogenic mutations in PARKIN are scattered 
throughout the full length protein, with clusters apparent in each of the domains (Figure 1.4a). 
Mutations include missense, exon duplications, rearrangements, deletions, and truncations, all 
seemingly causative of ARJPD (Dawson and Dawson, 2010; Kitada et al., 1998).  
Most patient mutations appear to impact E3 ligase activity or interactions with E2 
enzymes leading to a loss-of-function phenotype. Evidence also exists that PARKIN can be 
inactivated by dopaminergic, nitrosative, and oxidative stress in sporadic PD (Martin et al., 
2011). Clinically, patients with PARKIN mutations present classical signs of Parkinson’s but with 
striking sleep benefit, abnormal dystonic movements, and a good response to levodopa. 
Pathologically, patients show a characteristic loss of SNpc DA neurons most often without Lewy 
bodies (Dawson and Dawson, 2010). It is yet unclear precisely how loss of PARKIN function 
contributes to DA neuron dysfunction, but it is thought that accumulation of as yet unidentified 
PARKIN substrate(s) and failure of proteolysis mediated by the UPS may cause neuronal death. 
Research in recent years uncovering PARKIN’s role in mitochondrial homeostasis has 
energized the field and suggests that the significance of PARKIN and PINK deficiencies in PD 
pathogenesis is indeed strongly shaped by a loss of mitochondrial quality control (Narendra et 
al., 2008). PARKIN and PINK1 substrates at the mitochondria may be key to resolving those 
proteins vital for SNpc neuron survival. 
1.7.2 PARKIN is a member of the RBR E3 ligase family RING/HECT hybrid 
Parkin is a 465 amino acid protein and a member of the RING-between-RING (RBR) 
family of E3 ligases, which contain an RBR domain, composed of two RING fingers plus an In-
Between-RING (IBR) domain (Eisenhaber et al., 2007; Marin et al., 2004) (Figure 1.4a). Based 
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on structural analysis of the human homologue of Drosophila Ariadne (HHARI), the RING2 
domain appears to bind only a single zinc ion and so it was thought that RING2 of Parkin would 
behave similarly (Capili et al., 2004). However, RING1 of PARKIN is thought to bind two zinc 
ions and to fold into a classical RING finger while RING2 has also been recently shown to bind 
two zinc ions suggesting that diversity exists within these domains (Beasley et al., 2007; 
Hristova et al., 2009; Marin et al., 2004). Parkin also contains a unique regulatory domain, 
RING0, and the IBR domain, which both also bind two zinc ions and an N-terminal ubiquitin-like 
(UBL) domain which may mediate interactions with proteins containing ubiquitin binding 
domains (UBDs), such as the ubiquitin receptor, S5a/Rpn10, and the proteasome (Dachsel et 
al., 2005; Hristova et al., 2009; Safadi and Shaw, 2010; Um et al., 2010). The E2 ubiquitin-
conjugating enzyme, UbcH7 is thought to interact with PARKIN through RING1 while the RBR 
domain mediates protein-protein interaction (Beasley et al., 2007). RING E3s typically carry out 
ubiquitin transfer directly from an activated E2 to a lysine on a substrate protein while the 
hallmark of HECT-type ubiquitin transfer is the formation of an E3 ubiquitin thioester 
intermediate (Deshaies and Joazeiro, 2009; Metzger et al., 2012). Though they contain RING 
domains, some RBRs appear to function like RING/HECT hybrids, in which they bind E2 s via a 
RING domain, but transfer ubiquitin to substrates through an E3 thioester-linked ubiquitin 
intermediate requiring a cysteine residue in RING2 (Wenzel et al., 2011). The identification of 
the requirement for cysteine 431 in PARKIN’s enzymatic activity as well as a recent report that 
an oxyester intermediate can be seen on recombinant PARKIN C431S in vitro supports the 
validity of this cysteine as the site of a ubiquitin thioester intermediate (Lazarou et al., 2013; 
Wenzel et al., 2011). 
1.7.3 PARKIN E3 ligase activity and regulation 
Parkin was originally shown to have ubiquitin ligase activity through in vitro 
autoubiquitination assays, thus it was thought to be constitutively active (Shimura et al., 2000; 
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Zhang et al., 2000). However, consistent with the model that PARKIN is activated upon 
mitochondrial depolarization; recent studies have shown that PARKIN may exist in an 
autoinhibited state until triggered by post-translational modification. The closed conformation of 
this autoinhibited state is maintained by an intramolecular interaction between the N-terminal 
UBL domain and the C-terminal RING regions (Chaugule et al., 2011) (Figure 1.5a, b). Notably, 
the C-terminal RING regions have been shown to interact with ubiquitin and are required for 
efficient ligase activity. The RING2 domain, which contains C431, is essential for ligase activity 
and truncations or mutations which disrupt the folding of the zinc-coordinating residues result in 
inactive Parkin. However, N-terminal truncations leaving only the IBR-RING2 domains are 
active, which supports the notion that in the absence of the N-terminus, autoinhibition is relieved 
(Chaugule et al., 2011). Furthermore, some studies have shown that the presence of an N-
terminal affinity tag results in constitutively active PARKIN, presumably because it disrupts the 
intramolecular interaction (Burchell et al., 2012; Chew et al., 2011). Clearly, the N-terminal UBL 
and RING0 domains are not required for basal Parkin activity, but are likely necessary for 
regulating its activity (Hampe et al., 2006; Matsuda et al., 2006). Collectively, these data support 
a model wherein PARKIN is autoinhibited by internal binding of the N-terminal domain which 
inhibits autoubiquitination and presumably substrate interaction and ubiquitination (Figure 1.5b, 
c). 
In recent years, PINK1 was shown to be necessary for PARKIN recruitment to the 
mitochondria after depolarization (Narendra et al., 2008). Several groups have found evidence 
to support the hypothesis that PINK1 kinase activity is necessary for phosphorylation and 
translocation of PARKIN, though it has been difficult to prove direct phosphorylation (Matsuda et 
al., 2010; Narendra et al., 2010b). An alternative hypothesis proposes that PINK1-dependent 
activation of mitochondrial ubiquitination reflects phosphorylation of substrates, which PARKIN 
may then recognize and in fact, evidence has shown that the mitochondrial GTPase, Miro, is 
phosphorylated by PINK1 at Ser156 and  
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Figure 1.5 Regulation of PARKIN E3 ligase activity. a, PD mutations (yellow) in the UBL domain of 
PARKIN relieve autoinhibition. Ubiquitylation of lys27 and lys48 (blue) was identified in our study and 
may contribute to PARKIN activation (PDB code 1IYF (Sakata et al., 2003)). b, In the absence of 
stimulation, PARKIN exists in an autoinhibited state in which the UBL domain folds over to bind the C-
terminus of the protein in a region harboring UBL-domain/Ubiquitin binding capacity. A ubiquitin-
conjugated E2 enzyme may interfere with this interaction and allow substrate ubiquitination and/or 
Parkin autoubiquitination. PINK1 may also contribute to activation via phosphorylation of various sites 
within PARKIN. c, PARKIN lacking the UBL is thought to be constitutively active. 
subsequently ubiquitylated by PARKIN after mitochondrial depolarization (Wang et al., 2011b). 
However, another study has found this site to be nonessential for PARKIN-dependent Miro 
degradation (Liu et al., 2012). More recently, one group utilizing recombinant PINK1 found that 
the highly conserved residue serine 65 within the UBL domain of Parkin was directly targeted by 
PINK1 in vitro. Furthermore, phosphorylation of Ser65 enhanced PARKIN’s E3 ligase activity in 
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an in vitro ubiquitylation reaction and was also detected by mass spectrometry on 
immunoprecipitated PARKIN after mitochondrial depolarization in the presence of PINK1 
(Kondapalli et al., 2012). Though obviously regulated in a mitochondrial depolarization- and 
PINK1-dependent manner, the full functional consequence of phosphorylation of PARKIN at 
Ser65 is completely clear. Because the activity and substrate specificity of PARKIN is likely to 
be integrated with its mechanism of activation, it is essential to fully characterize how PARKIN is 
activated. 
Numerous PARKIN interactors and substrates have been reported over the years, 
however, during this time, the mechanism of autoinhibition was yet unknown and PARKIN was 
thought to be constitutively active. Furthermore, PARKIN itself is reported to be prone to 
misfolding, a complicating factor when attempting to study it in cells, particularly with 
overexpressed protein (Wang et al., 2005). Misfolded PARKIN may interact with other poorly 
folded proteins, aggregate, or bind proteins involved in quality control under these conditions 
thus obscuring identification of actual specific interactors. Numerous early studies have 
proposed candidate Parkin substrates, including CCNE, AIMP2, DJ-1, and RANBP2, though 
many of these and their functional consequences have not been reliably substantiated most 
likely due to the varying methods used, including yeast 2-hybrid assays, mass spectrometry, 
and co-immunoprecipitation from a diversity of cell types or tissues (Dawson and Dawson, 
2010). 
Another unanswered question is how ubiquitin chain linkage type produced by PARKIN 
is controlled and how it impinges on the fate of substrates. PARKIN has been reported to build 
numerous types of ubiquitin chains, including K27, K48, and K63 (Chan et al., 2011; Geisler et 
al., 2010). This has several implications that include not only the mechanism of PARKIN E3 
ligase activity, but also the processes that occur post-ubiquitylation, such as proteasome-
mediated degradation or downstream signaling. The means by which PARKIN might be capable 
of producing multiple different types of chain linkages may be a property of its unique RBR 
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structure. One mechanism which has been established for other RING-IBR-RING and HECT 
domain E3s may explain how PARKIN could also create distinct chain linkages.  The presence 
of C-terminal surfaces that are able to bind distinct faces of ubiquitin may be able to orient 
acceptor ubiquitin molecules on substrates for attack on the donor ubiquitin thioester; thus the 
use of a weak ubiquitin binding site, such as that which PARKIN utilizes for autoinhibition, may 
allow assembly of distinct chain linkages (Chaugule et al., 2011; Kulathu and Komander, 2012) 
(Figure 1.5b). 
1.7.4 Models used to study PINK1 and PARKIN 
Unexpectedly, neither PINK1 nor Parkin knockout mice present with a morphological or 
behavioral phenotype; however, Drosophila KO models do exhibit age-dependent loss of DA 
neurons and mitochondrial dysfunction and both Parkin and PINK1-deficient cultured cells show 
increased vulnerability to mitochondrial damage (Casarejos et al., 2006; Haque et al., 2012; 
Rosen et al., 2006; Sandebring et al., 2009). Because vertebrate KO models do not display age-
related loss of DA neurons, they may not faithfully recapitulate human PD pathogenesis. 
However, subtle phenotypes have been recorded, including abnormalities in the DA nigrostriatal 
circuit or noradrenergic system (Goldberg et al., 2003; Itier et al., 2003; Von Coelln et al., 2004). 
Interestingly, transgenic mice expressing Parkin mutants exhibited age-dependent DA neuron 
degeneration and hallmark characteristics of PD, suggesting that dominant toxicity of a Parkin 
mutant is sufficient to elicit PD symptoms, though this model requires further study but has been 
corroborated in flies (Lu et al., 2009; Sang et al., 2007; Wang et al., 2007). In 2011, Shin et al. 
produced a conditional Parkin KO mouse which showed that loss of Parkin function in adult 
mice led to progressive degeneration of DA neurons, suggesting that the lack of effects of 
germline Parkin KO in previous models had been masked by developmental compensation  
(Shin et al., 2011). Knockout of Parkin in Drosophila leads to mutant flies with reduced lifespan, 
male sterility, defects in muscle, and reduced mitochondria with loss of cristae structure. 
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Furthermore, degeneration of DA neurons with abnormal mitochondria was seen in both Parkin 
and PINK1-null flies and both are sensitive to oxidative stress and show increased levels of 
cellular ROS (Clark et al., 2006; Greene et al., 2003). Transgenic expression of Parkin is able to 
rescue PINK1 deficiency though the reverse is not true, confirming that PARKIN lies 
downstream of PINK1 in a common pathway. 
Cellular models examining PARKIN and PINK1 have often used HeLa cells because 
they do not endogenously express PARKIN, thus conveniently providing a null background on 
top of which to exogenously express the protein (Denison et al., 2003). Mitochondrial 
depolarization in HeLa cells exposed to the uncoupling agent carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) results in PINK1 processing and PARKIN translocation to the 
mitochondria and the induction of mitophagy (Narendra et al., 2008). In fibroblasts from PINK1-
null mice, PARKIN translocation is abrogated (Narendra et al., 2010b). Though HeLa cells are 
extremely useful for establishing the mechanisms of the PARKIN/PINK1 pathway, these studies 
have met with some criticism because there is little way of knowing if they are physiologically 
relevant, both because of the cell type used and because of the huge assault on the cellular 
population of mitochondria achieved by CCCP treatment. To address this, studies in neurons, 
which may more closely recapitulate the cellular environment in which PD arises, have 
examined whether PINK1 activation and PARKIN translocation are relevant. Results have been 
controversial; for example, one group has shown impaired recruitment of lentivirally-expressed 
Parkin to mitochondria in induced pluripotent stem (iPS) cells taken from fibroblasts of PD 
patients with PINK1 gene mutations that were differentiated into dopaminergic neurons (Seibler 
et al., 2011). However, others have presented evidence that endogenous levels of Parkin are 
not sufficient to initiate mitophagy after mitochondrial depolarization in human primary 
fibroblasts and iPS-generated neurons from controls and PINK1 mutant patients (Rakovic et al., 
2013; Van Laar et al., 2011). These negative results however, are called into question by 
reports that Pink1-dependent Parkin translocation does occur in mouse cortical neurons in 
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response to a variety of mitochondrial damaging agents but only in the absence of antioxidants 
in the neuronal culturing medium, implicating a key role of ROS in the response (Joselin et al., 
2012). Further studies have shown PINK1 stabilization and PARKIN recruitment to mitochondria 
in rat cortical neurons, rat hippocampal neurons, and mature cortical neurons treated with both 
CCCP and less globally damaging agents, such as Antimycin A, a complex I inhibitor (Cai et al., 
2012b; Narendra et al., 2010b; Wang et al., 2011b). Of note, when compared with non-neuronal 
cells, neuronal mitophagy occurs much more slowly and is a compartmentally restricted 
process, coupled with reduced anterograde mitochondrial transport. Ultimately, Parkin-targeted 
mitochondria accumulate in somatodendritic regions where mature lysosomes are located (Cai 
et al., 2012a; Cai et al., 2012b). A compartmentalized focus on damaged mitochondria in 
neurons is consistent with the likely mode of damage in living cells, in which a population of 
cellular mitochondria are damaged and selectively targeted for degradation. Though it has been 
suggested that mitophagy differs between human non-neuronal and neuronal cells and between 
endogenous and PARKIN-overexpressing cellular models, strong evidence is accumulating to 
suggest that this model does in fact represent a physiological response to mitochondrial 
damage. 
1.7.5 General features of autophagy and mitophagy 
Autophagy broadly refers to multiple pathways in the cell which exist to perform bulk 
degradation of cytosolic components and organelles. Macroautophagy, the main type of 
autophagy, which is well conserved from yeast to mammals is generally induced by cellular 
starvation and operates to provide the cell with essential nutrients. In juxtaposition with this, 
selective autophagy, such as mitophagy, acts to clear damaged or excess organelles, including 
mitochondria (Kim et al., 2007). Both processes employ a similar mechanism in which a double 
membrane structure, termed a phagophore, is formed around the cytosolic contents or targeted 
organelle. The membrane is eventually extended until closed, forming an autophagosome which 
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ultimately fuses with a lysosome to form an autolysosome, in which degradation of the 
autophagosome contents occurs via by lysosomal hydrolases (Levine and Klionsky, 2004; Yang 
and Klionsky, 2010b) (Figure 1.6). The basic autophagic machinery employed by 
macroautophagy is also used in mitophagy, however there are aspects of the specific pathways 
that differ or are yet unknown, for example, how the phagophore is selectively recruited to 
mitochondria is unclear. Autophagy consists of several sequential steps, initiation of the 
phagophore membrane and isolation of the contents, elongation and closure of the membrane 
to form the autophagosome, transport to lysosomes, fusion of the autophagosome and 
lysosome, and lysosomal degradation of the contents (Mizushima, 2007). 
First identified in yeast, nearly 30 ATG proteins acting in autophagy have been identified 
(Nakatogawa et al., 2009). The majority of these are also essential in mitophagy (Kanki et al., 
2010). ATG proteins are grouped based on their functions; the Atg1p-Atg13p-Atg17p kinase 
complex, the ULK1 complex in mammals, is normally inhibited by target of rapamycin complex 1 
(TORC1) which blocks Atg1 interaction with Atg13, thus controlling early steps in 
autophagosome formation (Figure 1.6). In mammalian cells, mitophagy can also be stimulated 
by the Hsp90-Cdc37 complex which acts through ULK1 for initiation (Ashrafi and Schwarz, 
2013). The next steps in assembly of the autophagosome are regulated by phosphatidyl inositol 
triphosphate (PIP3) signals which are controlled by the vacuolar protein sorting Vps34-Vps30p-
Atg14 complex in yeast, and it mammalian counterpart PIK3C3-BECN1 (beclin1). This PI3K-
mediated organization of PIP3-rich membrane domains is essential for nucleation of the 
isolation membrane, though it has been shown that stress-induced bulk autophagy and 
mitophagy can occur independently of Beclin1, however the mechanism of this is not 
understood (Ashrafi and Schwarz, 2013; Chu et al., 2007). A ubiquitin-like protein (UBL) 
conjugation cascade, comprised of the E1 enzyme Atg7p, the E2 enzymes (Atg10p and Atg3p) 
and two UBLs (Atg8p and Atg12p) is required for maturation of autophagosomes via elongation 
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of isolation membranes and cargo recruitment (Nakatogawa et al., 2009). At this step, the 
Atg12p-Atg5p complex binds to Atg16p, which moves to the isolation membrane to promote  
 
Figure 1.6 Overview of the autophagy pathway. The top right box depicts the molecular events 
involved in membrane initiation, elongation and completion of the autophagosome. After induction 
of autophagy, the ULK1 complex (ULK1–ATG13–FIP200–ATG101) (downstream of the inhibitory 
mTOR signaling complex) translocates to the ER and transiently associates with VMP1, resulting 
in activation of the ER-localized autophagy-specific class III phosphatidylinositol-3-OH kinase 
(PI(3)K) complex, and the phosphatidylinositol-3-phosphate (PtdIns(3)P) formed on the ER 
membrane recruits DFCP1 and WIPIs. WIPIs and the ATG12–ATG5–ATG16L1 complex are 
present on the outer membrane, and LC3–PE is present on both the outer and inner membrane 
of the isolation membrane, which may emerge from subdomains of the ER. The cellular events 
that occur during autophagy are depicted in the bottom diagram, including the major known 
cellular and microbial proteins that regulate autophagy initiation, cargo recognition and 
autophagosome maturation. Only those cellular proteins known to be adaptors for targeting 
microbes are shown; other proteins (not shown) also function in cargo recognition of mitochondria 
and other organelles. LIR, LC3-interacting region (motif); Ub, ubiquitin; UBA, ubiquitin-associated 
domain; UBZ, ubiquitin-binding zinc finger (adapted by permission from Macmillan Publishers Ltd: 
Nature (Levine et al., 2011)). 
Induction 
- Starvation 
- Growth factor deprivation 
- Energy depletion 
- ER stress 
- p53 (nuclear) 
- Sirtuins 
- Immune signals 
- Cell surface receptors 
- Infection 
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Suppression 
- Nutrient abundance 
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conjugation of Atg8p to phosphatidylethanolamine (PE) acting as a linker influencing formation 
and elongation of the phagophore membrane (Xie and Klionsky, 2007). The Atg5 complex can 
also promote incorporation of Atg8-PE (MAP1LC3 in mammals) into autophagosomes, which 
can then promote closure of autophagosomes as well as cargo recruitment. LC3 is synthesized 
in the pro-LC3 form, cleaved by Atg4b to produce LC3-I, and then conjugated to PE to form 
LC3-II which is required for membrane elongation and closure to form mature autophagosomes 
(Behrends et al., 2010; Yang and Klionsky, 2010b). LC3-II localizes selectively to forming and 
newly formed autophagosomes, thus it is often used as an autophagosomal marker.  
 Because it is known that most of the autophagy core machinery is required for 
mitophagy, studies have tried to discern how discrimination is introduced for selective 
autophagy in yeast (Itakura et al., 2012; Kanki et al., 2010). Nearly 40 genes found to be 
essential for mitophagy but not autophagy were identified, including Atg11 and Atg32, thought to 
function as adaptors between the mitochondria and Atg8 (LC3C) thus bridging the selected 
organelle and the canonical autophagy machinery (Kanki et al., 2009; Kanki et al., 2010). 
Though no homologs have been found in higher eukaryotes, possible functional homologs have 
been identified. The ubiquitin-binding adaptor protein p62 (SQSTM1) accumulates on damaged 
mitochondria and may aid in recruitment of mitochondria to the autophagosome by binding to 
LC3, though it does not appear to be essential for mitophagy (Geisler et al., 2010; Narendra et 
al., 2010a). Another known mitophagy adaptor is Nix (also known as BNIP3L), a mitochondrial 
protein, which is required for programmed mitophagy during reticulocyte maturation (Sandoval 
et al., 2008; Schweers et al., 2007). Nix directly binds LC3, possibly serving the function of both 
Atg11 and Atg32. The autophagy interactor is NBr1, which can cooperate with p62 and Nix, and 
is essential for pexophagy, the selective autophagy of peroxisomes, plays no known role in 
mitophagy as yet (Deosaran et al., 2012; Kirkin et al., 2009; Lamark et al., 2009).Some also 
consider PARKIN to be a mitophagy receptor, however, it is more likely that PARKIN serves to 
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designate damaged mitochondria for removal via attachment of ubiquitin, which is then 
recognized and targeted by ubiquitin-binding autophagy receptors. 
1.7.6 PARKIN targets damaged mitochondria for removal by mitophagy 
Though mitochondria were first seen in autophagosomes in the 1950s, this degradation 
was thought to be a general response to cellular stress or starvation (Yang and Klionsky, 
2010a). While mitophagy does occur to regulate mitochondria size and number under steady-
state conditions, it is also utilized by the cell to eliminate sperm-derived mitochondria after 
fertilization and during the process of erythrocyte maturation (Al Rawi et al., 2011; Sandoval et 
al., 2008). Because both the dopaminergic neurons of the substantia nigra appear to be 
especially sensitive to mitochondrial damage and genes found mutated in PD appear to play a 
role in mitochondrial quality control, mitophagy is being more thoroughly examined. Upon injury, 
mitochondria cannot maintain the electric potential gradient across the inner membrane, 
resulting in depolarization, a state which can be achieved through aberrant protein activity or the 
use of numerous drugs, such as CCCP or rotenone, treatment with which has been shown to 
reproduce features of Parkinson's disease in animal models (Betarbet et al., 2000; Sherer et al., 
2003). Furthermore, mitophagy in yeast can be activated by mutations that diminish the 
electrochemical gradient across the inner membrane (Nowikovsky et al., 2007; Priault et al., 
2005). Upon PINK1 stabilization at the mitochondrial outer membrane (MOM) after 
depolarization, PARKIN, normally a soluble cytosolic protein, is recruited to the MOM, in a 
PINK1-kinase dependent manner (Figure 1.4c). Subsequently, the damaged mitochondria are 
extensively decorated with ubiquitin, a process requiring PARKIN E3 ligase activity, thus 
selectively targeting damaged mitochondria for degradation via mitophagy (Matsuda et al., 
2010; Narendra et al., 2008). 
More specifically, it has been shown in HeLa cells expressing exogenous PARKIN that 
upon mitochondrial depolarization, PARKIN is recruited to the mitochondria in under an hour 
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and mitochondria are ultimately cleared from the cell by selective autophagy at around 24 hours 
post-drug (Geisler et al., 2010; Narendra et al., 2008). PINK1 kinase activity is required; 
however, membrane localized PINK1 may be sufficient to induce selective autophagy since 
PINK1 targeted to peroxisomes and lysosomes was able to recruit PARKIN and trigger the 
pathway (Lazarou et al., 2012). Thus, it is unclear whether selectivity is assured by targeting 
PINK1 via an MTS to the mitochondria or if PARKIN maintains any form of substrate specificity. 
So far, the best understood PARKIN substrates are MFN1/2 and RHOT1/2 (also called 
MIRO1/2), two MOM-tethered GTPases whose PARKIN-dependent proteasome turnover alters 
fission-fusion cycles and microtubule-dependent trafficking of mitochondria, respectively 
(Narendra et al., 2012; Tanaka et al., 2010; Wang et al., 2011b). The MOM porin proteins 
VDAC1/2/3 are also ubiquitylated by PARKIN, and are required for PARKIN localization on 
mitochondria through a poorly understood mechanism (Sun et al., 2012) Proteomic studies of 
purified mitochondria have also identified additional proteins whose abundance is either 
decreased or increased upon PARKIN activation or depolarization, but precisely how these 
proteins are regulated and the extent to which ubiquitin is involved is unclear (Chan et al., 
2011). At this point, we do not have a comprehensive understanding of cellular PARKIN targets, 
which will be critical for elucidating how PARKIN promotes mitochondrial homeostasis. 
An obvious role for PARKIN and PINK1 in maintaining a healthy population of cellular 
mitochondria is through sequestration of damaged organelles by regulation of fusion/fission 
cycles and trafficking. As mitochondrial homeostasis involves continuous cycles of fusion and 
fission which result in mixing of membranes and contents, any event which affects mitochondria 
may have implications for the entire mitochondrial population (Detmer and Chan, 2007; 
Okamoto and Shaw, 2005). Fusion and fission are controlled by separate members of a family 
of conserved GTPases. Dynamin-related protein 1 (Drp1) is a dynamin-like GTPase which 
oligomerizes into ring-like structures around the outer membrane of mitochondrial tubules, then 
constricts and severs the mitochondria (Okamoto and Shaw, 2005). Fission requires slightly 
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more machinery in order to fuse both the inner and outer mitochondrial membranes. Mitofusin 1 
and 2 (Fzo in yeast) are the only conserved outer membrane proteins involved in fusion (Liesa 
et al., 2009). In order to promote fusion, mitofusins on adjacent mitochondria form homotypic 
and heterotypic complexes that tether the mitochondria ultimately leading to full fusion (Chen et 
al., 2003). Optic atrophy 1 (Opa1) (Mgm1 in yeast) is required for fusion of the inner 
mitochondrial membrane. An extremely important consequence of fusion and fission is the 
distribution of mtDNA and proteins throughout the mitochondrial network (Detmer and Chan, 
2007). Though ubiquitination of the mitofusins and their removal from the MOM by p97 may help 
to sequester damaged mitochondria by preventing re-fusion with the healthy network, evidence 
suggests that this process is more complicated and studies have shown that in MFN-null MEFs, 
mitophagy is still completely blocked by proteasome inhibitor, indicating that degradation of 
additional proteins is essential for mitophagy caused by Parkin activation (Chan et al., 2011; 
Tanaka et al., 2010). It is possible that degradation of other outer membrane proteins, such as 
RHOT1, may also be necessary – in the case of RHOT1, degradation appears to halt axonal 
trafficking of damaged mitochondria, possibly another step in sequestration before removal.  
A recent study using a quantitative proteomic approach found a significant increase in 
both Lys48- and Lys63-linked polyubiquitin chains on depolarized mitochondria of HeLa cells 
overexpressing PARKIN (Chan et al., 2011). How PARKIN can direct two different chains 
linkages and which substrates receive each type of linkage is still a mystery. As expected, total 
levels of MFN1, MFN2, RHOT1 (Miro1), and RHOT2 (Miro2) decreased, supporting the notion 
that decreased MFN1/2 and RHOT1/2 protein levels can alter both mitochondrial dynamics and 
transport. However, proteasomal degradation of MOM proteins appears to be essential for the 
progression of PARKIN-dependent mitophagy as evidenced by proteasome inhibition, which 
blocks mitophagy (Chan et al., 2011; Yoshii et al., 2011). However, even in the absence of 
MFN1/2 tested using null mouse embryonic fibroblasts (MEFs), mitophagy was not impeded, 
suggesting that these are nonessential determinants in the progression of mitophagy. 
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Alternatively, it is possible that widespread, potentially nonspecific ubiquitination of 
mitochondrial proteins facilitates mitophagy by remodeling the MOM in bulk in response to 
depolarization (Sun et al., 2012; Tanaka et al., 2010). Ultimately this proteasome-mediated 
degradation coupled with nondegradative ubiquitin signals which presumable attract ubiquitin-
binding proteins that recruit the autophagy machinery, somehow selectively to the mitochondria. 
1.8 Unanswered questions in PINK1 and PARKIN-mediated mitophagy 
Though great progress has been made in deconstructing the intricacies of the 
autophagic clearance of mitochondria, clearly there must be numerous players and steps in the 
pathways that are yet to be discovered. Though both PARKIN and PINK1 have been shown to 
be required for mitophagy, it is yet unknown how these proteins selectively target mitochondria 
for autophagic degradation. The ubiquitination of mitochondrial proteins is clearly important, but 
the topology of the ubiquitin linkages and control of the ultimate recruitment of the 
autophagosome is still a mystery. The extent to which proteasomal degradation of PARKIN 
substrates versus recruitment of ubiquitin binding proteins to relevant ubiquitylated substrates is 
critical for mitophagy requires examination. Numerous early studies have proposed candidate 
PARKIN substrates, though many of these have not been reliably substantiated. However, more 
recent work is beginning to define some highly validated PARKIN substrates, though not clearly 
the ones important to mitophagy.   
Proteomic studies of purified mitochondria have also identified additional proteins whose 
abundance is either decreased or increased upon PARKIN activation or depolarization but 
precisely how these proteins are regulated and the extent to which ubiquitin is involved is 
unclear (Chan et al., 2011). We do not have a comprehensive understanding of cellular PARKIN 
targets, which is critical for elucidating how PARKIN promotes mitochondrial homeostasis, nor 
how PARKIN and PINK1, together with the proteasome, sculpt the MOM proteome to alter 
mitochondrial fate. Moreover, for the vast majority of E3s, including PARKIN, the extent to which 
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ubiquitin transfer is site-specific and signal-dependent is largely unknown, and we do not have a 
global understanding of site-specificity across a wide range of substrates for a single E3. Such 
information, however, is necessary for decoding the topology of E3 function and for defining 
how the ubiquitin system re-sculpts the proteome. 
A number of mysteries remain to be solved. For example, to what extent does PARKIN 
activate mitophagy by causing the degradation of MOM proteins or by ubiquitylating proteins on 
the mitochondrial surface? How do PINK1 and PARKIN interact with one another and with 
substrates on the mitochondrial surface to cause mitophagy? Is PARKIN-mediated 
ubiquitination required for mitophagy? Which targets and modes of ubiquitination are implicated 
in this process? Do certain PARKIN targets trigger mitophagy? How are autophagosomes 
directed selectively to mitochondria?  
We set out to systematically identify cellular PARKIN-dependent ubiquitylation targets 
and the dynamics of modification in a site-specific manner using quantitative diGly (QdiGly) 
proteomics and synthetic isotopic labeling with amino acids in culture (SILAC) to identify 
ubiquitylation sites that are dynamically induced upon mitochondrial depolarization. The diverse 
list of PARKIN substrates identified in the past implicates PARKIN in a range of cellular 
pathways, though confirmation or reproducibility of many substrates has been unsuccessful or 
conflicting. Therefore, identification of true PARKIN substrates and interactors and how these 
change in the presence of disease mutants is essential in order to gain real insight into the 
development of PD. PARKIN has been shown to ubiquitylate some proteins on the MOM, 
however, the complete PARKIN-dependent ubiquitylome remains poorly defined. We applied 
large-scale quantitative diGlycine capture proteomics to identify PARKIN-dependent 
ubiquitylation upon mitochondrial depolarization. We identified hundreds of ubiquitylation sites in 
dozens of proteins, many of which are located at the mitochondria, illustrating PARKIN’s 
capacity to radically remodel the ubiquitylation status of the mitochondrial proteome. We used 
parallel complementary interaction proteomics to further explore the roles of both PARKIN and 
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PINK1 in mitochondrial homeostasis. We found that PARKIN physically associated with a 
reproducible assembly of MOM proteins, many of which were also ubiquitylation targets, upon 
mitochondrial depolarization. Interactions with potential autophagy receptors and the 
proteasome were also wholly dependent upon mitochondrial damage. To understand the 
significance of our findings, we mapped ubiquitylation sites onto available protein structures 
highlighting PARKIN’s role at the MOM and the evolutionary conservation of ubiquitylation sites. 
In sum, our studies illuminate PARKIN and PINK1 modify the proteome to maintain 
mitochondrial homeostasis.  
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CHAPTER 2 
Global profiling of the PARKIN modified proteome in response to mitochondrial 
depolarization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: Sarraf SA, Raman M, Guarani-Pereira V, Sowa M, Huttlin EL, Gygi SP, Harper JW. 
Landscape of the PARKIN-dependent ubiquitin modified proteome in response to mitochondrial 
depolarization. Nature. 2013 Apr 18;496(7445):372-6. doi: 10.1038/ nature12043. Epub 2013 
Mar 17. 
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Chapter 2: Contributions 
Figure 2.13 Validation of PARKIN interactors identified via interaction proteomics. Experiments 
performed by Virginia Guarani-Pereira. 
Figure 2.18 Web-tool for interrogation and structural analysis of candidate PARKIN targets. 
Web tool designed and constructed by Mathew Sowa. 
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2.1 Introduction 
Parkinson’s disease is a degenerative disorder of the central nervous system resulting from the 
cumulative loss of dopaminergic neurons, the distinct causes of which are not fully understood. 
Defects in mitochondrial homeostasis have been well documented for many years, and appear 
to be common to both sporadic and genetic PD (Dawson and Dawson, 2010). In this scenario, 
mechanisms that serve to remove damaged mitochondria from cells may be defective thus 
selectively harming neurons, cells which maintain a high metabolic load. Ultimately, it is thought 
that this accumulated damage, which occurs as a result of defects in mitochondrial 
homeostasis, may induce cell death. The protein kinase, PINK1, and the E3 ubiquitin ligase, 
PARKIN, are both found mutated in early onset familial PD and act in the same pathway to 
regulate mitochondrial homeostasis (Narendra et al., 2008). Both proteins appear to be vital in 
the regulation of mitochondrial quality by directing degradation of damaged mitochondria via 
mitophagy. It has been shown that the kinase activity of PINK1 and the E3 ligase activity of 
PARKIN are both essential to this process; however, the molecular workings of numerous 
aspects of the pathway and the underlying mechanisms are poorly understood. One very 
important aspect of the pathway about which little is known is how the ubiquitin signal generated 
by PARKIN on damaged mitochondria is translated into a signal which activates and recruits 
autophagy machinery. Thus, to begin exploration of this question, we surveyed the effects of 
PARKIN activation using a variety of proteomic and cell biological approaches. 
Based on previous studies, we know that ubiquitination at the mitochondria after damage 
is both PARKIN-dependent and necessary for mitophagy (Narendra et al., 2009). In spite of 
years of work, many aspects of this pathway remain poorly understood. While a number of 
substrates have been identified for PARKIN, the full repertoire of PARKIN targets on the 
mitochondria as well as the effect of ubiquitination on the fate of individual substrates, are 
largely unknown. In fact, the actual physiological substrates of PARKIN’s ubiquitin ligase activity 
important for its quality control functions remain poorly defined, and in some cases controversial 
 
 
40 
 
(Dawson and Dawson, 2010). How PARKIN together with the proteasome sculpts the 
mitochondrial outer membrane proteome to alter mitochondrial fate remains one of the most 
pressing questions for the field. To explore these issues, we utilized proteomic approaches and 
numerous cell biological approaches in an attempt to provide a systematic and definitive 
understanding of the PARKIN-modified proteome. Our ultimate goal was to contribute 
information about how the PINK1-PARKIN pathway remodels the MOM proteome to control 
mitochondrial fate. To this end, we performed an unbiased quantitative proteomics analysis of 
cellular proteins that are ubiquitylated in response to mitochondrial damage in a PINK1-
PARKIN-dependent manner. This analysis revealed hundreds of candidate ubiquitylation sites 
in dozens of MOM and cytoplasmic proteins, including both novel and previously identified 
PARKIN substrates. Together with interaction proteomic studies and analysis of PARKIN 
disease mutants, these studies have provided the first integrated topological view of how the 
PARKIN pathway re-sculpts the MOM of damaged mitochondria. We believe our efforts provide 
the first systematic compendium of PARKIN targets as a resource for the Parkinson’s disease 
field. And we hope it can contribute to the understanding of the physiological functions of 
PARKIN in cells experiencing oxidative stress, for example as a consequence of aging or 
mitochondrial malfunction, and potentially provide targets or mechanisms which will aid in PD 
drug discovery. 
2.1.1 Complementary integrative proteomic approaches to study PARKIN and PARKIN 
targets 
In order to better understand PARKIN’s role in modifying damaged mitochondria and 
effecting its removal, we have used two complementary approaches, an interaction proteomics 
method developed in our lab to identify high-confidence candidate interaction proteins (HCIPs) 
and quantitative diGlycine (diGly) capture proteomics coupled with stable isotope labeling of 
amino acids in culture (SILAC) and liquid chromatography-mass spectrometry (LC-MS) to 
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determine specific targets of PARKIN ubiquitination after mitochondrial damage. These methods 
allow us both to identify substrates of PARKIN in response to mitochondrial depolarization as 
well as to determine those proteins with which PARKIN interacts, thus clarifying potential 
enzymatic partners, regulators, or substrates. This comprehensive approach allows us to 
examine multiple players in the pathway and to evaluate both their regulation and their targets. 
Furthermore, we demonstrate that quantitative diGly capture proteomics can be used to identify 
substrates for a single E3 ubiquitin ligase. 
Quantitative diGlycine (diGly) capture proteomics 
Historically, identifying targets of ubiquitylation has been very challenging. The ubiquitin 
modification is relatively large, at ~8800 Daltons (Da), when compared to other post-
translational modifications, such as phosphorylation, which adds only 80 Da to the mass of a 
protein. Furthermore, because ubiquitylation is often a signal for degradation of the modified 
protein, the turnover of ubiquitylated proteins is often very rapid, making it difficult to capture 
and detect modified proteins under steady-state conditions. Most studies have relied on either 
the use of ubiquitin binding domains, antibodies or overexpression of epitope-tagged ubiquitin in 
an attempt to capture ubiquitylated proteins for identification by mass spectrometry. Attempts to 
identify the total cellular ubiquitylome or changes in response to various stimuli, though have 
had limited success actually identifying or quantifying peptides containing a ubiquitin 
modification (Table 2.1) (Argenzio et al., 2011; Danielsen et al., 2011; Matsumoto et al., 2005; 
Meierhofer et al., 2008; Peng et al., 2003; Tagwerker et al., 2006). In most studies, tagged 
ubiquitin has been overexpressed in cells, after which ubiquitin is usually immunoprecipitated, 
thus allowing identification of the modified peptide. Though substrates have been identified 
using this method, we cannot be sure that modification and substrates found in the presence of 
overexpressed epitope-tagged ubiquitin truly represent endogenous circumstances. There is a 
concern that the excess ubiquitin may disrupt endogenous ubiquitin modification pathways to 
some degree and the extent to which overexpression may affect the occupancy and specificity  
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of ubiquitylation is unclear. Even with the application of these methods by numerous groups, the 
overall number of modification sites identified is small, particularly in comparison to the extent of 
acetylation and phosphorylation identified (Choudhary et al., 2009; Huttlin et al., 2010). This 
leaves us with the question, what are the endogenous sites of modification? 
Early work performed using tagged ubiquitin demonstrated that ubiquitin site identification is 
aided by the presence of a Gly-Gly remnant which is present as an isopeptide linkage with 
lysine residues in ubiquitylated proteins. This characteristic can be used diagnostically to 
identify ubiquitylated peptides by mass spectrometry (Peng et al., 2003). The Gly-Gly remnant is 
created by trypsin proteolysis of a ubiquitin-conjugated protein producing the two amino acid 
signature peptide at the ubiquitination site which is derived from the C-terminus of ubiquitin 
(Figure 2.1).  The Gly-Gly remnant remains covalently attached to the target lysine residue via 
an isopeptide bond and results in a mass shift at the lysine residue of 114.1 Da as well as a 
missed proteolytic cleavage because trypsin proteolysis cannot occur at the modified lysine. 
Peng et al. demonstrated the utility of these signature peptides by using them to identify 
Table 2.1 Identification of ubiquitin sites by mass spectrometry. Previous studies have 
predominantly relied upon exogenous expression of epitope-tagged ubiquitin. 
 
Organism Method Proteins Sites Study 
     
Yeast His-Ub 1075 110 (Peng et al., 2003) 
HEK293 His-Ub 22 4 (Kirkpatrick et al., 2005b) 
HEK293T Ub-antibody 670 18 (Matsumoto et al., 2005) 
Yeast HB-Ub 258 20 (Tagwerker et al., 2006) 
Liver cells GST-UIM 83 19 (Tan et al., 2008) 
HeLa HB-Ub 669 44 (Meierhofer et al., 2008) 
HeLa, Mouse Fibroblast Ub-antibody, Flag-His-Ub 1472 31 (Argenzio et al., 2011) 
U2OS – HEK293T Strep-HA-Ub 5756 753 (Danielsen et al., 2011) 
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epitope-tagged ubiquitin conjugates in yeast with mass spectrometry (Peng et al., 2003). Even 
with this precise and sensitive technique, the low occupancy of ubiquitylation makes detection of 
endogenously modified proteins extremely challenging in the absence of overexpression of 
either ubiquitin or substrate. 
Another challenge is the ability to detect substrates for a single E3 ubiquitin ligase. To date, 
the majority of E3 substrates have been identified based on a physical interaction between the 
E3 and the substrate followed by mutational analysis to identify candidate ubiquitylation sites in 
the targets. Often, both affinity techniques and bioinformatics approaches used to discover 
ligase substrates are unsuccessful both because substrates are not abundant and because 
affinity of ligase for the substrates is likely to be low. Furthermore, recognition elements in 
substrates are often poorly defined and may not be conserved, thus minimizing the probability 
that bioinformatic approaches will consistently identify E3 substrates. However, these 
approaches have worked fairly reliably on a small scale but do not always provide a direct route 
to the actual sites of endogenous ubiquitylation in vivo, due to the possibility of cryptic sites or 
 
Figure 2.1 Generation of the diGly remnant enables antibody-based capture of endogenous 
ubiquitylated proteins. Proteolysis with trypsin produces the unique diGly signature peptide which is 
then recognized by an antibody allowing quantitative examination of alterations in the ubiquitinome. 
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artifactual effects of overexpression. Furthermore, confirmation of the ubiquitylation of these 
substrates and identification of the modified sites has lagged further behind. Our study provides 
evidence that diGly capture proteomics can be used to identify substrates of a single E3 ligase 
in vivo. Unlike most previous approaches aimed at identifying ubiquitylated proteins which have 
relied on exogenously expressed tagged ubiquitin, our system relies on antibody-based capture 
of endogenous diGly-containing peptides to quantitatively monitor alterations in the ubiquitylome 
in response to mitochondrial depolarization and PARKIN activation (Figure 2.1).  
Our goal was to globally monitor changes in the ubiquitylated proteome after PARKIN 
activation; in order to address this question in the context of the limitations detailed above, we 
used a newly developed approach to enrich for and identify ubiquitylated peptides. Combination 
of a monoclonal antibody that specifically recognizes the diGly remnant of ubiquitylated proteins 
resulting from trypsinolysis with metabolic labeling in cell culture allowed us to identify and 
quantify ubiquitylated proteins and their sites of modification on a global scale. Using this 
method, a recent study was able to identify roughly 19,000 ubiquitylation sites in nearly 5000 
proteins in the process of monitoring temporal changes in diGly site abundance in response to 
proteasome inhibition, thus creating an extraordinary resource for the identification and 
classification of ubiquitin-modified lysine residues in both known UPS substrates and newly 
identified substrates (Kim et al., 2011). Using a similar approach with a different antibody, 
another group was able to map 11,000 endogenous ubiquitylation sites on more than 4,000 
human proteins, thus confirming the efficacy of the method (Wagner et al., 2011). Compared to 
previously used methods, such as western blotting or other MS-based approaches, our 
approach provides several advantages for ubiquitylation site mapping. For example, we are able 
to perform an efficient single-step enrichment for ubiquitylated peptides which enables the 
detection of low abundant modification sites. Furthermore, this method allows deep sampling 
and quantification of a proteome-wide analysis of endogenous ubiquitylation. 
 
 
45 
 
Deeper examination of the data produced from these studies shows that while they produce 
vast datasets consisting of endogenous ubiquitylation sites, the degree of overlap between 
biological duplicates is not necessarily as high as might be expected; however, amongst those 
sites repeatedly sampled, correlation of the fold-change in modification is high. Because 
previous papers published showed little success in the identification of substrates of a single E3, 
we performed preliminary experiments to determine how well the diGly approach might work for 
PARKIN (Lee et al., 2011). Due to what we expected to be the stochastic nature of the diGly 
capture, we chose to investigate an E3 which exhibits signal-dependent activity and which 
targets an abundant substrate population at the mitochondria. Through repeated sampling, we 
have identified the strengths and limitations of this technology, revealing that extensive 
sampling of the cellular ubiquitylome is required to fully populate the substrate list for a single 
E3 ligase because the diGly approach relies on antibody-based capture of substrates from the 
massive pool of ubiquitylated proteins available. Sampling of proteins from this immense pool 
results in repeated identification of abundant ubiquitylated proteins along with stochastic 
identification of less abundant ubiquitylated proteins (Figure 2.2). However, with increased 
sampling, less abundant proteins can be identified, though stochastically, meaning that a 
substantial number of peptides are identified only in a single replicate experiment. We have 
striven to circumvent the stochastic nature of the diGly approach by both repeated sampling and 
execution of multiple replicate experiments in numerous cell lines. This repeated sampling has 
allowed us to routinely capture and validate ubiquitylation sites present at high abundance while 
gradually populating the list with additional sites of lesser abundance, which we have a lower 
probability of identifying numerous times. By creating a large enough experimental pool, we are 
able to delve deeper into the substrate population to identify those lesser abundant, though truly 
ubiquitin-modified, substrates. Thus, the limitation we aimed to address is a detection limit or a 
limitation of capture, not an issue of noise or of sorting true from false identification. 
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Figure 2.2 Schematic representation of stochasticity in the diGly capture approach. 
a, Schematic displaying the basis for stochastic retrieval of low abundance peptides that 
nevertheless have high log2 (H:L) ratios in a SILAC experiment. Abundant proteins may be 
routinely sampled by diGly antibody regardless of their log2 (H:L) ratio but lower abundance 
proteins may be rarely captured, even though they may be highly regulated in response to a 
signal (log2 (H:L) ratio >3). Thus, multiple experiments may be required to substantially 
sample a wide cross section of ubiquitylation sites. b, Basis for stochastic capture of peptides 
across biological replicates, with peptides from abundant proteins being detected routinely 
whereas peptides for low abundance proteins are only captured within a subset of 
experiments. 
 
 
 
 
 
 
47 
 
Affinity-purification mass spectrometry (AP-MS) to determine PARKIN interactors 
Direct interrogation of physiological protein complexes can be achieved through 
interaction proteomics. Typically, this approach entails purification of a protein of interest and 
identification of co-purifying proteins or complexes via liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). A major pitfall of this approach is that a large number of nonspecific 
interacting proteins typically dominate the mass spectral analysis of purified complexes (Ewing 
et al., 2007). Our lab has sought to address this issue through the creation of a proteomic 
analysis software platform, termed CompPASS, which employs an unbiased comparative 
approach to identify high-confidence candidate interacting proteins from the hundreds of 
proteins typically identified in and AP-MS experiment. Any potential interactors then identified 
are then scored based on abundance, uniqueness, and reproducibility in order to pull out the 
true interactors (Sowa et al., 2009).  Using this method, we performed a series of studies to 
complement the quantitative proteomics approach described above. We examined interactors of 
PARKIN in the presence or absence of mitochondrial depolarization to identify depolarization-
dependent high confidence candidate HA-PARKIN-interacting proteins in numerous cell lines. 
We found depolarization-dependent PARKIN association with numerous MOM targets, 
autophagy receptors, and the proteasome in a manner that required the active site of PARKIN. 
We also examined a series of mutations found either in patients with PD or designed to affect 
PARKIN activation and dynamics. 
Integration of the quantitative and interaction proteomic methods together with cell biological 
studies has allowed us to perform a series of studies that have revealed the PARKIN-modified 
proteome, including hundreds of ubiquitylation sites on dozens of proteins, including known and 
novel targets. Using these methods, we have identified approximately 10,000 ubiquitylation sites 
in more than 2,000 proteins. Many of these candidate PARKIN targets are located on the MOM, 
where all sites identified are located on the cytoplasmic face, while other substrates identified 
are thought to be primarily cytoplasmic. Parallel interaction proteomic and in vivo functional 
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studies revealed signal dependent association of PARKIN with a cohort of MOM proteins in a 
manner that depends upon functionality of the active site of PARKIN. Our data suggest that 
PARKIN interacts with and promotes the site-specific ubiquitylation of numerous mitochondrial 
and cytoplasmic proteins, thereby extending previous studies examining abundance of 
mitochondrially-enriched proteins, thus allowing us to place candidate PARKIN-dependent 
ubiquitination targets into a structural and functional framework. This global and quantitative 
examination of proteins targeted for ubiquitylation after mitochondrial depolarization provides a 
dynamic readout of how the entire proteome is remodeled in response to this form of cellular 
stress as well as the identification of substrates for an individual E3 ligase implicated in multiple 
devastating diseases. 
2.2 Results 
2.2.1 PARKIN is recruited to depolarized mitochondria resulting in clearance via 
mitophagy 
To begin our investigation of the global effects of PARKIN activation, we sought to confirm 
previously published work describing the translocation of PARKIN to mitochondria after CCCP-
induced mitochondrial depolarization and resultant mitophagy. Therefore, we created stably 
expressed N-HA-FLAG-PARKIN HeLa cell lines in which we observed a shift from cytoplasmic 
to mitochondrial-associated PARKIN and extensive colocalization with TOMM20, a 
mitochondrial outer membrane protein, after 1 hour of CCCP treatment (Figure 2.3a) which we 
confirmed using transiently expressed N-GFP-PARKIN in HeLa cells (Figure 2.3b). 
Furthermore, upon PARKIN translocation, the mitochondria are extensively labeled with 
ubiquitin, which we confirmed using multiple antibodies to detect endogenous ubiquitin as well 
as an HA-ubiquitin construct (Figure 2.3c, d). Almost complete colocalization of PARKIN on  
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Figure 2.3 Mitochondrial depolarization results in translocation of PARKIN to the 
mitochondria and mitochondrial ubiquitylation. a, N-HA-Flag-PARKIN stably expressed in 
HeLa cell line treated with 10µM CCCP for various time points immunostained for HA-
PARKIN (green) or a mitochondrial marker, TOMM20 (red). b, N-GFP-PARKIN transfected 
HeLa cells treated with 10µM CCCP for various time points immunostained with anti-
TOMM20 (red). The white boxes highlight GFP-PARKIN expressing cells with decreased 
levels of mitochondria. c, Stably expressed GFP-PARKIN HeLa cell line stained with anti-FK1 
to detect colocalization of PARKIN with endogenous ubiquitin after 1 hour of 10µM CCCP 
treatment. d, Stably expressed GFP-PARKIN colocalizes with HA-ubiquitin (red) after 1 hour 
10µM CCCP. 
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clustered mitochondria and endogenous or tagged ubiquitin could be detected after as little as 
one hour (Figure 2.3c, d). 
To verify that the mitochondria were being removed from cells via mitophagy, we treated 
transiently transfected HeLa cells with GFP-PARKIN or stable N-HA-FLAG-PARKIN and treated 
with CCCP for 1, 2, 18, and 24 hours. As expected, GFP-PARKIN translocated to the 
mitochondria within 1 hour of CCCP treatment and was still visible at 6 hours post-drug (Figure 
2.3b). However, by 18 hours, though some GFP-PARKIN foci were still observable, the amount 
of signal was decreased. Furthermore, mitochondrial staining of TOMM20 also decreased in 
those cells transfected with GFP-PARKIN and by 24 hours, mitochondrial mass appeared to be 
significantly reduced (Figure 2.3b). To confirm that the removal of mitochondria occurred via 
autophagy, we treated cells with Bafilomycin A (BafA), which prevents maturation of autophagic 
vacuoles by inhibiting fusion between autophagosomes and lysosomes. Upon BafA treatment 
for 6 or 24 hours, we observed an increase in the number of cells containing mitochondrial GFP-
PARKIN and ubiquitin foci when compared to untreated cells, suggesting that the loss of 
mitochondrial from these cells was indeed through an autophagic mechanism (Figure 2.4).  
2.2.2 Quantitative profiling of the PARKIN-modified proteome 
We set out to systematically identify and quantify cellular PARKIN-dependent 
ubiquitylation targets and the dynamics of modification in a site-specific manner using 
quantitative diGly (QdiGly) capture proteomics. QdiGly merges antibody-based capture of “diGly 
remnant” containing peptides and SILAC to identify ubiquitylation sites that are dynamically 
induced, in this case, upon mitochondrial depolarization. To overcome the inherent stochasticity 
of diGly capture and ensure that we sampled low abundance ubiquitylated peptides, we 
designed a 3-tiered approach in which we performed 73 independent QdiGly profiling 
experiments using 4 different cell lines allowing us to compare the effects of endogenous and 
overexpressed PARKIN which we used in order to increase the ability to detect mechanistically 
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relevant ubiquitylation sites (Figure 2.5, Supplementary Table 1). We used 2 epithelial cell lines, 
HCT116 and HeLa, and one neuronal, SH-SY5Y, which has commonly been used to model PD 
in the past (Borland et al., 2008; Lopes et al., 2010; Xie et al., 2010). Both HCT116 and SH-
SY5Y cells express low levels of endogenous PARKIN while HeLa cells do not express any 
PARKIN due to a chromosomal rearrangement (Figure 2.6a-c) (Denison et al., 2003). Tier 1 
consisted of the epithelial colon cancer-derived HCT116 cell line stably expressing HA- FLAG-
PARKIN (HCT116PARKIN) at levels approximately 10-fold greater than endogenous, the 
expectation being that elevated PARKIN levels would allow us to identify mechanistically 
relevant ubiquitylation events that might otherwise not be detectable with lower levels of signal 
seen physiologically (Figure 2.5, Figure 2.6a). Tier 2 examined HeLa cells with or without 
lentiviral- expression of HA-FLAG-PARKIN (HeLaPARKIN) to formally identify PARKIN-dependent 
ubiquitination events among those found globally with depolarization (Figure 2.5, Figure 2.6b,c). 
 
Figure 2.4 Mitochondria are removed from PARKIN-expressing cells via mitophagy. a, 
HeLa GFP-PARKIN cell line treated with 10uM CCCP and/or 50nM BafA for 0, 6, 0r 24 hours. 
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Tier 3 identified ubiquitylation events in HCT116 and SH-SY5Y cells expressing endogenous 
PARKIN, thus serving to validate sites found to be PARKIN-dependent in HeLaPARKIN cells, and 
depolarization dependent in HCT116PARKIN cells (Figure 2.5, Figure 2.6a,c). Using this SILAC-
based tiered system, we examined the log2 ratio of Heavy:Light (H:L) diGly-containing peptides 
in cells with or without the addition of the uncoupling agent carbonyl cyanide 3-
chlorophenylhydrazone (CCCP). In order to increase the likelihood of detecting ubiquitylated 
peptides, turnover was blocked by proteasome inhibition with bortezomib (Btz) or autophagy 
inhibition with BafA in some instances (Supplementary Table 1). This approach allowed us to 
identify both potential substrates of PARKIN in response to mitochondrial depolarization as well 
as the modified lysine(s) within the substrates. 
Using this approach, we generated a comprehensive list of mitochondrial depolarization-
dependent PARKIN-modified proteins, identifying a total of 10,287 non-redundant sites of 
ubiquitylation in 2268 proteins and quantifying 7821 sites in 2116 proteins across all cell lines 
(Figure 2.7a, Supplementary Table 2). From the 34 Tier 1 control and QdiGly profiling 
 
 
Figure 2.5 Experimental scheme for QdiGly proteomics to determine PARKIN-dependent 
ubiquitylation.  
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experiments performed in HCT116PARKIN cells, we identified 6934 sites in 1993 proteins, 
quantifying 4772 sites, in 1654 proteins (Figure 2.7a, Supplementary Table 2). Though we 
performed experiments at multiple time points, we have mainly compared one hour of 
CCCP/Btz treatment across cell lines. In 18 experiments using HCT116PARKIN cells treated for 1 
hour with CCCP/Btz, we quantified 443 ubiquitylated sites (261 proteins) with a H:L log2 ratio 
greater than or equal to 1.0, which represents a 2-fold increase in ubiquitylation status in at least 
one experiment (Figure 2.7a-c). Comparison of two representative experiments displayed a 
Pearson’s correlation of 0.69, suggesting a good deal of overlap between experiments (Figure 
2.7d); similar overlap was observed among biological replicates in HCT116PARKIN cells (Figure  
 
 
Figure 2.6 Characterization of PARKIN expression in cell lines employed in this 
study. Extracts from the indicated cell lines were subjected to SDS-PAGE and 
immunoblotting with anti-PARKIN antibodies. a, Determination of the relative levels of 
PARKIN in SH-SY5Y, HCT116, and HCT116PARKIN cell lines. b, Characterization of N-HA-
FLAG-PARKIN expression in 293T and HeLa cells used for interaction proteomics. c, 
Demonstration of MFN2 ubiquitylation in HeLaPARKIN cells used for QdiGly profiling. d, 
Demonstration of MFN2 ubiquitylation in SH-SY5Y cells used for QdiGly profiling. *, 
PARKIN breakdown product. 
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Figure 2.7 QdiGly proteomics of the PARKIN-dependent ubiquitin modified proteome. a, diGly 
sites identified and quantified across 73 experiments. FDR, false discovery rate. b, log2(H:L) plots 
for quantified diGly peptides for HCT116PARKIN (experiment 17) or HeLaPARKIN (experiment 57) cells. 
c, Distribution of ubiquitylation sites (log2(H:L) ≥ 1) and proteins identified up to 6 times across 18 
independent HCT116PARKIN QdiGly experiments (1h 10µM CCCP, 1µM Btz). d, Pearson’s 
Correlation plots for 2 representative QdiGly experiments from HCT116PARKIN cells (left panel) and 
HeLaPARKIN cells (right panel). e, Overlap of ubiquitylation sites found in the three deepest sampling 
data sets of HCT116PARKIN biological replicates (1 h 10µM CCCP, 1µM Btz) (Supplementary Tables 
1, 2). f, Overlap between ubiquitylation sites and proteins for the various extended time point 
HCT116PARKIN QdiGly profiling experiments and the HCT116PARKIN 1h QdiGly profiling experiments. 
See Table S1 for conditions of the extended time course experiments. g, Heatmap of Log2(H:L) 
values for selected diGly peptides from untreated HCT116PARKIN cells at 1 and 8 h post CCCP 
treatment. Data are shown for those peptides that were quantified at both time points and in which 
at least one time point had a log2(H:L) value ≥1.0. h, Overlap of ubiquitylation sites in HeLaPARKIN 
biological triplicates (1 h 10µM CCCP, 1µM Btz). i, Overlap between triplicate QdiGly profiling 
experiments in SH-SY5Y cells (1 h 10µM CCCP, 1µM Btz). 
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Figure 2.7 (Continued) 
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Figure 2.7 (Continued) 
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2.7e). In sixteen additional Tier 1 experiments with depolarization treatment of up to 10 hours, 
we identified 537 non-redundant diGly sites (304 proteins), including 192 diGly sites (138 
proteins) also identified at 1h (Figure 2.7f, Supplementary Table 1). Furthermore, upon 
comparison of log2(H:L) ratios from 48 Tier 1 sites in 36 proteins at 1 and 8 h post CCCP/Btz 
treatment from parallel experiments, we found persistent or increased ubiquitylation for 34 sites 
(Figure 2.7g). 
 To differentiate between PARKIN-dependent and depolarization-dependent 
ubiquitylation events, we performed 9 control or 1 hour CCCP/Btz-treated QdiGly experiments in 
HeLa versus HeLaPARKIN cells and reversed the light and heavy amino acid labeling in these 
experiments to control for potentially inherent differences in ubiquitylation site abundance 
between heavy and light cultures that would otherwise contribute to false positives (Tier 2) 
(Figure 2.5, Figure 2.6b, c, Supplemental Table 1). As expected, depolarization induced 
ubiquitylation of MFN2 was wholly dependent on exogenous expression of PARKIN in HeLa 
cells (Figure 2.6b, c). We identified 582 PARKIN-dependent diGly peptides (303 proteins) with a 
log2 (H:L) ratio ≤ 1.0, consistent with a 2-fold increase in ubiquitylation (Figure 2.7a, b, 
Supplemental Table 2). Duplicate samples produced a Pearson’s correlation of 0.88 (Figure 
2.7d) and similarly, we saw significant overlap across biological triplicates (Figure 2.7h). 
Strikingly, 165 diGly sites (99 proteins) were common to Tiers 1 and 2 at 1 hour of mitochondrial 
depolarization (Figure 2.8a). This increased to 191 sites (144 proteins) when all Tier1 and Tier 2 
data were compared (Supplementary Table 2). We have termed the overlapping set of 
ubiquitylation sites with 1 hour of depolarization and their associated proteins as Class 1 
candidate PARKIN-dependent targets. Proteins found in both cell lines but with different sites of 
ubiquitylation are referred to as Class 2 (Supplementary Table 2). 
We set a 2-fold increase in H:L ratio as the threshold for regulated ubiquitylation; 
however, many sites of modification were induced 30 to 60-fold upon mitochondrial 
depolarization (Figure 2.8b, Supplementary Table 2), indicating highly dynamic target  
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Figure 2.8 Analysis of QdiGly proteomics to determine the PARKIN-dependent ubiquitin 
modified proteome. a, Ubiquitylation site and protein overlap between all HCT116PARKIN and 
HeLaPARKIN experiments treated with 10µM CCCP, 1µM Btz for 1 h (Tier 1). b, Log2(H:L) ratios for 
selected diGly sites from HCT116PARKIN (Ex17) and HeLaPARKIN (Ex57) (1 h 10µM CCCP, 1µM 
Btz). c, Overlap between Tier 1, 2 and 3 experiments (1 h 10µM CCCP, 1µM Btz). Venn diagram 
corresponds to diGly sites with log2(H:L) ≥ 1.0 and the corresponding proteins. Ex, experiment. 
 
modification via PARKIN. Furthermore, we found that Class 1 targets were highly enriched for 
mitochondrial proteins (p < 1.76 X 10-17) (FIGURE 2.9a). In total, 60 Class 1 and 2 targets were 
linked with mitochondria or ER-type membranes, including 36 MOM proteins (Figure 2.9b). 
Consistent with previous studies, we repeatedly identified MFN1/2, RHOT1/2 (Miro), and 
VDAC1/2/3 proteins as PARKIN substrates in numerous experiments, both suggesting the 
efficacy of our approach and providing evidence that diGly capture routinely and efficiently  
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Figure 2.9 PARKIN-dependent ubiquitylation sites revealed by QdiGly proteomics. a, Class 
1 target Gene Ontology Enrichment, determined used DAVID functional annotation enrichment 
tools. b, Class 1 sites are in black font. Additional sites found in Class 1 proteins are in red 
(HCT116PARKIN) or blue font (HeLaPARKIN). Site overlap in HCT116 and/or SH-SY5Y: magenta, 
orange, and green octagons. Dotted lines: interacting proteins. Rectangles represent Class 2 
substrates. Red or blue boxes refer to additional sites identified in either HCT116PARKIN and 
HeLaPARKIN cells (Supplementary Table 2). * and ^, protein levels decrease or increase, 
respectively, upon depolarization in a previous study by Chan et al., 2011.
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Figure 2.9 (Continued) 
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identifies those highly abundant substrates which were detectable by other methods in the past. 
However, using repeated sampling in conjunction with diGly capture, we were able to identify 
numerous additional proteins which have been impossible to distinguish in previous studies. 
Though enrichment for mitochondrial proteins was expected due to PARKIN translocation, we 
also identified numerous cytoplasmic proteins (Figure 2.9b). Of particular interest, candidate 
cytoplasmic targets included proteasome subunits, the VCP/p97 AAA ATPase, and the 
proposed autophagy adaptors (SQSTM1, CALCOCO2/NDP52, and TAX1BP1) (Figure 2.9b). 
 To validate our findings in HCT116PARKIN and HeLa PARKIN cells, we performed 22 QdiGly 
experiments using HCT116 and SH-SY5Y cells expressing endogenous PARKIN (Tier 3) 
(Figure 2.5, Figure 2.6a, c, Supplementary Table 1). By western blot, we were primarily able to 
detect only mono-ubiquitylated forms of MFN2 ubiquitylation in these cell lines upon 
mitochondrial depolarization presumably due to low levels of endogenous PARKIN (Figure 
2.6c). Out of 4,808 sites (1,645 proteins) quantified in HCT116 cells, we found a total of 838 
sites (391 proteins) whose log2 (H:L) ratios were ≥ 1.0 after mitochondrial depolarization in the 
presence of either Btz or BafA (Figure 2.7a, Supplementary Table 1, Supplementary Table 2). 
Under similar experimental conditions using SH-SY5Y cells, we quantified a total of 2687 sites 
(1120 proteins) from which 337 ubiquitylation sites in 235 proteins showed increased log2 (H:L) 
ratios (Figure 2.7a, Supplementary Table 1, Supplementary Table 2). Among biological 
triplicates in SH-SY5Y cells at 1 hour of CCCP/Btz we saw high degrees of overlap, again 
suggesting that the most abundant diGly sites are most easily reproducibly captured (Figure 
2.7i). When compared to Tier 1 and Tier 2 data sets, we found broad overlap with the Tier 3 
data (Figure 2.8c, Supplementary Table 2). Additionally, fifteen CCCP-dependent diGly sites in 
12 Class 1 or 2 PARKIN target proteins were found in both the HCT116 and SH-SY5Y cell lines. 
Individually, 29 sites in 27 Class 1 or 2 proteins were detected in SH-SY5Y cells and 27 sites in 
17 Class 1 or 2 proteins were detected in HCT116 cells (Figure 2.9b, Supplementary Table 2). 
Moreover, 124 sites identified in Tier 3 experiments were located in 29 Class 1 or 2 proteins, 
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though the sites themselves were distinct from Class 1/2 sites, possibly suggesting promiscuity 
of PARKIN targeting at the site level; regardless, Tier 3 provided extensive confirmation of many 
PARKIN-dependent diGly sites and proteins at endogenous PARKIN levels. 
 To further confirm that proteins identified via diGly capture were being ubiquitylated in a 
depolarization-dependent manner, we stably expressed a subset of C-terminally HA-Flag-
tagged substrates in HCT116 cells. We were able to confirm depolarization-dependent 
ubiquitylation of C1QBP, UQCRC2, FAF2, PHB, PHB2, VDAC3, NDUFA9, and ATP5F1 in 
HCT116 cells via immunoblotting at either 1 hour or 8 hours post-CCCP or CCCP/Btz treatment 
(Figure 2.10c). For some substrates, e.g. C1QBP, we could easily detect ubiquitylation at 1 hour 
in the presence of CCCP, regardless of Btz addition. However, for others, such as NDUFA9, we 
were unable to detect ubiquitylation at 1 hour, though the modification was detectable by 8 
hours (Figure 2.10c). For a subset of substrates, UQCRC2, C1QBP, ATP5F1, and PHB, we 
demonstrated that ubiquitylation was either greatly reduced or eliminated by RNAi-mediated 
depletion of PARKIN, suggesting PARKIN-dependent ubiquitylation (Figure 2.10a, b, d). Though 
we are able to validate PARKIN targets identified via QdiGly capture using this system, it often 
required longer time points after depolarization to detect the ubiquitylation modifications. 
Though this may at first appear to be a perplexing discrepancy, we believe this is accounted for 
by differences in sensitivity of the techniques used as well as the use of HCT116 cell lines 
expressing low levels of endogenous PARKIN which may require a longer period of time to 
produce detectable levels of ubiquitylation activity. 
2.2.3 Interaction Proteomics: PARKIN interaction is mitochondrial depolarization-
dependent 
To complement the QdiGly capture substrate identification and to determine whether PARKIN 
might stably associate with candidate substrates, we employed anti-HA affinity purification and 
mass spectrometry in 293T and HeLa cells stably expressing N-terminally tagged HA-Flag- 
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Figure 2.10 Validation of candidate PARKIN targets. a, Validation of siRNAs targeting PARKIN 
by immunofluorescence. HeLa cells stably expressing HA-FLAG-PARKIN were transfected with 
PARKIN siRNAs and the depletion of PARKIN examined by confocal microscopy after 
immunostaining with anti-HA and anti-TOMM20 antibodies. Nuclei were stained with Hoechst 
dye. b, Validation of siRNAs targeting PARKIN by immunoblotting. The indicated siRNAs were 
transfected into HCT116 expressing endogenous levels of PARKIN or HeLa cells stably 
expressing HA-FLAG-PARKIN cells and after 72 h, cell extracts were immunoblotted with anti-
PARKIN, anti-HA, or anti-PCNA antibodies. c, HCT116 cells stably expressing the indicated 
candidate PARKIN targets as C-terminal HA-FLAG-tagged fusions were treated with CCCP 
(10µM) and/or Btz (1µM) for the indicated period of time prior to harvesting proteins in 8 M urea. 
Extracts were subjected to immunoblotting with the indicated antibodies. d, HCT116 cells stably 
expressing the indicated candidate PARKIN targets as C-terminal HA-FLAG-tagged fusions were 
transiently transfected with either control siRNA or a validated siRNA targeting PARKIN. After 72 
h, cells were treated with CCCP (10µM) and/or Btz (1µM) for the indicated period of time prior to 
harvesting proteins in 8 M urea. Extracts were subjected to immunoblotting with the indicated 
antibodies. 
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Figure 2.10 (Continued) 
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PARKIN (Figure 2.6d, e). Analysis of the proteomic data with CompPASS identifies high-
confidence candidate interacting proteins based on the abundance (average assembled peptide 
spectral matches, APSMs), reproducibility, and frequency of interactors found in numerous 
parallel AP-MS experiments using both NWD and Z-scores (Sowa et al., 2009). Presumably, 
PARKIN interactors will vary throughout any time course experiment due to a number of 
possible reasons, including transient or low affinity enzyme:substrate interactions, degradation 
of interactors or PARKIN itself by the proteasome after ubiquitylation or autoubiquitylation, 
respectively, or destruction via mitophagy. Because we expected PARKIN action to by dynamic, 
we examined 293T N-HA-Flag-PARKIN cells treated with CCCP alone or with the addition of 
Btz to inhibit proteasomal degradation, or BafA, to inhibit autophagy for 1, 4, or 8 hours in 
biological duplicate (Figure 2.11). To allow a semi-quantitative assessment of interactions, we  
 
Figure 2.11 Schematic illustration of the major steps in our interaction proteomics 
platform. (see Chapter 5: Materials and Methods). 
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compared bait-normalized APSMs for proteins that were HCIPs under at least one condition 
examined unless otherwise noted. PARKIN did not reproducibly interact with any proteins in the 
absence of depolarization, suggesting that PARKIN requires activation and may need to 
overcome an autoinhibited state as described previously (Figure 2.12a, Supplementary Table 3) 
(Chaugule et al., 2011). Strikingly, after one hour of CCCP-induced mitochondrial 
depolarization, we identified more than 15 mitochondrial proteins that pass our CompPASS 
parameters to be classified as HCIPs (Figure 2.12a, b, Supplementary Table 3). 
In response to depolarization, 4 major classes of HCIPs were identified under at least 
one of the conditions examined: 1) twenty mitochondrial outer membrane proteins involved in 
fusion-fission cycles and trafficking, metabolism, and protein or small molecule translocation 
across the MOM, 2) autophagy adaptors, 3) numerous components of the 26 proteasome, and 
4) the VCP/p97 AAA+-ATPase implicated in MFN1 turnover. Amongst the mitochondrial 
proteins identified were known PARKIN substrates, MFN1/2, RHOT1, and VDAC1/2/3; however, 
we also identified FIS1, RHOT2, and MARCH5, additional proteins involved in control of 
mitochondrial membrane fusion and organelle trafficking (Figure 2.12a, b, Supplementary Table  
3). Marking of these proteins for degradation may be an early step in PARKIN-mediated 
remodeling of the outer mitochondrial membrane. Additionally, we identified 2 components of 
the MOM translocase (TOMM70A and TOMM20), which act as receptors and mediators for 
protein import across the outer mitochondrial membrane, the autophagy adaptor SQSTM/p62, 
and several proteins involved in metabolism, including HK1/2 (Figure 2.12a, b, Supplementary 
Table 3). TOMM70A and HK1, as well as multiple subunits of the proteasome, and VCP were 
identified under all conditions examined whereas other proteins including the candidate 
autophagy receptors CALCOCO2 and TAX1BP1, and the RAB7 GAP TBC1D15, which is 
known to interact with FIS1 to promote mitochondrial fission cycles, were primarily detected at 
either late time points or in response to BafA treatment (Figure 2.12a, b, Supplementary Table 
3). CALCOCO2 is a Ca+2 binding protein that functions to remove bacteria from cells via  
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Figure 2.12 PARKIN associates with mitochondrial proteins and the proteasome in 
response to depolarization. a, Heat map of HCIPs (represented by APSMs) for 293T HA–Flag–
PARKIN cell lines (left panel) and HeLa HA-Flag-PARKIN cell line (right panel) in response to 
mitochondrial depolarization, with or without Btz or BafA. Proteins indicated had weighted and 
normalized D-scores ≥ 1.0, Z-score ≥ 5, and APSMs ≥ 2 for 293T biological duplicates unless 
otherwise noted (see Methods). HeLa data is from single experiments and proteins indicated had 
weighted and normalized D-scores ≥ 1.0 unless otherwise noted (see Methods). b, Summary of 
PARKIN-interacting proteins in 293T and HeLa cell lines and integration with diGly sites. 
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                         Figure 2.12 (Continued) 
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autophagy by binding to ubiquitin on bacteria and to ATG8 (LC3) on autophagosomes, thereby 
recruiting ubiquitylated bacteria to the autophagosome. TAX1BP1 is also a ubiquitin binding 
protein involved in innate immunity that has only recently been linked with autophagy (Newman 
et al., 2012); however, their copurification with PARKIN after depolarization, but only in the 
presence of autophagy inhibitor, suggests that they might act as cargo adaptors for mitophagy. 
While components of all sub-complexes of the proteasome co-purified with PARKIN after 
mitochondrial depolarization, proteins comprising the 19S regulatory particle (PSMC and 
PSMD) were most prominent (Figure 2.12a, b, Supplementary Table 3). Additionally, 
proteasome regulators, including RAD23, ADRM1, and the proteasome activator subunit 
PAAF1, appeared as PARKIN interactors after depolarization, suggesting that after activation, 
PARKIN may translocate to the mitochondria where it ubiquitylates substrates while bringing 
them in close proximity to the proteasome. In fact, the abundance of several proteins purified in 
association with PARKIN was reduced at 4 or 8 hours post-depolarization in samples treated 
with BafA, such as MFN2 and RHOT1/2, consistent with these proteins being targeted to the 
proteasome (Figure 2.12a, b, Supplementary Table 3). 
Numerous proteins identified as PARKIN HCIPs were validated as interactors in HeLa 
cells stably expressing N-HA-PARKIN treated with CCCP and either Btz or BafA from 1 to 20 
hours post CCCP treatment (Figure 2.12a, Supplementary Table 4).. Strikingly, in the absence 
of Btz, the majority of these interactions were lost starting as early as 2 hours post CCCP 
treatment. This decrease in association was largely blocked by addition of Btz or BafA (Figure 
2.12a, Supplementary Table 4), suggesting a possible role for the proteasome and autophagy in 
loss of these proteins. Nevertheless, 19 of the 26 mitochondrial and autophagy proteins and 39 
of 40 proteasome subunits found in 293T cells were identified in at least one condition 
examined in HeLa cells (Figure 2.12b).  As in 293T cells, the interaction of PARKIN with 
CALCOCO2 and TAX1BP1 in HeLa cells was only seen in the presence of BafA.  
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Because antibodies that efficiently immunoprecipitate endogenous PARKIN were not available, 
we further validated a subset of the depolarization-dependent interactions using a 293T N-HA-
Flag-PARKIN stable cell line together with anti-FLAG antibodies. Anti-Flag immunoprecipitation 
of stably expressed HA-FLAG-PARKIN confirmed depolarization-dependent interaction between 
PARKIN and HK1, TOMM70, and the proteasome subunits ADRM1, RPN10, and PSMD2 
(Figure 2.13).  
Remarkably, of the mitochondrial and autophagy proteins identified by AP-MS, all but 2 
(MARCH5 and TBC1D15) were also identified as candidate PARKIN substrates by QdiGly 
proteomics (Figure 2.9, Figure 2.12b, Supplementary Table 2). Moreover, multiple subunits of 
 
 
Figure 2.13 Validation of PARKIN interactors identified via interaction proteomics. Validation of 
PARKIN interaction with TOMM70, HK1, and proteasomal subunits ADRM1, RPN10, and PSMD2. 
Extracts from 293T cells stably expressing HAFLAG-PARKIN with or without treatment with CCCP 
(10 μM) or CCCP and Btz (Velcade) (1 μM) were immunoprecipitated with anti-FLAG antibodies and 
immunoblotted with the indicated antibodies. Anti-PCNA was used as a loading control. Experiments 
were performed by Virginia Guarani-Pereira. 
 
 
 
 
71 
 
the regulatory particle of the proteasome, ubiquitin receptors (RAD23B), and VCP were found to 
be ubiquitylated in a PARKIN-dependent manner by QdiGly proteomics (Figure 2.9b, Figure 
2.12b, Supplementary Table 2). Together with the QdiGly proteomics, we have constructed a 
PARKIN interactome and PARKIN-modified proteome providing a vast resource to the field and 
identifying numerous candidates for further characterization. 
2.2.4 Interaction Proteomics: effects of PARKIN mutations  
Because PARKIN is so clearly regulated upon mitochondrial depolarization, we 
questioned whether PARKIN mutations would affect the interaction landscape. To examine how 
structural and functional elements within PARKIN contribute to interaction with its binding 
partners and the proteasome, we performed AP-MS experiments with 4 mutants: 1)∆UBL, in 
which the N-terminal UBL domain (residues 1-80) implicated in auto-inhibition is deleted 
(Chaugule et al., 2011), 2) K27R, K48R, which replaces two sites of regulated ubiquitylation 
identified by QdiGly profiling, 3) S65A or S65E, which blocks PINK1-dependent phosphorylation 
in a process that has been implicated in PARKIN activation in vitro, (Kondapalli et al., 2012) and 
4) C431S, wherein the active site cysteine in the second RING domain (reported to be required 
for ubiquitin thioester formation (Wenzel et al., 2011) is replaced by serine, thereby rendering 
the protein inactive as an E3 (Figure 2.14a). This mutation is reminiscent of a PD patient 
mutation, C431F, which fails to localize to mitochondria in response to depolarization (Cookson 
et al., 2003).  
Interestingly, mutation of cysteine 431 resulted in loss of regulatable PARKIN activation; 
the mutant neither translocated to the mitochondria upon CCCP treatment nor was able to 
promote ubiquitination of MFN2 in response to mitochondrial depolarization (Figure 2.14b, c 
Figure 2.15a, Supplementary Table 3). We were particularly interested in mutants in the 
ubiquitin-like domain of PARKIN due to recent reports implicating the UBL in autoinhibition, 
specifically S65, phosphorylation of which was reported to be required for activation of PARKIN 
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Figure 2.14 Functional properties and interaction partners of PARKIN mutants. a, Summary of 
functional experiments on selected PARKIN mutant proteins. ∆UBL-PARKIN, residues 81-465. b, 
MFN2 ubiquitylation by selected PARKIN mutants in 293T cells. *, PARKIN breakdown products. c, 
Heatmaps for a series of interacting proteins with a WDN-score ≥ 1.0, Z-score ≥ 5, APSMs ≥ 2, and 
found in biological duplicates for various PARKIN mutants, unless otherwise noted (see Methods).
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Figure 2.14 (Continued) 
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(Chaugule et al., 2011; Kondapalli et al., 2012). Additionally, the sites we identified via QdiGly, 
K27 and K48, lie in the UBL of PARKIN and are ubiquitylated in a depolarization-dependent 
manner. Unlike C431S, we found that ∆UBL, S65A/E, and K27/48R mutants maintained their 
ability to localize to mitochondria and to promote ubiquitination of MFN2 in response to 
depolarization (Figure 2.14b, c Figure 2.15a). 
Our AP-MS results are generally consistent with these results in that the ∆UBL, S65A/E, 
and K27/48R mutants retained strong interactions with mitochondrial proteins and the 
proteasome upon depolarization in the presence of Btz (Figure 2.14c, Supplementary Table 3). 
Interestingly, the ∆UBL mutant more efficiently captured mitochondrial proteins in response to 
CCCP when compared with wild-type (WT) PARKIN, consistent with this mutant displaying 
enhanced activity, possibly as a result of removal of auto-inhibition through this domain. 
Conversely, its interaction with the proteasome was decreased relative to WT PARKIN (Figure 
2.14c, Supplementary Table 3). Unexpectedly, we found that all of the PARKIN UBL mutants 
were still regulated, showing translocation to the mitochondria only upon depolarization and 
associating with the same proteins identified in the WT AP-MS experiments only after 
mitochondrial depolarization (Figure 2.14b, c, Supplementary Table 3). Though we cannot 
discount possible autoinhibition by the ∆UBL, it does not appear to be wholly essential for 
regulation of substrate interaction or depolarization-mediated translocation. Thus 
phosphorylation of S65 by PINK1 does not appear to be absolutely required for these aspects of 
PARKIN function in vivo, although we cannot rule out a kinetic effect of these mutations. 
However, consistent with the absence of mitochondrial localization of the C431S mutant, 
depolarization resulted in strong reduction in capture of mitochondrial proteins relative to WT 
PARKIN. Thus, the catalytic activity of PARKIN may be required for activation via depolarization 
and PINK1. 
 
 
75 
 
 
Figure 2.15 Localization of PARKIN and selected mutants to mitochondria in response 
to depolarization. HeLa cells stably expressing wild-type PARKIN or the indicated PARKIN 
mutants as HA-FLAG fusion proteins were treated with CCCP (10 μM, 1h), cells were fixed, 
stained with anti-HA (green) and anti-TOMM20 (red), and nuclei stained with Hoechst 33342. 
Images of representative cells were collected using a Nikon confocal microscope and percent 
colocalization calculated. See Methods and Supplementary Table 6 for details of quantification. 
Percent colocalization determined by Malavika Raman. 
2.2.5 Analysis of PARKIN target site conservation and structural topology 
Our data suggest that PARKIN interacts with and promotes the site-specific 
ubiquitylation of numerous mitochondrial and cytoplasmic proteins; therefore, in order to gain a 
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better understanding of the relationship between PARKIN and its interacting partners and 
substrates, we sought to examine PARKIN ubiquitylation targets in the context of their 
conservation and in vivo organization. We explored the spatial relationship between protein 
localization, structure, and conservation for 90 Class 1 sites on 36 candidate PARKIN 
substrates (Figure 2.16a-e, Supplementary Table 5). Overall, we found extensive conservation 
of ubiquitylated lysine resides in PARKIN targets for the 29 proteins displaying clear orthologs. 
In mouse (Mus musculus), 90% of sites were conserved, compared to 78% in zebrafish (Danio 
rerio), and 51% in Drosophila melanogaster, one of the lowest eukaryotes known to contain an 
active PARKIN-PINK1 pathway. Additionally, 38% of sites were conserved in all three species 
and in 22 out of the 36 proteins examined, at least one site was conserved from human to D. 
melanogaster (Figure 2.16a-e). 
  We then examined the protein domains containing ubiquitylation sites to determine 
whether there was any pattern to PARKIN’s substrate targeting. We found that ubiquitylation 
sites primarily occurred in globular domains and were not restricted to any particular structural 
feature; sites were observed on all three major classes of structural elements (α-helices, β-
sheets, and loops). Using MOTIFX, we analyzed the sequence motifs of all Class 1 candidate 
PARKIN targets for a consistent pattern; however, we found no conserved sequence motifs, 
suggesting that PARKIN specificity may be driven by its activation and recruitment to the 
mitochondria and substrates rather than a particular target sequence within substrates. 
We therefore wanted to better understand the relationship between PARKIN-mediated 
sites of ubiquitylation and the physical structures of the mitochondrial and cytoplasmic proteins  
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Figure 2.16 Structural anatomy and conservation of PARKIN-dependent diGly sites. 
Structures or domain schematics are shown for Class 1 depolarization and PARKIN-
dependent diGly sites (PDB codes, Supplementary Table 5). a, Legend for color-coded circles 
that indicate the conservation of Lys at homologous positions in M. musculus, D. rerio and D. 
melanogaster (Supplementary Table 5). For structures, regulated sites are shown in red 
space-filled models. b, Cytoplasmic proteins. c, MOM proteins. d, MIM and matrix proteins. e, 
Proteasome, RPN10, red circle. 
targeted. To do so, we mapped the positions of ubiquitylation onto existing 3-D structures of 
proteins in the Protein Database (PDB) allowing us to examine the sites as they appear on 
substrate proteins. Of the 17 MOM targets whose structures or membrane orientations are 
defined, all identified ubiquitylation sites were presented on the cytoplasmic surface (Figure 
2.16c), consistent with the idea that PARKIN re-sculpts the MOM proteome after translocation 
from the cytoplasm. Fifty-nine percent of Class 1 and 2 targets had one or two sites of 
ubiquitylation while 41% of targets had 3-15 sites that were PARKIN-dependent based on Tier 2 
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analysis (Figure 2.17a). Of the 8 Class 1 and Class 2 sites identified in MFN1, all but 2 are 
located in helical motifs flanking the 2 C-terminal membrane-spanning regions, suggesting 
localized ubiquitylation (Figure 2.9b, Figure 2.16c). We detected 14 Class 1 and 2 sites in HK1, 
but unlike MFN1, these sites were comparatively delocalized across both globular domains in 
HK1 (Figure 2.16b). Similarly, TOMM70 was decorated extensively over its 10 cytoplasmic TPR 
motifs (Figure 2.9b, Figure 2.16c). VDAC ubiquitylation occurred at multiple sites on the 
cytoplasmic lip of its central transmembrane pore, suggesting a potential regulatory effect on 
small-molecule transport upon depolarization in a PARKIN-dependent manner (Figure 2.16c). 
In addition to the numerous mitochondrial outer membrane proteins that we identified, 
we also observed modifications on mitochondrial inner membrane and matrix proteins (Figure 
2.16d). It is possible that these proteins are trapped outside the mitochondria prior to import. 
However, in some cases (e.g. components of ATP synthase), the extent of ubiquitylation 
increased substantially at longer time points after depolarization (Supplementary Table 2), 
potentially reflecting disruption of mitochondrial structure allowing the ubiquitylation machinery 
access to this compartment. Additionally, the diGly sites we identified in each of the three 
 
Figure 2.17 Characteristics of candidate PARKIN targets. a, Distribution of the number of 
Class 1 and 2 ubiquitylation sites identified across all Class 1 and 2 targets. b, Comparison 
between cytoplasmic proteins identified as PARKIN targets (Class 1 and 2) in this study, and 
proteins whose abundance accumulated in mitochondria as determined by SILAC-based 
proteomics (Chan et al., 2011). 
 
 
79 
 
ATPase subunits of the regulatory particle of the proteasome (PSMC1/RPT2, PSMC2/RPT1, 
and PSMC3/RPT5) occur within extended helices that form coiled-coils with neighboring RPT 
subunits and are clustered together on a surface of the regulatory particle that is proximal to the 
RPN10 subunit (Figure 2.9b, Figure 2.16e). Previous studies have reported an interaction 
between the C-terminal UIM domain of RPN10 and the UBL domain of PARKIN (Sakata et al., 
2003). Thus, our finding that association of PARKIN with the proteasome is greatly stimulated 
by mitochondrial depolarization suggests that PSMC ubiquitylation is likely linked to assembly of 
PARKIN with the proteasome, as association of PARKIN with the RPN10 subunit is likely to 
favor ubiquitylation of nearby PSMC subunits (Figure 2.16e). 
In order to place candidate PARKIN-dependent ubiquitination targets into a structural 
and functional framework, we have created an interactive resource that integrates dynamic 
ubiquitylation data with available structural information (Figure 2.18a, b and METHODS). This 
tool can be used to visualize sites of ubiquitination in proteins with known structures as well as 
examine the magnitudes of induction of modifications (log2 (H:L) ratio) across the 73 
experiments we performed. These data suggests that PARKIN activation leads to widespread 
ubiquitylation of a dozens of proteins, including a cohort of proteins associated with 
mitochondria. By examining the sites as they appear on substrate proteins, we are able to place 
targets into a structural and contextual framework and form a comprehensive view of the entire 
pathway. 
2.2.6 Development of PARKIN in vitro assay and substrate validation 
To facilitate both mechanistic examination of the PARKIN enzymatic process as well as 
validation of substrates identified via QdiGly proteomics, we developed a system allowing us to 
recapitulate PARKIN activity in vitro. Preliminary experiments showed extensive post-
translational modifications on PARKIN after mitochondrial depolarization with CCCP which were 
sensitive to both the deubiquitylating enzyme, USP2, and λ phosphatase treatment (Figure  
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Figure 2.18 Web-tool for interrogation and structural analysis of candidate PARKIN 
targets. a, Web tool. In order to aid in the analysis of the PARKIN-dependent ubiquitin modified 
proteome, a web-based tool was developed for retrieval, plotting of data for individual sites across 
multiple experiments, and visualization of structures for candidate PARKIN targets. On the front 
page (panel a), you can enter 3 analysis areas: structural analysis, plotting of ubiquitylation sites 
across experiments, and access to tables and retrieval of data. Panel b, shows an example of a 
plot of log2 SILAC ratios for a MFN2 site across several experiments using Site-Surveyor.  For 
structural analysis, individual experiments can be selected from a drop-down menu, which then 
populates a table collecting PDB identifiers for proteins having structures in the PDB. Individual 
PDB identifiers are linked to a page, which collects relevant quantitative proteomics data 
(principally the log2 ratio for identified and quantified peptides and the peptide sequences), and 
displays the structure in a new window, allowing 3-D rotation and visualization (Panel c). Lysines 
that were identified as ubiquitylated are shown in space-filling models and are color-coded based 
on the log2 ratio for regulated sites (sites showing an increased diGly ratio in red. Sites that are 
identified but not quantified are shown in white. The web tool can be accessed at 
http://harper.hms.harvard.edu. Web tool designed and constructed by Mathew Sowa. 
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                Figure 2.18 (Continued) 
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2.19a). Therefore, we reasoned that because PARKIN activity requires activation by PINK1 
and/or another unidentified enzyme, which were presumably absent in bacterial or insect cell 
preps as these produced highly insoluble protein with little activity. Therefore, we isolated HA-
Flag-PARKIN WT or catalytically defective HA-Flag-PARKIN C431S from 293T cells either  
 
Figure 2.19 Development of an in vitro system for PARKIN validation. a, N-HA-Flag-
PARKIN purified from 293T cells after 1 h 10µM CCCP and/or 1µM Btz (left panel). N-HA-
Flag-PARKIN purified from 293T cells (1 h 10µM CCCP) treated with USP2 or λ phosphatase 
followed by in vitro ubiquitylation reaction (right panel). b, Scheme of in vitro approach. Inset 
photograph contains an example of purified mitochondria verified by electron microscopy. c, 
In vitro ubiquitylation reaction using either PARKIN WT or C431S purified from 293T cells (1h 
10µM CCCP) and purified mitochondria as substrate. Mitochondrial protein MFN2 is used as 
a readout of PARKIN activity on the mitochondria (bottom panel). PARKIN autoubiquitylation 
is shown in the top panel. d, In vitro ubiquitylation reactions were performed as described 
above and blotted for mitochondrial candidate PARKIN targets. 
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untreated or treated with CCCP for 1 hour. In parallel, we isolated intact mitochondria from 
either untreated or depolarized HeLa cells which do not contain endogenous Parkin and further 
removed any existing ubiquitin conjugates using treatment with USP2, followed by NEM 
treatment to block USP2 activity (Figure 2.19b). We then performed in vitro ubiquitylation 
reactions using this purified mitochondria as substrate and found that only HA-Flag-PARKIN 
purified from depolarized cells (Figure 2.19c, lane 2, 4), but not from untreated cells (lanes 1, 3) 
was capable of ubiquitylating MFN2 on mitochondria. Interestingly, MFN2 ubiquitylation 
occurred regardless of whether the mitochondria itself was purified from depolarized or 
untreated cells (Figure 2.19c, lanes 2, 4). As expected, HA-Flag-PARKIN C431S did not 
promote MFN2 ubiquitylation (Figure 2.19c, lanes 5-8). Compared to previously published work 
featuring bacterial recombinant PARKIN protein, our method of purification post-CCCP 
treatment appears to result in more robust and stronger Parkin activity. Using this system, we 
can detect increased ubiquitylation of QdiGly-identified PARKIN substrates in vitro including 
MFN1, MFN2, VDAC1, CYB5R3, PHB, and PARKIN via immunoblotting with antibodies against 
the endogenous proteins. Western blot for total ubiquitin also shows increased ubiquitylation on 
mitochondria which have been exposed to CCCP-treated PARKIN WT (Figure 2.19d).  
After careful analysis of AP-MS data obtained from PARKIN WT and C431S cell lines, 
we realized that there was a possibility that WT PARKIN purified from depolarized cells had the 
potential to co-purify with ubiquitylated MFN2, thus there was the possibility of obtaining a false 
positive; though, due to the extent of ubiquitylation seen on MFN2, unlikely. To address this 
issue, we set up a number of experiments which will allow us to definitively confirm our in vitro 
ubiquitylation result. The first approach is based on the in vitro assay described above. We have 
developed a parallel approach that seeks to quantitatively examine PARKIN-dependent MOM 
ubiquitylation in vitro via a PARKIN-dependent “heavy-label transfer” approach (Figure 2.20a). 
The key to this method is the use of uniformly isotopically heavy-labeled ubiquitin in the in vitro 
reaction thus allowing us to distinguish between it and any pre-existing “light” ubiquitin. If  
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Figure 2.20 Quantitative in vitro system for PARKIN target validation. a, Scheme for in 
vitro system utilizing heavy-labeled ubiquitin to “mark” in vitro PARKIN-mediated 
ubiquitylation events. b, Heavy-label ubiquitin transfer sites identified and quantified on 
MFN1, MFN2, and SQSTM1. *** sites regulated in vivo. 
 
successful, the in vitro ubiquitylation reaction produces a diGly tag on PARKIN substrates with a 
6 Da increase in mass relative to any pre-existing ubiquitin modifications on the mitochondria, 
thus allowing in vitro PARKIN-dependent events to be identified by MS. We have performed a 
pilot experiment using this method allowing us to quantitatively examine PARKIN-dependent 
MOM ubiquitylation in vitro via this PARKIN-dependent “heavy-label transfer” approach. In this 
preliminary experiment, we identified 3, 4 and 2 heavy-label transfer sites for MFN1, MFN2, and 
SQSTM1, respectively (Figure 2.20b). Seven of these sites were found to increase in 
abundance in at least one in vivo diGly IP experiment. Recently, another group published a 
similar assay, thus confirming the validity of our approach in demonstrating activation of 
PARKIN’s enzymatic activity toward mitochondria (Lazarou et al., 2013). However, our 
approach further demonstrates a method to quantitatively measure this activity on intact purified 
mitochondria in vitro, which will allow extensive future investigation of PARKIN targets and 
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activity, especially in regards to how these are affected by mutations found in Parkinson’s 
disease. 
 In order to improve the efficiency of the in vitro reaction to make it useful for validation of 
PARKIN targets found via QdiGly proteomics, our second approach employs the ongoing 
development of a variety of new reagents to optimize the assay. To avoid the need to purify 
activated PARKIN from mammalian cells, we are expressing full length (FL), ∆UBL, or C431S 
PARKIN constructs together with mammalian PINK1 in Sf9 insect cells. Purified PARKIN and 
PINK1 will then be mixed with purified mitochondria in an in vitro ubiquitylation reaction will can 
then be assayed by immunoblotting and mass spectrometry. These approaches are allowing us 
to simultaneously develop an important in vitro system for studying PARKIN function while 
providing a means by which to validate targets of PARKIN and to demonstrate that they are 
direct. 
2.2.7 PARKIN is post-translationally modified in response to mitochondrial depolarization 
Reports in recent years have suggested that under normal conditions, PARKIN exists in 
an autoinhibited state in which the N-terminal UBL domain binds a ubiquitin/UBL binding site in 
the C-terminal portion of the protein thus both keeping the protein closed and preventing binding 
to ubiquitin (Chaugule et al., 2011). Upon mitochondrial damage, PARKIN activation occurs, 
requiring phosphorylation by PINK1, potentially on multiple sites; activity also appears to require 
the active site Cys of PARKIN. This supports the possibility of a multi-step mechanism of 
activation in which initial PINK1-dependent phosphorylation events are followed by PARKIN 
auto-ubiquitylation, both of which might be required for activation of maintenance of an “open” 
state. As PINK1 is known to be required for PARKIN activation, much effort has been devoted to 
identification of PINK1 phosphorylation sites on PARKIN; however, confirmation of direct 
phosphorylation has been difficult and many of the reports remain unsubstantiated (Kim et al., 
2008b; Kondapalli et al., 2012; Lazarou et al., 2013; Sha et al., 2010; Shiba et al., 2009; Um et 
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al., 2009). In the last year, new data has suggested that phosphorylation of S65 in the PARKIN 
UBL domain can promote ubiquitin-transfer by PARKIN in vitro (Kondapalli et al., 2012). 
However, we have found that this residue is not essential for MFN2 ubiquitylation in vivo, 
PARKIN translocation to the mitochondria, or for interaction with substrates, indicating 
involvement of potential additional PINK1-dependent events (Figure 2.14b, c, Figure 2.15). We 
have observed USP2- and λ-phosphatase-sensitive CCCP-induced modification on PARKIN 
purified from 293T cells (Figure 2.19a). Therefore, we re-examined our AP-MS data utilizing 
search conditions optimized for identification of phosphorylation modifications. We identified 
additional phosphorylation and ubiquitylation sites in PARKIN, many of which lie outside of the 
UBL domain and may contribute to activation (Figure 2.21, Supplementary Table 7). In total, we 
found 24 phosphorylation sites occurring on serines, threonines, and tyrosine residues. Not all 
of the sites appear to be depolarization-dependent; however, we are in the process of testing 
whether any of these sites are necessary for PARKIN activation in vivo. Additionally, we found  
that depolarization is not sufficient to induce robust association of PARKIN C431S with 
the cohort of MOM proteins normally bound by PARKIN under these conditions (Figure 2.14c). 
We believe PARKIN activation may involve a two-step mechanism in which PINK1 
phosphorylation promotes partial loss of auto-inhibition via the UBL domain or possibly at  
 
 
Figure 2.21 Post-translational modification of PARKIN. Phosphorylation and ubiquitylation 
sites identified on PARKIN via AP-MS. 
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additional sites outside this domain, and subsequent auto-ubiquitylation completes the process. 
This proposed model will be examined both in vivo and using the in vitro system through the 
analysis of phosphorylation and ubiquitylation site mutants. 
2.2.8 Determining the role of candidate PARKIN targets in initiation or progression of 
mitophagy 
The steps that occur downstream of PINK1 and PARKIN activation remain unknown. How 
PARKIN gets to the mitochondria and how ubiquitylation of mitochondrial outer membrane or 
other proteins leads to mitophagy is unclear. To systematically test proteins identified in our 
studies, we have begun RNAi-mediated depletion and high-throughput microscopic screening to 
determine whether a subset of the proteins identified as PARKIN interactors or targets are 
important in these processes (Figure 2.22a). First, we created a clonal HeLa-N-HA-Flag-
PARKIN cell line to minimize variability throughout the screening process (Figure 2.22b). To 
determine if any of the proteins of interest were essential for PARKIN translocation after 
mitochondrial depolarization, we treated cells with siRNA for 72 hours prior to treatment with 
CCCP for 2 hours, after which cells were stained and imaged. To measure PARKIN 
translocation, we are working with Tiao Xie (IDAC) to create a custom script that measures the 
percent of PARKIN signal which colocalizes with the mitochondria. Though screening and 
analysis are still ongoing, preliminary analyses have allowed us to classify genes based on the 
percent of PARKIN colocalization compared to siControl. Proteins whose RNAi-mediated 
depletion results in 75% or greater loss of PARKIN translocation are termed Class 1 and those 
proteins whose depletion results in 50% or greater loss of translocation are Class 2 proteins 
(Figure 2.22c, e, Supplementary Table 8). Within each Class, we further ranked genes based on 
the number of siRNAs out of four giving a positive result for each gene. Amongst the proteins 
we identified at the most stringent cut-off are the hexokinases and IMMT, a protein known to 
mediate outer and inner membrane dynamics. 
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We also want to determine whether one or more PARKIN interactors or substrates is 
required for the initiation or progression of mitophagy. To do so, we are using a very similar 
approach to that described above employing RNAi-mediated depletion and high-throughput 
microscopic screening (Figure 2.22a). This second portion of our screen employs siRNA-
mediated depletion of candidate mitophagy regulators in HeLa-N-HA-FLAG-PARKIN cells for 48 
hours prior to treatment with CCCP for 24 hours, followed by fixation and imaging. We first 
looked at the overall changes in the average mitochondrial area per cell in comparison to control 
cells (Figure 2.22d). Depletion of the majority of genes did not have a drastic effect on 
mitochondrial area, which will allow us focus on those with greater changes for follow-up 
studies, for example those with at least a 1.25-fold increase. If a gene is necessary in the 
progression of mitophagy, we would expect that RNAi-mediated knockdown would result an 
increase in total mitochondrial area compared to siPINK1- or siPARK2-treated cells. These 
proteins are most likely not targeted for degradation by PARKIN, but instead may be modified 
with ubiquitin for another purpose, such as signaling or regulation. To identify these genes, we 
compared mean mitochondrial mass per cell to that observed in cells treated with either siRNA 
targeting PINK1 or PARKIN. Because siPINK1 consistently evoked a more drastic phenotype 
than siPARKIN, we set the threshold for Class 1 genes at this level. These are considered the 
highest confidence targets in terms of a potential effect on progression of mitophagy. Class 2 
genes passed the threshold set by cells treated with siPARKIN. Within each class, genes were 
further ranked based on how many siRNAs of out four provided a positive result (Figure 2.22e, 
Supplementary Table 8). Based on these classifications, Class 1 genes for which >2 shRNAs 
reduce mitophagy will be primary targets for future studies and fully characterized. 
In contrast, it is also possible that depletion of certain PARKIN substrates might result in 
increased levels of mitophagy thus resulting in decreased total mitochondrial area compared to 
siControl-treated cells.. Such a result might indicate the loss of an inhibitor of mitophagy – a 
protein likely to be targeted for degradation in a PARKIN-dependent manner. To determine  
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Figure 2.22 RNAi screening with candidate-PARKIN substrates and interactors. a, Flow 
chart of high-throughput RNAi screen used to determine effects of candidate PARKIN-target 
depletion on PARKIN translocation or mitophagy. b, Staining of HA-PARKIN (green), TOMM20 
(red), or nuclei (blue) in the clonal HeLa N-HA-Flag-PARKIN cell line used in this study. Cells 
were either untreated, treated with 1hr 10µM CCCP, or 72h siPARK2 and 1h 10µM CCCP. c, 
Graph depicting Class 1 and Class 2 hits for PARKIN translocation screen. Class 1, 75% 
decrease in translocation compared to siControl, Class 2, 50% decrease in translocation 
compared to siControl, Level 1, 4/4 positive siRNAs for a given gene, Level 2, 3/4 positive 
siRNAs. d, Mitophagy screen: dot-plot of fold-change in mean mitochondrial area compared to 
siControl for all genes tested. e, Shown are the numbers of individual siRNAs targeting each 
gene that scored positive in each screen. Red, genes with 2 or more positive siRNAs; Green, 
genes with <2 positive siRNAs. siRNA screening and microscopy performed by Malavika 
Raman. Custom script written by Tiao Xie (IDAC). 
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genes which might play these roles, we again used a custom script to compare the total 
mitochondrial area per cell for each siRNA-treated well with siControl-treated cells and those 
genes whose depletion resulted in less mitochondrial area than control cells were considered 
positive. Figure 22.2 displays the results of this analysis, including the number of positive 
siRNAs per gene. We are the process of repeating this analysis with a newly created cell line 
which exhibits a greater degree of mitophagy than the current cell line being used, providing a 
greater dynamic range that allow us to make better comparisons and higher confidence 
predictions of proteins important in this process. Because we cannot rule out the possibility that 
depletion of some of these proteins may result in toxicity to the mitochondria or the cell as a 
whole, a second portion of our screen is underway examining the same outcomes in the 
absence of CCCP-induced depolarization, thus distinguishing siRNA-mediated defects in the 
presence and absence of depolarization. Thus, we are still in the process of analyzing and 
collecting all the data generated from these screens and repeating portions which require 
optimization. 
2.3 Discussion  
Here we describe systematic target identification and ubiquitylation site-specificity for the 
E3 ligase, PARKIN, thereby revealing the diversity and complexity of PARKIN function after 
mitochondrial depolarization. Using integrated approaches to identify both interactors and 
substrates of PARKIN, we have constructed the first quantitative description of the PARKIN-
modified proteome. Our analysis reveals both increased ubiquitylation of mitochondrial targets 
and a distinct set of mitochondrial PARKIN-interactors present only after mitochondrial 
depolarization. Our work contributes to numerous areas of Parkinson disease research, 
illuminating aspects of mitochondrial quality control and regulation, PARKIN function on the 
MOM and in the cytoplasm, and PARKIN regulation. Our data represents a powerful resource 
for the identification and classification of ubiquitin-modified lysine residues and proteins after 
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PARKIN activation allowing for direct future interrogation of individual sites and proteins in both 
the mechanism by which PINK1-PARKIN pathway remodels the MOM proteome to control 
mitochondrial fate and how this remodeling may affect the initiation or progression of 
Parkinson’s disease. 
2.3.1 Potential impact of mitochondrial outer membrane protein ubiquitylation by PARKIN 
on the activity of individual proteins 
By examining ubiquitylation sites on substrate proteins, we were able to place targets 
into a structural and contextual framework thus forming a comprehensive view of the entire 
pathway. We have consistently found that PARKIN is targeting outer membrane proteins on the 
mitochondrial surface; some of these proteins are most likely being targeted for degradation by 
the proteasome. For example, among the proteins we consistently identified are MFN1/2 and 
RHOT1/2, known PARKIN substrates involved in outer membrane dynamics which have been 
shown to be degraded in a PARKIN-dependent manner after mitochondrial depolarization. We 
also identified the VDAC proteins as both PARKIN substrates and interactors. Strikingly, when 
we mapped the ubiquitylation sites we identified onto existing VDAC structures, we determined 
that ubiquitylation occurred at multiple sites on the cytoplasmic rim of its central transmembrane 
pore. The VDAC proteins regulate the exchange of metabolites between the mitochondria and 
the cytosol which is tightly coupled to cell survival (Colombini et al., 1996). Since VDAC1 is the 
most abundant protein of the mitochondrial outer membrane, it may act as a hub for PARKIN 
recruitment or activity at the mitochondria. Because some of the ubiquitylation sites we identified 
may block the pore, we suspect that PARKIN is potentially mediating both the function and the 
fate of this substrate. Blocking metabolite conductance through VDAC could affect respiration or 
apoptotic factors, highlighting the potential for a PARKIN-dependent regulatory effect on small-
molecule transport. Closure of VDAC in the mitochondrial outer membrane has been shown to 
occur after various cellular stresses resulting in global suppression of mitochondrial metabolism 
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and respiration (Lemasters and Holmuhamedov, 2006), thus insight into the mechanism by 
which VDAC may be regulated by the binding of PARKIN will be of immense value. 
Previous studies indicate that PINK1 interacts stably with the TOMM complex through 
TOMM40 (Lazarou et al., 2012). Together with our findings that TOMM70 and TOMM22 are 
depolarization-dependent PARKIN-interacting proteins in addition to the identification of 
PARKIN-dependent ubiquitylation sites on TOMM70 (Figure 2.9b, Figure 2.12b), these data 
suggest that the TOMM complex may serve as a nexus for regulation of PARKIN by PINK1. 
Additionally, translocase function, for example, interaction with transport substrates, may be 
dynamically altered by ubiquitylation of numerous TPR repeats in TOMM70. Previous studies 
have shown regulation of the TOMM complex by phosphorylation (Schmidt et al., 2011), thus it 
seems likely that ubiquitylation could also act as a regulatory signal on these proteins. We 
intend to investigate the potential impact of PARKIN recruitment to the TOMM complex on 
mitochondrial protein import using in vitro import assays; we believe that PARKIN may be 
shutting down mitochondrial protein import after depolarization. 
Also of interest, we identified ubiquitylation sites in each of three ATPase subunits of the 
regulatory particle of the proteasome (PSMC1/RPT2, PSMC2/RPT1, and PSMC3/RPT5) 
(Figure 2.9b, Figure 2.16e). These ubiquitylation events occur within extended helices that form 
coiled-coils with neighboring RPT subunits and are clustered together on a surface of the 
regulatory particle proximal to the RPN10 subunit. Previous studies indicate that the C-terminal 
UIM domain of RPN10 associates with the UBL domain of PARKIN (Sakata et al., 2003). Thus, 
our finding that association of PARKIN with the proteasome is greatly stimulated by 
mitochondrial depolarization suggests that PSMC ubiquitylation is likely linked to assembly of 
PARKIN with the proteasome, as association of PARKIN with the RPN10 subunit is likely to 
favor ubiquitylation of nearby PSMC subunits. Determination of whether this modification affects 
proteasome assembly or function downstream of PARKIN activation or is merely a “bystander 
effect” is crucial to resolve. 
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In addition to modification of MOM proteins, we also observed modification of proteins 
resident in the MIM or matrix (Figure 2.16d). Ubiquitylation of these proteins may reflect 
disruption of mitochondrial structure, which could allow MIM or matrix proteins to escape into 
PARKIN’s vicinity. Alternatively, membrane disruption might permit the ubiquitylation machinery 
to gain access to these compartments (Yoshii et al., 2011). We observed a number of instances 
in which the extent of ubiquitylation increased substantially at longer times of depolarization, for 
example with components of ATP synthase, potentially reflecting local disruption of 
mitochondrial structure after extended exposure to CCCP. However, we cannot exclude the 
possibility that PARKIN’s association with the TOMM complex allows ubiquitylation of proteins 
whose transport is stalled as a result of depolarization or PARKIN-dependent TOMM70 
ubiquitylation. If this occurs, the repeated identification of the same subset of sites in multiple 
experiments employing 1 hour of depolarization would suggest a highly stereotypical 
ubiquitylation mechanism. Investigation of this phenomenon will require additional QdiGly 
experiments involving both mitochondrial depolarization and inhibition of protein synthesis in 
order to determine the cellular compartment or source of the ubiquitylated proteins. 
Furthermore, import assays described above will also clarify the role of the TOMM complex and 
potentially PARKIN’s interactions with mitochondrial matrix or inner membrane proteins. 
2.3.2 PARKIN targets in the cytoplasm 
PARKIN may promote rapid turnover of some targets but not others. We identified a 
number of proteins in our Class 1 and 2 lists including MFN1/2 and RHOT1/2, which have been 
shown to undergo proteasomal turnover (Chan et al., 2011; Liu et al., 2012; Tanaka et al., 2010; 
Wang et al., 2011b). Most likely, a number of the proteins we identified, such as C1QBP1, FIS1 
and CISD1, are also degraded after mitochondrial depolarization, as their total levels are also 
decreased upon PARKIN activation (Chan et al., 2011; Narendra et al., 2012). In contrast, a 
previous study identified 50 preferentially cytoplasmic proteins or protein complexes that are 
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enriched in mitochondria in response to depolarization (Chan et al., 2011). Consistent with this, 
we identified 11 of these proteins or components of protein complexes as Class 1 or 2 targets 
(Figure 2.17b), possibly reflecting an under-appreciated dynamic recruitment process affecting 
mitochondrial homeostasis. These include the autophagy adaptor p62, previously linked with 
mitochondrial clustering after damage, as well as TBC1D15 and DNML1, which are known to 
interact with FIS1 to regulate fission–fusion cycles (Narendra et al., 2010a; Onoue et al., 2012). 
In addition to p62, we also identified candidate autophagy receptors, CALCOCO2 and 
TAX1BP1, which are ubiquitylated upon depolarization and associate with PARKIN in the 
presence of BafA. Because CALCOCO2 has been shown to target bacteria for autophagy 
(Shpilka and Elazar, 2012; von Muhlinen et al., 2012), it is an attractive candidate for 
involvement in mitophagy and we currently in the process of examining it. Additionally, it is 
possible that additional cytoplasmic proteins identified here as PARKIN-dependent targets are 
transiently recruited to mitochondria but below the level of detection in previous studies. It is 
also likely that ubiquitylation of PARKIN targets alters their enzymatic properties or functions 
before their turnover by the proteasome or autophagy. 
2.3.3 Relationship of PARKIN to other potential ubiquitin ligases acting on mitochondria. 
We have identified numerous proteins on the MOM and in the cytoplasm that are 
ubiquitylated in a depolarization and PARKIN-dependent manner. In addition, we demonstrated 
that a substantial fraction of these proteins are captured as PARKIN-associated proteins by 
affinity chromatography-MS. However, we did not detect a substantial number of candidate 
substrates in physical association with PARKIN. This could reflect low abundance, difficulty in 
extraction from the MOM, or transient association with PARKIN. However, we are not able to 
conclude that all depolarization and PARKIN-dependent proteins are direct substrates. Another 
prominent mitochondrial E3 is MARCH5. Interestingly, we have identified MARCH5 as a 
PARKIN-associated protein (Figure 2.12), although we did not identify any PARKIN- or 
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depolarization-dependent ubiquitylation sites in MARCH5. Previous studies have implicated 
MARCH5 in cell cycle dependent control of MFN1 turnover (Park et al., 2010). While we cannot 
rule out a role for MARCH5 in ubiquitylation events seen here, our studies did not directly 
examine cell cycle dependent changes in ubiquitylation-site occupancy. Further studies will be 
required to fully understand the involvement of MARCH5 in the PARKIN-dependent ubiquitin 
modified proteome. 
2.3.4 Parkin regulation and activity  
Under normal conditions, PARKIN seems to exist in an autoinhibited state in which the 
UBL domain folds back upon the protein to interact with a ubiquitin/UBL binding site in the C-
terminal portion of PARKIN (Chaugule et al., 2011). Activation requires PINK1 kinase activity as 
well as PARKIN ligase activity. Many studies have attempted to identify PINK1 phosphorylation 
sites on PARKIN; however, confirmation of direct phosphorylation has been difficult and remains 
unsubstantiated in vivo (Kim et al., 2008b; Kondapalli et al., 2012; Lazarou et al., 2013; Sha et 
al., 2010; Shiba et al., 2009; Um et al., 2009). Recent data suggests that phosphorylation of 
Ser65 in PARKIN’s UBL domain promotes activation of PARKIN Ub-transfer activity in vitro 
(Kondapalli et al., 2012); however, we have not found Ser65 to be essential for MFN2 
ubiquitylation in vivo, nor does mutation to Ala appear to affect substrate interaction, indicating 
the potential for additional PINK1-dependent events. In support of this idea, we have identified 
additional phosphorylation sites in PARKIN which we believe could contribute to activation, 
potentially in collaboration with Ser65. Furthermore, the ∆UBL mutant we examined more 
efficiently captured mitochondrial proteins compared to WT PARKIN in response to 
mitochondrial depolarization, potentially suggesting a loss of autoinhibition (Figure 2.14). 
However, the ∆UBL was still regulated, showing translocation to the mitochondria upon 
depolarization and associating with the same proteins identified in the WT AP-MS experiments 
after mitochondrial depolarization. We cannot discount possible autoinhibition by the ∆UBL or 
 
 
96 
 
potentially kinetic defects in both the ∆UBL and S65A mutants; however, neither appears to be 
absolutely essential for control of substrate interaction or depolarization-mediated translocation. 
We also found that PARKIN C431S failed to associate with the cohort of MOM proteins normally 
bound by WT PARKIN under depolarizing conditions, suggesting that PARKIN ligase activity is 
also required for activation. These observations lead us to support the presence of a multi-step 
activation mechanism in which PINK1 phosphorylation promotes partial loss of auto-inhibition 
via the UBL domain, and subsequent auto-ubiquitylation completes the process. 
In addition to previously unidentified phosphorylation sites, we also discovered 6 sites of 
ubiquitylation spanning the length of the protein on PARKIN itself after mitochondrial 
depolarization (Figure 2.21). Two of the sites, Lys27 and Lys48 are located in the UBL domain; 
however, mutation of both sites to arginine does not appear to affect PARKIN interaction with 
MOM proteins after CCCP treatment. We believe that both phosphorylation of sites other than 
S65 by PINK1 as well as ubiquitylation on internal lysines is likely to be required for both 
activation of PARKIN, mitochondrial recruitment and interaction, and target ubiquitination. We 
are in the process of testing this proposed model through the analysis of phosphorylation and 
ubiquitylation site mutants using both in vivo methods and the in vitro system described earlier. 
The wealth of studies that have examined PARKIN regulation and activity have employed an 
extensive array of recombinant proteins, cell types, organisms, and techniques resulting in an 
abundance of information, often conflicting or unsubstantiated. The majority of studies 
examining PARKIN regulation have utilized bacterially purified recombinant protein. While 
useful, these systems most likely do not recapitulate the complexity of PARKIN activation and 
regulation that occurs in vivo. Questions remain regarding direct phosphorylation by PINK1 and 
whether autoubiquitylation truly occurs in vivo and is required for either activation or degradation 
of PARKIN, or possibly there is a threshold which regulates both. An understanding of the native 
state of Parkin in cells is emerging, and our data contributes to the understanding of how activity 
may change after activation. 
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2.3.5 Role of PARKIN targets in initiation and progression of mitophagy 
Though our screening for PARKIN interactors or targets that are required for PARKIN 
translocation or the progression of mitophagy is not yet completed, we have started more 
focused studies on some proteins of interest. As described above, CALCOCO2 has been shown 
to be necessary to target bacteria for autophagy (Shpilka and Elazar, 2012; von Muhlinen et al., 
2012); therefore, it is an appealing to speculate that it may play a role in mitophagy. We have 
shown that candidate autophagy receptors, CALCOCO2 and TAX1BP1, are ubiquitylated upon 
depolarization and associate with PARKIN in the presence of BafA. We propose that these 
related autophagy adaptor proteins may be dynamically recruited to the MOM and may link the 
depolarization response to the recruitment of autophagy machinery. These proteins did not 
score highly in the RNAi screen. However, we believe that co-depletion of these proteins may 
be required to see the true effect on mitophagy. However, codepletion appears to cause toxicity, 
thus underscoring the importance of these proteins, but making it difficult to study them. 
Our expectation is that one or more PARKIN substrates will be ubiquitylated in a form 
that is recognized by the autophagy machinery, potentially CALCOCO2 or 
TAX1BP1/CALCOCO3. Developmental mitophagy requires NIX to bridge an interaction with 
ATG8/LC3 and ATG32 has been shown to play this role in yeast, however, corresponding 
proteins in mammalian cells are unknown (Kanki et al., 2009; Schweers et al., 2007). The 
requirement for p62 in mitophagy remains somewhat controversial – it has been shown both to 
be required for mitochondrial removal or merely for mitochondrial clustering after damage 
(Geisler et al., 2010; Narendra et al., 2010a). CALCOCO2 removes bacteria from cells via 
autophagy.by binding to ubiquitin on bacteria and to ATG8/LC3 on autophagosomes, thereby 
recruiting ubiquitylated bacteria to the autophagosome (von Muhlinen et al., 2012). TAX1BP1 is 
a ubiquitin binding proteins that is involved in innate immunity and only recently linked to 
autophagy (Newman et al., 2012; Thurston et al., 2009). Alignment of these two proteins shows 
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that the sequence in CALCOCO2 that interacts with LC3C is conserved in TAX1BP1. We intend 
to test whether mutation of this sequence may block mitophagy or affect mitochondrial 
clustering. Using both proteomics and immunofluorescence, our lab and others have shown that 
both CALCOCO2 and TAX1BP1 localize to autophagosomes, that TAX1BP1 colocalizes with 
P62, and CALCOCO2 with LC3B, supporting their role as cargo adaptors for autophagy 
(Newman et al., 2012), thus making these two proteins likely candidates for potential mitophagy 
receptors. 
2.3.6 Comparison of PARKIN interaction data and candidate substrates with historical 
studies 
Using interaction proteomics, we identified a reproducible cohort of depolarization-
dependent PARKIN-interacting proteins and candidate substrates, many of which are 
mitochondrial, consistent with the model of PINK1-dependent recruitment of PARKIN to the 
mitochondria after damage. While we cannot exclude the possibility that some ubiquitylation 
events occur downstream of PARKIN activation, the fact that we find many of the targets as 
PARKIN-interacting proteins is consistent with direct ubiquitylation. Identification of 
ubiquitylation sites on many of these proteins via QdiGly analysis further supports the view that 
these proteins both interact with and are substrates of PARKIN. However, a number of 
candidate PARKIN binding proteins and substrates reported prior to the discovery of this PINK1-
dependent conversion of PARKIN from an inactive to active form - including CCNE, AIMP2, DJ-
1, and RANBP2 - were not detected here, and some of these interactions have been called into 
question as PARKIN targets based on other grounds (Dawson and Dawson, 2010). In contrast, 
activated PARKIN displays robust signal-dependent association with MOM-derived proteins, 
consistent with a primary role in mitochondrial ubiquitylation in response to this particular type of 
cellular challenge. 
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2.3.7 Conclusion 
We have identified a wide cross-section of ubiquitylation sites and target proteins in 3 
distinct cell lines. To our knowledge, this is only the third paper which has used the diGly 
capture approach to perform dynamic measurements of ubiquitylation. To complement this data, 
we have also systematically examined PARKIN interacting proteins. This work, together with 
previous studies, supports a model wherein PINK1-dependent recruitment of PARKIN allows its 
interactions with and ubiquitylation of numerous MOM proteins, likely resulting in widespread 
alterations in protein-protein interactions and turnover rates for many key mitochondrial proteins. 
Our data highlight a number of areas that will require future research. Numerous questions 
remain to be addressed, both on a global level and more specifically about PARKIN regulation 
and activation. We look forward to better understanding how PARKIN activity may create a 
signal which triggers mitophagy. Another question that arises is how PARKIN recognizes such a 
diverse array of substrates – are they all directly targeted? Perhaps some of the interacting 
proteins identified act as substrate-binding adaptors. To fully understand PARKIN activity, there 
are a number of issues to resolve, for example, does PARKIN interact with multiple E2 ubiquitin 
conjugating enzymes, possibly to affect the type of ubiquitin chain produced? Questions remain 
as the field progresses towards a better understanding of PARKIN and its role in PD. We have 
produced a compendium of PARKIN-dependent ubiquitylation sites and interactors, thus 
providing a resource for further dissection of the PARKIN-dependent and depolarization-
dependent ubiquitin modified proteome. We hope our work will contribute toward a deeper 
understanding of how PARKIN contributes to mitochondrial homeostasis thus furthering efforts 
to overcome Parkinson’s disease.  
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CHAPTER 3 
Insight into the PINK1/PARKIN pathway through examination of PINK1 and a novel 
interacting protein, CLU1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Contributions 
Figure 3.6 Genetic interactions between clu, park, and Pink1. Data obtained in collaboration 
with the Artavanis-Tsakonas lab with all Drosophila experiments performed by Mark Kankel.
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3.1 Introduction 
Evidence has shown that defects in mitochondrial homeostasis may be largely 
responsible for the accumulation of damaged mitochondria in dopaminergic neurons, ultimately 
leading to the cell death seen in Parkinson’s disease (Dawson and Dawson, 2010). It is known 
that both PARKIN and PINK1 are commonly mutated in recessive forms of genetic Parkinson’s 
disease (Corti et al., 2011) contributing to a pathology in which mechanisms which function to 
remove damaged mitochondria from cells may be defective. Both proteins appear to be vital in 
the regulation of mitochondrial quality by directing degradation of damaged mitochondria via 
mitophagy (Narendra et al., 2008). Though much of our work has focused on determining the 
effects of PARKIN activation, it is truly essential to clarify as much of the pathway involved as 
possible in order to progress in our understanding of Parkinson’s disease, therefore, to 
complement our studies of PARKIN, we sought to expand current knowledge regarding the role 
of PINK1 in relation to PARKIN and mitochondrial homeostasis. As we have described, PARKIN 
has been shown to translocate to the mitochondria after membrane depolarization in a PINK1-
kinase dependent manner. Under normal conditions, PINK1 is constitutively degraded; however, 
it is stabilized at the mitochondrial outer membrane upon mitochondrial depolarization where it 
acts to recruit PARKIN. Consequently, the outer mitochondrial membrane is extensively 
decorated with ubiquitin and the damaged organelles are eliminated via mitophagy. In order to 
better understand the role of PINK1 in this process, we have used mass spectrometry (LC-
MS/MS) and the Comparative Proteomics Analysis Software Suite (CompPASS) to identify 
high-confidence candidate interacting proteins (HCIPs) of PINK1 after CCCP-induced 
mitochondrial depolarization.  
Using our interactive proteomics platform we identified CLU1 as a PINK1-interacting 
protein. We have demonstrated that depletion of CLU1 in HeLa cells disrupts mitochondrial 
morphology and identified a genetic interaction between Pink1 and Clu, and Parkin and Clu in 
Drosophila. Though we have not yet completed our investigation of the role of CLU1 in the 
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PINK1/PARKIN pathway, evidence suggests that it may be a regulatory factor controlling the 
activity or localization properties of PINK1. 
3.1.1 PINK1 regulation and activation  
Though it accounts for a lesser percentage of cases than PARKIN, numerous mutations 
in PINK1 have been shown to cause early-onset familial Parkinson’s disease (Valente et al., 
2004). Originally identified as a PTEN-induced gene in cancer  cells, PINK1 contains an N-
terminal MTS, putative transmembrane region, Ser/Thr kinase domain, and C-terminal 
regulatory domain (Chu, 2010) (Figure 3.1a). Bioinformatic analysis has revealed unique 
sequences within the kinase domain and functional motifs in the C-terminal region that may be 
involved in unique regulation of kinase activity, substrate selectivity and stability (Mills et al., 
2008). PD mutations span the protein with varying effects on its function including stability of the 
protein, expression levels, truncation, association with chaperones such as HSP90, and 
importantly, activity of the kinase domain (Mills et al., 2008). PINK1 overexpression is protective 
against proteasome inhibitor-mediated cell death, MPTP and rotenone toxicity, and oxidative 
stress (Haque et al., 2008; Pridgeon et al., 2007; Valente et al., 2004; Wang et al., 2011a), 
effects which are eliminated by PD-associated mutations (Chu, 2010). Additionally, PINK1 may 
protect against injury associated with dominant genetic PD models as it has been shown to 
reduce α-synuclein-mediated retinal degeneration in Drosophila (Todd and Staveley, 2008, 
2012), while knockdown of PINK1 appears to contribute to proteasomal impairment and α-
synuclein aggregation in tissue culture cells (Liu et al., 2009a). Despite these striking effects on 
survival, little was known about PINK1 regulation, activation, or targets until recently and still, 
only a few target pathways have been identified. Evidence supporting the involvement of PINK1 
in regulating mitochondrial function, trafficking, and structure is now well confirmed, however, 
how PINK1 is regulated and how PINK1 exerts its neuroprotective function remain unclear. 
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Figure 3.1 PINK1 protein, import and processing. PINK1 contains a mitochondrial targeting 
sequence (MTS), transmembrane domain (TM), and kinase domain. b, Model for PINK1 import 
and processing. PINK1 is targeted to the mitochondria by the N-terminal MTS and imported into 
the inner mitochondrial membrane via the general mitochondrial import machinery, TOMM and 
TIM23 complexes. Under normal conditions, MPP cleaves the MTS to generate a 60-kD ∆MTS-
PINK1. PINK1 is then cleaved to a 52-kD form within the inner mitochondrial membrane by 
PARL. The 52-kD PINK1 is then degraded by an MG132-sensitive protease. Upon damage, 
When mitochondrial membrane potential is dissipated, PINK1 accumulates as a 63-kD full-length 
form on the OMM where it can recruit PARKIN to impaired mitochondria. OMM, outer 
mitochondrial membrane; IMM, inner mitochondrial membrane. 
Reports assert that PINK1 carries out both cytoplasmic and mitochondrial functions 
(Gandhi et al., 2006; Haque et al., 2008; Lin and Kang, 2008; Muqit et al., 2006; Narendra et al., 
2010b). For example, cytosolic PINK1 was shown to confer resistance to MPTP-induced stress 
in dopaminergic neurons (Haque et al., 2008), though staining of the WT protein supports 
mitochondrial localization (Gandhi et al., 2006; Haque et al., 2008; Lin and Kang, 2008; Muqit et 
al., 2006; Narendra et al., 2010b). Since the determination that PINK1 played a role in 
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mitochondrial function, a number of studies have been undertaken in attempts to understand its 
regulation. Under normal conditions with a healthy population of cellular mitochondria, PINK1 is 
constitutively degraded in a manner dependent upon mitochondrial membrane potential 
(Narendra et al., 2010b). Though rapidly turned over, PINK1 is targeted to the mitochondria by 
its MTS and imported via the general mitochondrial import machinery of the TOM/TIM23 
complexes into the inner mitochondrial membrane where it is cleaved by the mitochondrial 
processing protease (MPP) to produce a 60 kD ∆MTS-PINK1 (Figure 3.1b). A hydrophobic 
region downstream of the MTS may impede complete translocation of PINK1 across the inner 
membrane (Becker et al., 2012). Import is followed by a second cleavage within the inner 
mitochondrial membrane by presenilin-associated rhomboid like protease (PARL) which 
produces a 52 kD form of the protein that is subsequently degraded by an MG132-sensitive 
protease, presumably the proteasome (Deas et al., 2011; Jin et al., 2010; Meissner et al., 2011). 
Though evidence supporting this processing of PINK1 is compelling, it is not yet clear where the 
proteolysis occurs; however, if the proteasome is responsible, PINK1 is presumably removed 
from the mitochondria via reverse translocation. 
Exposure to ionophores, such as CCCP or valinomycin, results in mitochondrial 
depolarization, meaning the coupled reactions of electron transfer and H+ migration are 
uncoupled, allowing H+ ions to bypass ATP synthase and diffuse through the inner membrane 
thus destroying the pH and electrical gradients. Upon depolarization, full-length 63 kD 
endogenous PINK1 is immediately stabilized at the mitochondria in HeLa cells while no increase 
in PINK1 is seen in the cytoplasm (Narendra et al., 2010b). A similar phenomenon was 
observed in rat cortical neurons expressing tagged exogenous PINK1 (Narendra et al., 2010b; 
Zhou et al., 2008). Another approach used MFN1/2 null MEFS, which contain a heterogeneous 
mitochondrial population, some of which are bioenergetically uncoupled and others which are 
intact (Chen et al., 2005). As with treatment with uncoupling drugs, MFN1/2-/- mitochondria 
exhibit low membrane potential resulting in accumulation of PINK1 only on those affected 
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subsets of the population, an effect also observed after paraquat-induced oxidative stress, thus 
validating the selective stabilization of full-length PINK1 on mitochondria with low membrane 
potential  (Cocheme and Murphy, 2008; Narendra et al., 2010b). Thus, perturbation of the 
mitochondrial membrane potential results in accumulation of the full-length 63 kD form of PINK1 
on the outer mitochondrial membrane where it can extend its kinase domain into the cytoplasm. 
Evidence suggests that inner membrane proteases are nonfunctional after 
depolarization, potentially explaining how PINK1 escapes degradation (Jin et al., 2010). 
Furthermore, the C-terminus of the protein is thought to promote retention of PINK1 at the outer 
membrane (Becker et al., 2012). After being transferred laterally into the outer mitochondrial 
membrane, PINK1’s kinase domain is exposed to the cytoplasm allowing recruitment of 
PARKIN, which in turn, induces the degradation of the damaged mitochondria (Meissner et al., 
2011; Narendra et al., 2010b). This model of PINK1 regulation and activation provides an 
explanation of how the cytoplasmic protein, PARKIN, is itself selectively recruited to damaged 
mitochondria and explains how PARKIN distinguishes injured from healthy mitochondria. A 
recent study in HeLa cells showed that after repolarization, PINK1 is rapidly reimported and 
degraded, presumably via lateral opening of the TOMM complex which permits PINK1 to re-
enter the import pathway (Harner et al., 2011). Thus, association with the TOMM complex in 
depolarized mitochondria mediates rapid reimport and allows precise regulation of PINK1 levels 
resulting in displacement of mitochondrial PARKIN and rescue of repolarized mitochondria from 
the mitophagy response (Lazarou et al., 2012). 
Upon stabilization, PINK1 is active at the outer mitochondrial membrane, where it may 
target substrates, itself, or both, though few substrates have been reported or confirmed and 
reports of autophosphorylation have conflicted. A recent reported showed that 
autophosphorylation on PINK1 Ser228 and Ser402 after a decrease in membrane potential was 
essential for efficient mitochondrial localization of PARKIN (Okatsu et al., 2012). However, other 
groups have identified several other sites of autophosphorylation, including the depolarization-
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dependent modification of Thr257, though it does not appear to be required for PINK1 activation 
and is not highly conserved (Kondapalli et al., 2012). It is not clear how many and precisely 
which sites may be required for full activation of depolarization-dependent PINK1 kinase activity 
or if some of these sites may be off-target or nonessential consequences of kinase activation. In 
terms of PINK1 targets, very few have been identified. TNF receptor-associated protein 1 
(TRAP1), a mitochondrial chaperone of the HSP90 family, and HtrA2/Omi, a mitochondria 
serine protease, were both identified as substrates and shown to play roles in mediating 
protection against oxidative stress (Plun-Favreau et al., 2007; Pridgeon et al., 2007). Miro, a 
Rho-like GTPase located in the outer mitochondrial membrane, is also a PINK1 substrate 
targeted after mitochondrial depolarization (Wang et al., 2011b). Through binding to Milton, Miro 
promotes an interaction with kinesin heavy chain which results in trafficking of mitochondria 
along microtubules for axonal transport (Glater et al., 2006; Guo et al., 2005) (Figure 3.2). 
Overexpression or activation of PINK1 results in degradation of Miro and arrest of mitochondrial 
transport, contributing to the sequestration of the damaged population of mitochondria (Wang et 
al., 2011b). Obviously the best studied candidate substrate of PINK1 is PARKIN. Though PINK1 
kinase activity is required for PARKIN recruitment to the mitochondria and induction of 
mitophagy after depolarization, evidence for direct phosphorylation has been unsubstantiated 
and remains somewhat controversial (Becker et al., 2012; Kim et al., 2008b; Lazarou et al., 
2012; Moore, 2006; Sha et al., 2010; Shiba et al., 2009; Um et al., 2009). A recent report using 
recombinant insect PINK1 found direct phosphorylation on Ser65 of PARKIN leading to 
activation of its E3 ligase activity in an in vitro ubiquitylation assay (Kondapalli et al., 2012). 
However, though we do identify Ser65 phosphorylation in a depolarization-dependent manner, 
our in vivo data does not support an essential role for it in PARKIN activation. 
Mitochondria are actively transported throughout the cytosol, mainly along microtubules 
in mammalian cells  (Frederick and Shaw, 2007). In neurons, movement is regulated both by 
active transport and fusion/fission cycles (Sheng and Cai, 2012; Wang et al., 2011b). Through  
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Figure 3.2 PINK1/PARKIN-dependent arrest of mitochondrial trafficking. Mitochondrial 
depolarization stabilizes PINK1 on the OMM were it both recruits PARKIN and interacts with 
Miro. PINK1 phosphorylation of Miro appears to target it for PARKIN-mediated ubiquitylation 
and subsequent degradation by the proteasome. Milton and kinesin, which bridge the 
interaction with microtubules, are released from the mitochondria resulting in arrest of 
movement. 
effects on trafficking and fusion, PINK1 and PARKIN work together to affect mitochondrial 
localization (Figure 3.2); loss of balance between these proteins and their substrates leads to 
striking effects. For example, co-overexpression of PARKIN and PINK1 has been shown to 
disrupt the normally tubular mitochondrial network resulting in aggregation and perinuclear 
clustering of mitochondria (Vives-Bauza et al., 2010). Treatment with the microtubule 
depolarizing agent, nocodazole, causes dispersal of clustered mitochondria, thus underscoring 
the importance of microtubule transport networks in mitochondrial transport and maintenance of 
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the cellular pool of mitochondria (Vives-Bauza et al., 2010). It is also possible that mitophagy 
requires trafficking of damaged mitochondria to the perinuclear region for degradation, 
particularly in neurons, where the mitochondria may be dispersed at synaptic terminals, 
however, this retro-translocation of mitochondria remains controversial (Vives-Bauza et al., 
2010). Regardless, association with microtubules is essential in mitochondrial trafficking, 
response to injury, and the preservation of a healthy population of mitochondria. 
3.1.2 CLU1, a novel PINK1 interactor 
Though it is well substantiated that PINK1 is essential for PARKIN recruitment to 
mitochondria after CCCP treatment (Narendra and Youle, 2011), the specifics of PINK1 
regulation and its promotion of Parkin activity are incompletely understood. The ability to 
determine candidate interactors, regulators, or substrates of PINK1 may allow us to better 
understand how PINK1 regulation of PARKIN occurs. Through a proteomic approach, we have 
identified a candidate PINK1 regulatory factor, CLU1, shown to interact genetically with parkin in 
Drosophila (Cox and Spradling, 2009). Furthermore, mutation or depletion of CLU1 orthologs 
identified in Drosophila, Dictyostelium, and S.cerevisiae result in similar mitochondrial defects 
(Cox and Spradling, 2009; Fields et al., 1998; Zhu et al., 1997).  
First identified in Dictyostelium discoideum, the cluA gene encodes a 150 kDa protein 
which, when depleted, results in clustering of normally uniformly dispersed mitochondria in the 
center of the cell (Figure 3.3a, b) (Zhu et al., 1997). The cluA- mutant also displays an increase 
in multinucleated cells, potentially suggesting a cytokinesis defect (Zhu et al., 1997). These 
observations led to the hypothesis that cluA may link mitochondria and the cytoskeleton. Under 
normal conditions, mitochondria are generally dispersed throughout eukaryotic cells, though 
they can also be found concentrated in areas with high levels of ATP consumption. The position 
of microtubules within cells have been shown to determine mitochondrial distribution as well as 
ensure proper mitochondrial replication, division, and transport to daughter cells  (Berger and 
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Yaffe, 1996). Both cytoskeletal elements and components of mitochondrial membranes have 
been shown to be required for proper mitochondrial morphology and trafficking, especially in 
neurons which require a high density of mitochondria at synaptic terminals thus relying heavily 
on axonal trafficking of mitochondria (Glater et al., 2006; Itoh et al., 2013; Matsuda et al., 2009). 
By immunostaining, cytoskeletal structures appear normal in cluA- cells and the phenotype is 
not mimicked by cytoskeletal disruptive drugs (Fields et al., 2002). However, the clustered 
mitochondria in cluA- cells were often found to be interconnected by narrow membranous 
strands suggesting a blockage at a very late step in fission of the outer mitochondrial membrane 
(Fields et al., 2002). 
 
Figure 3.3 CLU1 domain structure and mitochondrial phenotype. a, CLU1 orthologs are 
highly conserved. Percentages indicate amino acid identity of the CLU and TPR domains. 
CLU, CLUstered mitochondria domain, TPR, tetratricopeptide repeat. b, WT Dictyostelium 
cells stained with DAPI to visualize nuclei and mitochondria (top panel). Mitochondria are 
clustered near the cell center in cluA- cells (bottom panel).  c, Anti-porin staining of wild-type 
(CLU1) cells displays normal branched mitochondrial morphology (top panel). Staining of 
mutant (clu1∆) cells displays clustered mitochondrial phenotype. d, Wild-type stage 5 follicles 
lack clustered mitochondria (green) (top panel). Extreme mitochondrial clustering in a stage 9 
park1/Df follicle (bottom panel). e, Wild-type stage5 nurse cells in a cyst contain  dispersed 
mitochondria (top panel) but cluster (arrows) in clu-  nurse cells (bottom panel). Microscopy 
images adapted from (Cox and Spradling, 2009; Fields et al., 1998; Zhu et al., 1997). 
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In Saccharomyces cerevisiae, the identification of a large protein, 27% identical and 
50% similar to cluA, termed CLU1, also showed mitochondrial defects upon disruption (Fields et 
al., 1998) (Figure 3.3a, c). In clu1∆ cells, the normally highly reticulated mitochondria are 
condensed to one side of the cell; however, upon transformation of CLU1 into cluA- 
D.discoideium cells, normal cell cycle is restored and mitochondria are once again dispersed 
throughout the cell, confirming that CLU1 is a functional homolog of cluA (Fields et al., 1998). 
Homology with the predicted sequence of the cluA gene product is also found in metazoans, for 
example friendly mitochondria (fmt) in Arabidopsis, shown to be required to prevent 
mitochondria from clustering. Also identified are the C. elegans gene clu-1 and the human 
ortholog, KIAA0664 (CLU1), though neither of these has been studied. Though clu appears to 
be highly conserved, little functional information has emerged. In 1999, it was identified as a 
possible component of the translation initiation factor eIF3 in yeast via co-immunoprecipitation 
and referred to as the gene, TIF31, and protein, p135 (Vornlocher et al., 1999). However, clu1∆ 
cells had no defect in activity of the eIF3 enzyme complex and it was later shown that homologs 
of CLU1 did not co-purify with the eIF3 complex from human or plant cells (Browning et al., 
2001). 
The PINK1/PARKIN pathway is known to be conserved in Drosophila, therefore it has 
commonly been used as a model for Parkinson’s disease. PARKIN null flies exhibit shortened 
life span, male sterility, and locomotor defects (Greene et al., 2003). The decreased fertility 
occurs due to a defect in spermatogenesis while apoptotic muscle generation causes the flight 
and climbing defects (Greene et al., 2003). Both phenotypes result from altered mitochondrial 
structure which affects both the germ line and muscle degeneration, indicating the potential 
significance of mitochondrial dysfunction in PD. The ortholog of cluA, clueless (clu), which 
encodes a highly conserved protein has been identified in Drosophila and is 53% identical to 
human Clu (Cox and Spradling, 2009) (Figure 3.3a). Similar to orthologous proteins in 
Dictyostelium and yeast, loss of Drosophila clu results in mitochondrial clustering (Figure 3.3d), 
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possibly at microtubule plus ends. In their effect on mitochondrial function, clu mutations 
resemble parkin mutations with null animals exhibiting decreased life span, sterility, and severe 
mitochondrial abnormalities in flight muscle (Figure 3.3c)  (Cox and Spradling, 2009). 
Though mammalian CLU1 is a large protein, approximately 150 kD, it contains few 
identifiable motifs. However, it does contain four highly conserved tetratricopeptide (TPR) 
repeats; TPR repeats usually fold together to produce a single, linear solenoid TPR 
domain which can form scaffolds to mediate protein–protein interactions or assembly of 
multiprotein complexes. CLU1 also contains an uncharacterized CLU (CLUstered mitochondria) 
domain unique to eukaryotic CLU1 orthologs (Figure 3.3a). Though not well studied, the CLU 
domain appears to be essential for proper mitochondrial function and the full-length protein is 
required for a late stage of MOM fission in Dictyostelium (Fields et al., 2002). Genetic interaction 
between parkin and clu was demonstrated by enhanced mitochondrial clustering in park/+; clu/+ 
trans-heterozygotes (Cox and Spradling, 2009). A role for CLU in mitochondrial localization and 
possibly mitochondrial dynamic and fusion/fission is strongly supported by evidence in multiple 
species. To our knowledge, our findings provide the first evidence of direct interaction between 
PINK1 and CLU1 and we are currently investigating whether CLU1 may control the activity, 
stability, or localization properties of PINK1. 
Protein networks are increasingly serving as tools to unravel the molecular basis of 
disease allowing the identification of new disease genes and identifying disease-related 
subnetworks. In order to better understand the PINK1/PARKIN pathway as a whole, we have 
again utilized the interaction proteomics method developed in our lab to identify high-confidence 
candidate interacting proteins of PINK1. Direct interrogation of physiological PINK1 protein 
complexes can be achieved through this approach allowing us to determine the interactors, 
regulators, or substrates of PINK1 with and without the induction of mitochondrial 
depolarization. Coupled with a variety of cell biological approaches, we hope to better 
understand how PINK1 regulation of PARKIN or other targets occurs. Using these methods, we 
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identified depolarization-independent PINK1 interactors located on the MOM, cytoplasmic 
interactors, such as CLU1, and the proteasome. PARKIN and PINK1-mediated remodeling of 
the outer mitochondrial membrane signifies an important step in the progression of mitophagy. 
An understanding of the networks surrounding these proteins may ultimately provide information 
about the progression and possible treatment of neurodegenerative disorders. 
3.2 Results 
3.2.1 Identification of novel PINK1 interactors 
In order to better appreciate PINK1’s contribution to the PINK1/PARKIN pathway, we 
utilized AP-MS and our interactive proteomics platform, CompPASS to interrogate this node of 
the pathway. After verifying mitochondrial localization and depolarization-dependent processing 
of C-HA-Flag-tagged PINK1 in 293T cells (Figure 3.4a), we performed HA-immunoprecipitation 
followed by mass spectrometry both in the presence and absence of 1 hour of CCCP. Using our 
interactive proteomics platform, we have identified candidate interactors, regulators, or potential 
substrates of PINK1, including both mitochondrial and cytoplasmic proteins. Under both 
untreated and depolarized conditions, PINK1 interacted with multiple components of the TOMM 
complex, including TOMM40, TOMM22, TOMM70, TOMM6 and TOMM34. Furthermore, PINK1 
co-purified with a number of proteasome subunits and numerous mitochondrial outer membrane 
proteins, such as VDAC2, in addition to cytoplasmic proteins (Figure 3.4b, Supplementary Table 
9). A number of other MOM proteins, including HK1, HK2, and HK3 were also identified but did 
not pass our stringent threshold for HCIPs. Of particular interest was KIAA0664, or CLU1, which 
was identified as a high confidence interacting protein under both treatment conditions.  
Numerous proteins identified as PINK1 HCIPs were validated as interactors in HeLa 
cells stably expressing PINK1-C-HA-Flag which were either untreated or subjected to 
mitochondrial depolarization by treatment with CCCP for 1 hour (Figure 3.4b). As in 293T cells, 
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the majority of PINK1 interactors in HeLa cells, including subunits of the TOMM complex and 
CLU1, were seen both in the presence and absence of CCCP. 
 
Figure 3.4. PINK1 interaction proteomics. a, Fractionation of C-HA-Flag-tagged PINK1 stable 
cell line used in this study. WCE, whole cell extract, MITO, mitochondrial fraction, CYTO, 
cytoplasmic fraction. Cells were either untreated or treated with 10µM CCCP and/or 1µM Btz for 1 
h. Arrows indicate PINK1 full-length protein (63 kD) and cleavage products, 60 kD, which is 
lacking the MTS, and 52 kD. b, Summary of subset of PINK1-interacting proteins found under 
both untreated and depolarized conditions (1h 10µM CCCP and/or 1µM Btz) in 293T and HeLa 
cell lines. Full dataset is included in Supplementary Table 9. 
3.2.2 CLU1 is a bona fide PINK1 interactor 
Based on the interaction data generated from both 293T and HeLa cells lines stably 
expressing PINK1, we identified CLU1 as a candidate PINK1 interacting protein. Because 
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antibodies that efficiently immunoprecipitate endogenous CLU1 were not available, we further 
validated the interaction of CLU1 with endogenous PINK1 in HeLa cells transiently transfected 
with N-MYC-CLU1 either untreated or treated with CCCP for 1 hour. Using anti-MYC agarose to 
purify N-MYC-CLU1, we confirmed depolarization-independent interaction with endogenous 
PINK1 via immunoblotting (Figure 3.5).  
 
 
Figure 3.5 Validation of interaction between CLU1 and PINK1. Reciprocal interaction 
between CLU1 and PINK1 was identified in HeLa cells transiently transfected with N-MYC-
CLU1. After 48h, cells were treated with 1h CCCP (10µM) and subjected to 
immunoprecipitation with anti-MYC agarose and immunoblotted with the indicated antibodies. 
3.2.3 clueless interacts genetically with both pink1 and park in Drosophila 
A previous report identified a genetic interaction between clueless and park in 
Drosophila (Cox and Spradling, 2009). In collaboration with the Artavanis-Tsakonas lab, we 
sought both to confirm this finding in Drosophila and to examine the relationship between the fly 
orthologs, clueless (clu) and pink1. We examined three Exelixis clueless alleles for modification 
of the held out wing phenotype of tubGAL4 directed expression of multiple UAS-parkinRNAi and 
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UAS-Pink1RNAi alleles. Clu alleles tested included the null alleles, d08713 and f04554, and a 
hypomorph, f04554, based on Cox and Spradling, 2009 (Figure 3.6a, b). The penetrance of the 
phenotypes of the sample genotypes, clueless/tubGAL4-parkin and clueless/tubGAL4-Pink1 
were calculated (Figure 3.6c, Supplementary Table 10). In addition to validating the clueless 
and park interaction, we also determined that clueless null mutations enhance the classic “held 
out wing” phenotype seen in tubGAL4:UASpink1RNAi and tubGAL4:UAS-parkRNAi flies, thus 
establishing that a genetic interaction may exist between clueless and PINK1. 
 
 
Figure 3.6 Genetic interactions between clu, park, and Pink1. a, Map of the clu locus showing 
sites of insertion mutation (triangles) and the translation start (arrow). Black boxes are exons 
(adapted from Cox and Spradling, 2009). b, Clueless alleles and associated phenotypes 
observed in a previous study (Cox and Spradling, 2009). c, Summary of the clueless interactions 
with multiple parkin alleles. d, Summary of the clueless interactions with multiple Pink1 alleles. 
This data was obtained in collaboration with the Artavanis-Tsakonas lab with all experiments 
performed by Mark Kankel. 
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3.2.4 CLU1 interaction and domain analysis 
To better understand how CLU1 might be influencing the PINK1/PARKIN pathway, we 
created a 293T cell line stably expressing CLU1-C-HA-Flag (Figure 3.7b). Via anti-HA 
immunoprecipitation, we purified CLU1 with and without 1 hour of CCCP treatment.  Using AP-
MS in conjunction with the CompPASS proteomics software platform, we attempted to identify 
high confidence CLU1-interacting proteins. Unexpectedly, CLU1 interacted with very little both 
in the presence and absence of depolarization; indeed, we did not identify PINK1 as a high 
confidence interacting protein (Supplementary Table 11). We considered the possibility that C-
terminal tagging of CLU1 might have interfered with its ability to interact with binding partners or 
with proper folding or localization of the protein. To address this potential issue, we created a 
293T cell line stably expressing N-HA-Flag-CLU1. However, AP-MS analysis again produced no 
reproducible interactors for CLU1, suggesting that ectopically tagging CLU1 may not be a 
suitable way in which to study the protein. Alternatively, we may not have captured CLU1 under 
conditions which allow its interactions to occur, though transient transfection of N-MYC-CLU1 
did validate interaction with PINK1 (Figure 3.5). 
In an effort to characterize CLU1 and dissect its interaction with PINK1, we constructed 
truncation mutants of CLU1. We examined the protein sequence of CLU1 to identify any known 
or potential domains in addition to the TPR repeats and CLU domain. Truncations were 
designed based on alignment of human CLU1 with the Drosophila clueless protein (Figure 
3.7a). We created five truncation mutants spanning the whole protein, including isolated CLU 
domain and TPR motif mutants expressed as C-terminally HA-Flag-tagged proteins. Similarly to 
the full-length protein, AP-MS analysis of the CLU1 domains did not reveal any high confidence 
interacting proteins (Supplementary Table 11). 
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3.2.5 Depletion of CLU1 alters mitochondrial morphology 
To elaborate on the role of CLU1 in mitochondrial maintenance, we use RNAi to deplete 
CLU1 in HeLa cells for 72 hours, after which cells were fixed for immunofluorescence 
depolarization. We found that loss of CLU1 led to alterations in mitochondrial morphology in 
comparison to control siRNA-treated cells (Figure 3.8). Additionally, the total amount of 
mitochondria per cell appeared to be increased in cells treated with CLU1 siRNA. Likewise, the 
network of mitochondria was expanded throughout the cell and seemingly more fragmented 
than in control cells, consistent with a role for CLU1 in mitochondrial dynamics independently of 
PARKIN. CLU1 was also included in our RNAi screen for PARKIN interactors (Chapter 2.2.8) 
and scored as a positive in the screen for increasing total mitochondrial area after depletion 
(Figure 2.22), thus validating our original finding. 
3.2.6 CLU1 may affect PINK1 activity 
We have established that CLU1 interacts genetically with both PINK1 and PARKIN, 
interacts physically with PINK1, and appears to be necessary for maintenance of normal 
mitochondrial morphology. Both because it interacts with PINK1 in the presence and absence of 
mitochondrial depolarization and contains a TPR domain, often involved in protein-protein  
 
 
Figure 3.7 CLU1 constructs used in this study. a, Full-length human CLU1 and truncation 
mutants used in AP-MS experiments. b, 293T cell extracts immunoblotted to detect CLU1 C-HA-
Flag-tagged constructs used for AP-MS experiments. 
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Figure 3.8 Effects of CLU1 depletion on mitochondrial organization. Mitochondrial marker, 
TOMM20, is used to stain the mitochondria in HeLa cells. 
interaction or scaffolding, we believe that CLU1 may control the activity status or localization 
properties of PINK1. To determine whether PINK1 activity is affected by loss of CLU1, we 
treated HeLa cells with siRNA targeting CLU1, followed by transient transfection of MYC-
PARKIN 24 h later. Finally, at 72 hours post-siRNA transfection, we treated cells with 1 h of 
CCCP (10µM) or CCCP (10µM) and Btz (1µM). Depletion of CLU1 did not affect processing of 
PINK1 after mitochondrial depolarization, however, total levels of PINK1 appear to be slightly 
reduced upon immunoblotting (Figure 3.9a). Ubiquitylation of MFN2, catalyzed by PARKIN in a 
PINK1-dependent manner after CCCP treatment, is a useful readout of PINK1 activity. MFN2 
ubiquitylation was reduced upon CLU1 depletion, though not completely abolished; however, we 
did not achieve complete knockdown of the highly expressed CLU1 protein (Figure 3.9a). We 
then examined the effects of PINK1 depletion on CLU1. As expected siRNA targeting PINK1 
abolished MFN2 ubiquitylation (Figure 3.9b). However, we also noted that CLU1 levels were  
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Figure 3.9 Effects of CLU1 depletion in HeLa cells. a, siRNA-mediated depletion of CLU1 in 
HeLa cells diminished MFN2 ubiquitylation and may decrease total PINK1 and PARKIN levels. b, 
siRNA-mediated depletion of PINK1 in HeLa cells abolishes MFN2 ubiquitylation. PINK1 loss 
appears to increase total levels of CLU1 and may decrease total PARKIN levels. Cells are treated 
with 1 h of CCCP (10µM) or CCCP (10µM)  and Btz (1µM). *, non-specific band recognized by α-
PINK1 antibody. Arrows indicate PINK1 forms (full-length, 63kD; ∆MTS, 60kD; and PARL-cleaved, 
52kD). 
 
drastically increased in the absence of PINK1 (Figure 3.9b). It is possible that CLU1 and PINK1 
may physically interact in a manner that supports the other’s stability, though we need further 
studies to fully understand this data. Of interest, we also noted that MYC-PARKIN levels varied 
considerably in the absence of PINK1 and CLU1, corresponding to the degree of knockdown 
(Figure 3.9a, b). There have been a few reports suggesting that PINK1 regulates total PARKIN 
cellular levels (Um et al., 2009), however, until we repeat this result in cells stably expressing 
PARKIN, we cannot rule out variability due to transfection. 
3.3 Discussion  
Loss-of-function mutations in PINK1 are associated with genetic Parkinson’s disease 
(Valente et al., 2004). PINK1 and PARKIN have been shown to function in the same pathway to 
maintain mitochondrial fitness thus further supporting the model for mitochondrial dysfunction in 
Parkinson’s disease. The process of PINK1 and PARKIN-mediated remodeling of the 
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mitochondrial membrane after depolarization is an important step in the progression of 
mitophagy and our aim is to better understand how this signaling is regulated. We know that the 
PINK1 kinase can recruit PARKIN to the mitochondria to facilitate ubiquitylation on the 
mitochondria after membrane depolarization, however, it is currently being debated as to 
whether PINK1-dependent phosphorylation of PARKIN is direct or if another substrate might 
contribute toward mitochondrial translocation and activity of Parkin. Here we describe the 
results of PINK1 interaction proteomics both before and after mitochondrial depolarization, 
revealing the context in which PINK1 functions in cultured cells. 
Our analysis revealed an interaction with the translocase of the outer membrane 
complex (Figure 3.4b). This interaction was recently reported by another laboratory using native 
gels to demonstrate that endogenous PINK1 binds the TOMM complex on depolarized 
mitochondria, a scenario which is proposed to allow rapid reimport of PINK1 in order to rescue 
repolarized mitochondria from mitophagy (Lazarou et al., 2012). Interestingly, we found that 
PINK1 interacted with approximately equivalent amounts of TOMM subunits both in the 
presence and absence of depolarization. It is possible that our method is more sensitive thus 
more likely to identify the interaction. It is also possible that overexpression of PINK1 in our 
assay could be increasing the amount of full-length PINK1 available for binding – possibly it is 
overwhelming the PINK1 processing machinery. However, western blot analysis of our stable C-
terminally tagged PINK1 cell lines showed that processing appeared to occur as expected – we 
saw the expected increase in full-length PINK1 after CCCP treatment and the cleaved 52 kD 
form after proteasome inhibition (Figure 3.4a). Regardless of this discrepancy, our data is in 
agreement with the finding that PINK1 strongly interacts with the TOMM complex, with the 
highest scoring interactors including TOMM40, TOMM70, TOMM22, and TOM20, which was 
shown to mediate the interaction with PINK1 (Lazarou et al., 2012). 
 Though the interaction with the translocase was exciting, we were very intrigued by the 
identification of CLU1 as a candidate PINK1 high confidence interacting protein. Based on the 
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data available about its role in Drosophila and yeast (Cox and Spradling, 2009; Fields et al., 
1998), we think CLU1 may potentially control the activity, localization properties, or cytoskeletal 
interactions of PINK1. Furthermore, because we showed the genetic interaction between CLU1 
and both PINK1 and PARKIN, we expect that CLU1 is important for PINK1-PARKIN function in 
human cells, as it appears to be in Drosophila. To date, we have confirmed the interaction with 
PINK1 in two cell types and determined that loss of CLU1 drastically affects mitochondrial 
morphology and may have an effect on PINK1 activity (Figure 3.5, Figure 3.8, Figure 3.9). 
Though our study is not yet complete, we are interested in determining in detail how CLU1 is 
affecting the mitochondria. There are numerous ways in which CLU1 may be linked to the 
PINK1/PARKIN pathway. First, loss of CLU1 may cause damage to the mitochondria, resulting 
in loss of membrane potential, thus activating the PINK1/PARKIN response. It is likely that the 
phenotype observed upon CLU1 knockdown may affect membrane potential similarly to the way 
MFN1/2 knockout does through an effect on fusion/fission cycles. The increase in total cellular 
mitochondria that we observe may be the result of a fission defect, possibly a defect late in 
mitochondrial fission of the MOM, an explanation offered for the phenotype in cluA- 
Dictyostelium (Fields et al., 2002). However, we do observe a direct interaction of PINK1 with 
CLU1, suggesting that the relationship between these proteins is more than just indirect 
activation of PINK1 by mitochondrial damage. 
 A second way in which CLU1 might be affecting PINK1 is through a scaffolding or 
regulatory role, which might ultimately affect PINK1 activity. The CLU domain and TPR repeats 
found in CLU1 are highly conserved in eukaryotic CLU1 orthologs, indicating that they are likely 
extremely important for CLU1 function. In fact, rescue of the null requires the full-length protein 
in Dictyostelium, further underscoring the importance of each domain, however, the precise 
function of the CLU domain remains unknown (Fields et al., 2002). In Dictyostelium, cluA may 
regulate interaction with microtubules (Fields et al., 2002). A dysregulated interaction with 
microtubules could also explain the mitochondrial clustering seen in yeast and Dictyostelium 
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upon knockout. Mitochondrial movement is regulated by engagement of plus-end-directed 
Kinesin motors and minus-end-directed Dynein motors. Because most membranous organelles 
are moved around the cell by trafficking via microtubules, any interference with this pathway 
could easily lead to abnormally situated or possibly unhealthy mitochondria – proper 
mitochondrial movement and distribution are critical for their localized function in cell 
metabolism, growth, and survival. CLU1 is thought to be a cytoplasmic protein; therefore, we 
need to understand where it might be interacting with PINK1. It is possible that CLU1, PARKIN, 
and PINK1 interact at the mitochondrial interface with motor proteins on microtubules thus 
potentially regulating mitochondrial movement by bridging different motors and transport 
systems. Such regulation can also be important for maintenance of healthy mitochondria. For 
example, fusion events can occur when two mitochondria are in close proximity, allowing 
exchange of soluble intermembrane and matrix proteins (Liu et al., 2009b). Furthermore, fusion 
can allow damaged mitochondria to merge with healthy mitochondria and be restored through 
mixing of contents. These events both require and promote mitochondrial motility and contribute 
fundamentally to mitochondrial maintenance. Furthermore, mitochondria are typically found 
distributed along cytoplasmic microtubules and evidence has shown that intact 
microtubule/mitochondrial interaction may be necessary for proper mitochondrial biogenesis 
(Karbowski et al., 2001).  
In the case of neurons, loss of the ability to transport and localize mitochondria correctly 
could be particularly deleterious. Research has shown that disruption of microtubules decreases 
membrane potential and alters Ca2+ levels in neuronal mitochondria in addition to interfering 
with necessary mitochondrial and ER contacts mediated by microtubules (Mironov et al., 2005). 
Additionally, microtubules are required for axonal transport of mitochondria, a pathway to which 
PINK1 and PARKIN have already been linked through interaction with RHOT1 and kinesin 
heavy chain (Wang et al., 2011b). The tetratricopeptide repeats present in CLU1 also suggest 
that it may play some sort of scaffolding role as they are primarily found to mediate protein-
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protein interaction, often contributing to the assembly of multiprotein complexes (Das et al., 
1998). TPR repeat regions are involved in a variety of biological processes, including 
mitochondrial protein transport – they are found in TOMM70 and thought to be required for 
recruitment of soluble proteins to the mitochondrial surface essential for maintaining 
mitochondrial shape (Kondo-Okamoto et al., 2008). It is possible that CLU1 may play a role in 
linking PINK1 and PARKIN with the microtubule network and possibly contribute to 
mitochondrial homeostasis. Further studies are necessary to determine how loss of CLU1 may 
affect mitochondrial membrane potential as well as motility. 
Our first approach for studying CLU1 though interaction proteomics has proven 
challenging since CLU1 did not appear to reproducibly interact with any proteins. Furthermore, 
truncation mutants designed to examine the individual domains also showed few reproducible 
interactors. It may be that expressing a tagged version of CLU1 interferes with either its own 
folding or its potential scaffolding function. We will need to perform further experiments using 
different approaches to understand CLU1’s functions. Amongst the data necessary to collect 
includes determining how loss of CLU1 affects membrane potential, cell cycle, and PINK1 
localization. Fractionation experiments or native gel assays from whole cell lysate will be useful 
in determining CLU1 interactors. Because the mechanism by which PINK1 recruits PARKIN to 
mitochondria is still unclear, we will determine whether loss of CLU1 affects the kinetics of 
PARKIN recruitment to mitochondria after PINK1 activation, a possibility supported by the 
interaction data from Drosophila. Additionally, we are developing an in vitro kinase which will 
allow us to examine PINK1 activity using phosphorylation of PARKIN as a readout. We are 
using a baculovirus produced in the Shokat lab expressing PINK1 together with chaperone 
protein TRAP1, which allows active PINK1 kinase to be purified.  
PINK1 acts as a pivotal regulator of mitochondrial quality control through numerous 
avenues. In conjunction with PARKIN and the autophagy machinery, PINK1 effectively removes 
unhealthy mitochondria from the cell. Failure of this ultimate stage of quality control leads to cell 
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death. Therefore, identification and characterization of PINK1 interacting proteins, such as 
CLU1, is also critical in understanding how cells maintain a healthy mitochondrial population. 
Thus, PINK1, and potentially CLU1, plays a fundamental, multifactorial role in mitochondrial 
homeostasis, study of which will prove effective for better understanding the pathology and 
treatment of Parkinson's disease.  
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CHAPTER 4 
Significance and Future Directions  
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4.1 Significance 
Mutations in PARKIN or PINK1 are the most common causes of recessive familial 
parkinsonism. These proteins form a mitochondria quality control pathway that identifies 
dysfunctional mitochondria, isolates them from the mitochondrial network, and promotes their 
degradation by autophagy. Our study provides the first quantitative description of the PARKIN-
modified proteome, including the identification of hundreds of ubiquitylation sites in candidate 
PARKIN targets. This information holds the potential to reveal countless aspects of 
mitochondrial quality control and regulation, some of which we have started to explore and 
develop for future projects. Additionally, we have demonstrated that diGly capture proteomics 
can be used to identify substrates of a single E3 in a signal-dependent manner. Additionally, we 
have established numerous assays, including a new approach for studying PARKIN-dependent 
ubiquitin transfer to MOM substrates in vitro, which will allow the lab to continue to explore the 
wealth of data our study has produced. Our data physically links PARKIN targets to mitophagy 
and quantitatively describes the magnitude of depolarization-dependent ubiquitylation. 
Furthermore, we have created a map depicting the topology and landscape of PARKIN action 
on the MOM as well as on an assortment of previously unrecognized cytoplasmic proteins. 
Finally, we have created a web resource which provides public access to all of our diGly data. 
We hope this will provide a valuable resource for the PARKIN field, which can be used to 
interrogate the structural biology and dynamic changes that occur in the PARKIN-modified 
proteome. 
 In parallel, we have sought to expand current knowledge of PINK1’s role in this pathway 
and have identified a novel interactor, CLU1, shown to regulate mitochondrial morphology in 
lower eukaryotes. Our data suggests that CLU1 may function to regulate PINK1 activity and 
contributes to mitochondrial maintenance in mammalian cells. This protein may represent a 
newly identified node of regulation for the PINK1/PARKIN pathway which we have yet to fully 
understand. Though our work is removed from the direct alleviation of the distress of a 
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Parkinson’s-afflicted patient, we believe that in order to truly treat or attempt to cure Parkinson’s, 
it is essential to understand the molecular basis of the disease. Though great advances in 
managing Parkinson's disease have been made in the last few decades, dopamine replacement 
remains the most potent drug for controlling PD symptoms. However, it is associated with 
numerous side-effects after prolonged treatment, including loss of efficacy. Knowledge of the 
contributions of disparate genetic and environmental factors to development of PD continues to 
be expanded, thus highlighting the need for individualized and tailored treatment options. This 
further underscores the need to fully understand the molecular origins of the disease. We began 
with a global approach to define the altered landscape of the cellular proteome upon 
mitochondrial depolarization. The role of mitochondrial dysfunction in neurodegenerative 
disease is currently an area of intense study since perturbation of these vital organelles can 
affect energy production, free radical generation, Ca2+ buffering, and cell death, ultimately 
leading to the failure of dopaminergic neurons in Parkinson’s disease. Our approach has helped 
us identify numerous new subjects of interest spanning the entirety of the PINK1/PARKIN 
pathway which will be introduced in the following section. 
The roles of PARKIN and PINK1 have been established in the turnover of damaged 
mitochondria and possibly other processes linked with reactive oxygen species and even 
tumorigenesis. Nevertheless, the actual physiological substrates of PARKIN’s ubiquitin ligase 
activity important for its quality control functions have been poorly defined until now. We expect 
the compendium of validated PARKIN targets we have constructed to have significant impact in 
the field. Because the majority of previously published PARKIN targets have not been 
successfully validated, it has been difficult to move forward with an understanding of PARKIN 
function and potential therapeutic modalities. Our studies have provided a validated list of 
candidate substrates for further analysis by the field. We also believe it will be incredibly useful 
to develop reagents (i.e. antibodies or proteomic standards) that will allow detection of 
ubiquitylation of validated PARKIN targets in various disease tissues, potentially revealing 
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defects in the PARKIN system in a clinical setting. Finally, the ultimate application of our work 
would be to provide opportunities for development of therapeutics that circumvent a role for 
PARKIN or PINK1 in promoting mitochondrial and neuronal health.  
4.2 Future Directions 
4.2.1 CALCOCO2, TAX1BP1, LC3C, and TBC1D15 may link mitochondria and autophagy 
machinery 
Despite extensive investigation by numerous groups, much of the detail of the mitophagy 
pathway – from specific steps in initiation to details of autophagy regulation – remains a 
mystery. Though it will involve effort from multiple labs and many years to construct a full and 
detailed map of the pathway, we have selected a number of pressing unanswered questions on 
which to focus our future studies. In order to place in context the PARKIN substrates that we 
have identified, we intend to further develop our RNAi-screening strategy. We have identified 
proteins which may be important in the initial translocation of PARKIN to the mitochondria as 
well as proteins which may have a role in the overall progression of mitophagy. We intend to 
follow-up on the initial list of hits for both screens through targeted studies of the individual 
genes of interest. One way to do this will include examining the requirement for PARKIN-
mediated ubiquitination of these candidate substrates via RNAi depletion experiments in 
conjunction with rescue using substrates lacking the lysine of interest. Certain subsets of these 
genes are of particular interest, particularly those which may play roles as autophagy adaptors 
(TAX1BP1, CALCOCO2, and SQSTM1). 
TAX1BP1 and CALCOCO2/NDP52 are structurally related and may work together to 
bridge ubiquitylated mitochondria with the autophagy machinery. CALCOCO2 was shown to 
interact with the ATG8 protein LC3C via an LC3-interacting region (LIR) to promote autophagic 
clearance of Salmonella (Thurston et al., 2009). Staining of LC3 is often used to demonstrate 
colocalization of a protein or organelle of interest with autophagosomes; however, though some 
studies have demonstrated colocalization of damaged mitochondria and LC3B, the degree of 
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overlap is generally unimpressive. We believe this may be because LC3C, for which efficient 
antibodies do not yet exist, may actually be the ATG8 protein associated with mitophagy. Both 
TAX1BP1 and CALCOCO2 are highly enriched in purified autophagosomes and 
immunofluorescence experiments indicate that the endogenous proteins colocalize with 
autophagosomes (Newman et al., 2012; Thurston et al., 2009). In support of a role for these 
proteins, we have found that both CALCOCO2 and TAX1BP1 are ubiquitylated in a PARKIN-
dependent manner and associate stably with PARKIN in the presence of BafA. In addition, 
TBC1D15, a candidate RAB GAP, is ubiquitylated in a PARKIN-dependent manner, interacts 
with FIS1 on the MOM (Onoue et al., 2012), binds PARKIN in the presence of BafA, and 
interacts with the ATG8 isoform GABARAP in a LIR-dependent manner (Behrends et al., 2010). 
Our preliminary RNAi-mediated depletion experiments suggest that loss of LC3C or the 
combined absence of CALCOCO2 and TAX1BP1 results in a delay in clearance of 
mitochondria. In combination with LC3C depletion and colocalization experiments, we hope to 
show that these proteins are involved in mitochondrial clustering or targeting the delivery of 
ubiquitylated mitochondria to the autophagosome for destruction. 
4.2.2 Non-specific ubiquitylation on the mitochondrial surface may trigger mitophagy 
 We have repeatedly identified a cohort of mitochondrial outer membrane proteins as 
both substrates and interactors of PARKIN; therefore, it seems that PARKIN could be targeting 
a specific population of proteins after mitochondrial depolarization. However, though it is very 
possible that PARKIN does recognize specific substrates, perhaps through cooperation with 
varied E2 or scaffolding proteins, we cannot rule out the possibility that once activated, PARKIN 
may ubiquitylate nonspecifically. Using motif-x, we were unable to identify any pattern 
similarities in the ubiquitylation sites of Class 1 PARKIN targets, the highest confidence 
substrates. Additionally, ubiquitylation occurred on α-helices, β-sheets, and globular domains of 
these proteins with the most apparent similarity being that many were located on the 
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mitochondrial outer membrane. This has led us to consider the possibility that ubiquitin density 
on mitochondria as opposed to site-specific ubiquitylation is central to mitophagy. Fusion of a 
ubiquitin G76V mutant to peroxisomal membrane proteins was shown to be sufficient to induce 
their selective autophagy if ubiquitin was extended into the cytosol (Kim et al., 2008a), 
supporting the notion that this process may be regulated more by the presence of ubiquitin 
rather than exactly where the ubiquitin is conjugated. 
 To attempt to test this alternative hypothesis, we are developing reagents to use a 
chemical dimerizer approach to directly examine the effects of targeting ubiquitin to the 
mitochondria in the absence of depolarization. Similar to a previously published report (Komatsu 
et al., 2010), we have created cell lines expressing TOM20-YFP-FRB which dimerizes with 
CFP-FKBP-ubiquitin upon the addition of a rapalog, thus promoting recruitment of the FKBP 
construct to the mitochondrial outer membrane. This approach has been attempted by one 
group using transient co-transfection of UbG76V-EGFP-FKBP and a FRB-FIS1 construct 
(Narendra et al., 2010a). Though ubiquitin was observed at the mitochondrial membrane, no 
detectable reduction in mitochondrial mass was observed after 24 hours of rapalog treatment. 
We intend to further optimize this approach, first by stably expressing all of the FRB and FKBP 
constructs in HeLa cells to reduce variability inherent in transient transfection. Second, we are 
developing a variety of constructs that will allow us to test this model using recruitment of 
various types of ubiquitin chains to the MOM. We will fuse the FKBP protein to non-hydrolyzable 
tetra Ub or mono-Ub, or to degrons that are constitutively ubiquitylated with the desired chain 
types, thus allowing us to create a system in which levels of ubiquitin on the MOM can be 
temporally controlled independently of depolarization. Because PARKIN appears to be capable 
of constructing both K48- and K63-linked chains, we will attempt to target both of these chain 
types to the mitochondria. CFP-FKBP will be expressed in fusion with a degron from surfactant 
protein C (SPC) that is recognized by the WW-domain of the NEDD4 ubiquitin ligase, a 
constitutively active E3 (Conkright et al., 2010; Kotorashvili et al., 2009). A well-characterized 
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lysine residue in SPC will serve as the site of constitutive K63 poly-ubiquitylation, which can be 
targeted to the mitochondria upon the addition of a rapalog. We will also attempt to create K48-
linked chains at the mitochondria using a similar approach employing the fusion of CFP-FKBP 
with a constitutively phosphorylated transferable degron containing lysine recipient sites for 
SCF-βTRCP from Vpu (phosphorylated by CK1) or employ an auxin-inducible degron (AID) 
system which uses a small molecule to conditionally control ubiquitin chain assembly 
(Estrabaud et al., 2007; Nishimura et al., 2009). If we are able to successfully observe 
ubiquitylation at the mitochondria, we will be able to use this system to measure the kinetics and 
saturation of the ubiquitin/degron-CFP-FKBP loading onto mitochondria (with and without BafA 
to block degradation) as well as mitochondrial clustering, total area, and co-localization of 
mitochondria with ATG8-positive autophagosomes as a measure of mitophagy. This effort will 
allow us to address our alternative hypothesis that ubiquitin density rather than site-specific 
ubiquitylation is the rate-limiting signal in mitophagy. 
However, the induction and progression of mitophagy is likely not quite so simple. Some 
proteins, for example, MFN1/2, are degraded in a PARKIN-dependent manner prior to 
mitophagic clearance of mitochondria. There must be some way in which these proteins are 
being targeted for degradation while others create a signal for autophagy. This may be through 
the different chain linkages which PARKIN is presumably attaching to these proteins, thus 
highlighting another area of interest. 
4.2.3 Determination of PARKIN chain linkages in vivo and in vitro PARKIN activation and 
mechanism 
 One extremely important aspect of PARKIN biology which needs to be better understood 
is the type of ubiquitin chain linkages PARKIN creates and how PARKIN directs construction of 
these specific linkages on, presumably, specific substrates. An understanding of the functional 
and mechanistic basis for chain-linkage specific PARKIN-mediated poly-ubiquitylation will 
provide us with an understanding of the molecular mechanisms underlying PARKIN function 
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and how PD mutations might affect mitochondrial homeostasis. Investigation of this question is 
linked to improving our understanding of how PARKIN is activated and the enzymatic 
mechanism though which PARKIN ligase activity is controlled. We have proposed a few ways in 
which to explore these questions which combine proteomic and genetic approaches. 
 Previous work has shown that PARKIN may catalyze K6-, K27-, K48- and K63-linked 
chains (Chan et al., 2011; Durcan et al., 2011; Geisler et al., 2010). It is a mystery and also 
somewhat controversial as to how one E3 ligase is able to do this; however, little is actually 
known about the mechanism of PARKIN activity. Ubiquitin chain-type specific antibodies have 
been used in the past to examine PARKIN substrates, but at present, antibodies targeting only 3 
out of 7 chain types are available. We want to systematically and quantitatively examine the 
ubiquitin chains present after PARKIN activation using multiplex AQUA proteomics the employ 
heavy-labeled diGly peptides corresponding to the 7 possible lysine linkages in ubiquitin 
(Kirkpatrick et al., 2005a). We believe we can examine the types of chains present on purified 
mitochondria as well as purified PARKIN substrates, and PARKIN itself. Furthermore, we can 
combine AQUA proteomics with our in vitro ubiquitylation system to precisely and quantitatively 
monitor PARKIN-dependent chain formation. 
4.2.4 Mechanism of PARKIN activation and effects of disease mutations 
 The study of how PARKIN directs specific chain linkages is intertwined with the 
investigation of PARKIN enzymatic function on a mechanistic level. The mechanism of the 
RING-IBR-RING family of E3 ligases, of which PARKIN is a member, is poorly understood. 
Furthermore, the recent identification of a HECT-like active site in PARKIN demonstrates the 
enigmatic nature of this enzyme. Dissection of the enzymatic mechanism by which PARKIN 
functions and determining whether it behaves in vivo as it has been shown to in vitro is crucial. 
We have already discussed recent studies which suggest that PARKIN exists in an auto-
inhibited form until activation. Our data supports the model that upon mitochondrial damage, 
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PARKIN becomes activated in a process that requires phosphorylation by PINK1 (likely on 
multiple sites) and the active site Cys of PARKIN. We will further investigate this process in cells 
and in vitro while optimizing the in vitro ubiquitylation system we have already developed in 
combination with biochemical and cell biological assays. 
It is still unclear how PARKIN’s E3 function is activated in response to mitochondrial 
damage and, once activated, how PARKIN maintains substrate specificity and chain linkage 
specificity. Ser65 of PARKIN, which lies within the UBL domain, was recently reported as a 
PINK1 phosphorylation site required for the activation of ubiquitin transfer in vitro. However, we 
have found that Ser65 is not absolutely required for PARKIN recruitment to mitochondria, 
ubiquitylation of MFN2, or association with a host of ubiquitylation targets Indeed, we have 
found that removal of the UBL domain resulted in increased interaction of PARKIN with MOM 
proteins, however, upon depolarization, this mutant was further stimulated, suggesting that 
there is an activating signal that occurs outside of the UBL domain. We have found additional 
phosphorylation sites as well as ubiquitylation sites within PARKIN which we believe may be 
important in its activation and are in the process of creating point mutations in these sites in 
order to determine their effects which we will test both in vivo and in vitro. 
We can perform these assays in parallel with functional studies using an array of PD-
patient derived PARKIN mutations. To determine how particular PARKIN mutants are defective, 
we will assess the kinetics of translocation via microscopy as well as activity in vitro, thus also 
allowing the use of quantitative proteomics to determine the kinetics and type of ubiquitin chain 
assembly. We already have a panel of 9 different PARKIN patient mutations spanning the 
length of the protein (R33G, R42P, K161N, K211N, T240R, R275W, G328E, G430D and 
C431F) stably expressed in multiple cell lines with which we can begin these analyses. Though 
these targeted analyses, we can contribute towards an understanding of how these mutations 
impact PARKIN activity and disease progression. Taken together, these studies will help us 
expose the functional roles and complexity of the PARKIN-modified proteome and provide new 
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insights into PARKIN’s mechanism of action, which may also be applicable to other RING-IBR-
RING family members.  
4.2.5 Role of PARKIN-mediated ubiquitylation on mitochondrial trafficking and fusion 
Ubiquitylation is often associated with protein degradation as an end point; however, 
ubiquitin operates in dynamic signaling systems whose ultimate function is often non-
degradative but regulatory. We know that PARKIN and PINK1 are key components of the 
signaling pathway that controls mitochondrial homeostasis after depolarization. This regulation 
is carried out both by targeted protein degradation and alterations in mitochondrial dynamics. 
For example, known targets of PARKIN include the mitochondrial outer membrane proteins, 
MFN1/2 and the RHOT1/2 Miro GTPases, which alter mitochondrial fission-fusion cycles and 
trafficking on microtubules respectively (Chen et al., 2003; Wang et al., 2011b). Ubiquitylation 
and degradation of the Mitofusin proteins is thought to halt fusion-fission cycles, thus promoting 
sequestration of the damaged population of mitochondria which can then be efficiently targeted 
by the autophagy machinery. Furthermore, RHOT1 and RHOT2 regulate kinesin-dependent 
mitochondrial trafficking on microtubules and are targeted for ubiquitin dependent turnover by 
the PINK1-PARKIN pathway after mitochondrial damage (Glater et al., 2006). 
A critical factor in demonstrating the utility of the data we have generated is to reveal the 
biological significance of ubiquitylation sites identified on PARKIN-modified proteins. To begin 
this process, we want to evaluate the effects of site-specific ubiquitylation of MFN1/2 and 
RHOT1/2. We have created arginine point mutations for all of the lysines found modified via 
QdiGly analysis in these proteins and will test whether the kinetics of turnover in HeLa cells is 
affected or blocked completely after mitochondrial depolarization. Examination of functional 
effects of site mutations in the Mitofusin proteins will be tested via observation of mitochondrial 
dynamics and fragmentation after depolarization to determine whether the kinetics of these 
processes are altered. We will also collaborate with the Schwarz lab (Children’s Hospital) to test 
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the effects of Lys-to-Arg mutations in RHOT1/2 on mitochondrial trafficking on microtubules in 
axons of hippocampal neurons using live-cell imaging. If these sites are important, we would 
expect to observe a loss in mitochondrial trafficking upon PARKIN activation. 
4.2.6 Role of CLU1 in mitochondrial homeostasis and the PARKIN and PINK1 pathway 
Much of chapter three focused on the identification of a novel PINK1 interacting protein, 
CLU1, which is genetically implicated in mitochondrial dysfunction in mammals and Drosophila 
and which appears to be required for proper mitochondrial morphology. We do not yet fully 
understand the role of CLU1 in these processes and therefore plan to continue to explore and 
characterize it. There are a number of questions to address, including whether CLU1 may be a 
PINK1 substrate, if it truly affects PINK1 kinase activity, and how it is regulating mitochondrial 
morphology. We intend to address these and further questions using the assays we have 
developed to test CLU1 effects on PINK1 and PARKIN activity in vivo and in vitro. Additionally, 
we will address whether CLU is required for PARKIN-mediated ubiquitylation events 
4.2.7 The need to study the PARKIN/PINK1 pathway in neurons 
Cell culture models are indisputably useful in discerning the molecular mechanisms of 
biological pathways. Because mitochondrial quality control is universally important, studying it in 
numerous cell types allows us to determine those aspects of the pathways which are generally 
important as well as those that may be cell- or tissue-type specific. To advance the Parkinson’s 
field faster, our data now needs to be applied to more physiological models of disease. Though 
Parkinson’s disease elicits systemic effects as evidenced by global defects in null animal 
models, much of the impairment of motor function may develop in part due to the accumulation 
of mitochondrial damage in neurons, thus it is essential to validate our data in these cell types 
as well as begin functional studies. It is not clear why neurons of the substantia nigra are so 
sensitive to the triggers of PD, be they genetic or environmental, thus highlighting the need to 
study the PINK1/PARKIN pathway in relevant cell types. Determination of the PARKIN 
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ubiquitylome in primary cells, such as neurons, would likely be very technically challenging. 
Therefore, the lab will attempt profiling of PARKIN targets in iPS cells derived from PD patient 
fibroblasts harboring a PARKIN deletion mutation. This approach will allow us to validate and 
extend our site-specific data and test these sites and identified substrates via cell biological 
assays in relevant models. 
4.2.8 Concluding remarks 
 There are so many fascinating aspects of the PINK1/PARKIN pathway that have not yet 
been well defined, and undoubtedly many more that have not even been identified. Our 
contribution to this field includes the systematic analysis of PARKIN substrates and interacting 
proteins and the development of a comprehensive compendium of PARKIN targets, which we 
hope will serve as a resource for the PD field. Along the way, we have also explored more 
focused areas of PARKIN and PINK1 biology illuminating the complexity of PARKIN regulation 
and perhaps creating as many new questions about the pathway as we have addressed. 
Evidence clearly demonstrates the crucial role of specific mitochondrial functions in maintaining 
neuronal integrity, emphasizing the need to understand the molecular basis of mitochondrial 
maintenance and the mechanisms and targets of the PINK1-PARKIN pathway. The overall 
driving force of our research persists - the pressing need for insight into the pathogenesis of PD 
in order to accelerate understanding of PARKIN, PINK1, and mitochondrial homeostasis in 
Parkinson’s disease. 
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CHAPTER 5 
Materials and Methods 
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Cell culture 
For all experiments excluding SILAC, 293T and HeLa cells were grown at 37°C in 
Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% (v/v) FBS (Gibco). 
Antibodies 
The antibodies used are as follows: anti-HA (Covance, 16B12), anti-PCNA (Santa Cruz, sc-56), 
anti-TOMM70, (Proteintech, 14528-1); anti-MFN2, (Epitomics, 3272-1 or Sigma, 
WH0009927M3); anti-ADRM1, (Enzo Scientific, BML-PW9910); anti-Rpn10, (Enzo Scientific, 
BML-PW9250); anti-HK1, (Cell Signaling, C35C4); anti-PSMD2, (Affinity BioReagents, PA1-
964); anti-PARKIN, (PRK8, Santa Cruz, sc-32282); anti-Myc, (9E10, Santa Cruz); anti-TOMM20 
(Santa Cruz, FL-145 ); and anti-PINK1 (Novus Biologicals, BC100-494). 
Plasmids 
DONR223-open reading frames (ORFs) were either harvested from the mammalian 
genome collection (MGC) or were cloned from cDNA vectors (Open Biosystems, MGC) by PCR 
with KOD polymerase (Novagen). The wild-type PARKIN ORF was a gift from Brenda 
Schulman. PCR products were cloned in pDONR223 using the Gateway system (Invitrogen). 
For stable expression vectors, ORFs were recombined into the appropriate recipient/destination 
vector using λ-recombinase. All open reading frames were sequence validated. 
BP reactions 
2µl of PCR product, 1µl DONR (150ng/µl), 2µl 5X BP buffer (100mM Tris-HCl, pH 7.5; 
20mM EDTA; 30mM spermidine; 25% glycerol; 225mM NaCl), and 1µl BP enzyme were mixed 
with H2O to 10µl. The reactions were incubated at RT for several hours or overnight. Reaction 
products were then transformed into 20µl of competent DH5alpha cells and plated on 
Spectinomycin. Individual colonies were picked, miniprepped, and sequence verified. ORFs in 
pDONR were sequenced using M13 For (-21) and M13 Reverse (Invitrogen). 
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LR Reactions 
1µl of DONR plasmid, 1µl destination/recipient plasmid (150ng/µl), 1µl 5X LR buffer 1µl 
H2O, and 1µl LR clonase were mixed and incubate at RT for several hours or overnight. 
Reaction products were transformed into competent DH5alpha cells and plate on Carbenicillin. 
Individual colonies were picked, miniprepped, and verified by BsrGI digest (NEB). For viral 
production, ORFS were cloned into either MSCV-N-HA-Flag-GAW-IP (Gateway Ires-Puro), 
pHAGE-N-HA-Flag-GAW, pHAGE-C-HA-Flag-GAW, or pHAGE-N-eGFP-GAW.  
Site-Directed Mutagenesis 
 pDONR223-PARKIN was used as a template for PCR with KOD polymerase (Novagen). 
The reaction was performed as described by the manufacturer except 5uM of each primer was 
used; primers are listed in Table 5.1. PCR reaction products were incubated with 2µl DpnI for 
several hours to overnight at 37°C. 2µl of the DpnI-treated PCR products were transformed into 
20µl competent DH5alpha cells and plate on Spectinomycin. Single colonies were picked, 
prepped, and sequence verified. 
Sample preparation for diGly capture 
HCT116, HeLa or SH-SY5Y cells (108) were grown in lysine-free DMEM supplemented 
with 10% dialysed FBS (v/v) (Gibco), 2 mM L-glutamine, 1% (v/v) penicillin/streptomycin (Gibco) 
and light (K0) lysine (50 μg ml−1), which contained no heavy isotopes. Heavy media was the 
same except the light lysine was replaced with K8-lysine (L-Lysine:2 HCl (u-13C6, 99%, u-
15N2, 99%) (Cambridge Isotopes) at the same concentration (Kim et al., 2011). Where 
indicated, cells were treated with Btz (1 μM), CCCP (10 μM), and/or BafA (50 nM) for the times 
indicated. After the indicated treatments, heavy and light cells were mixed 1:1 by cell number 
and lysed in 8 ml of denaturing lysis buffer (8 M urea, 50 mM Tris pH 8.2, 75 mM NaCl, 
protease inhibitors (EDTA-free), Roche). Samples were incubated on ice for 10 min and then  
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Table 5.1 DNA primers for site-directed mutagenesis used in this study. 
                 For = forward, Rev = reverse. 
 
Construct Primer 5' - 3' 
PARKIN S65A For TTGTGACCTGGATCAGCAGGCCATTGTTCACATTGTGCAG 
Rev CTGCACAATGTGAACAATGGCCTGCTGATCCAGGTCACAA 
PARKIN S65E For GAATTGTGACCTGGATCAGCAGGAGATTGTTCACATTGTGCAGAGAC 
Rev GTCTCTGCACAATGTGAACAATCTCCTGCTGATCCAGGTCACAATTC 
PARKIN K27R For ACACCAGCATCTTCCAGCTCAGGGAGGTGGTTG 
Rev CAACCACCTCCCTGAGCTGGAAGATGCTGGTGT 
PARKIN K27A For CCAGCATCTTCCAGCTCGCGGAGGTGGTTGCTAAGC 
Rev GCTTAGCAACCACCTCCGCGAGCTGGAAGATGCTGG 
PARKIN K48R For CGTGTGATTTTCGCAGGGAGGGAGCTGAGGAAT 
Rev ATTCCTCAGCTCCCTCCCTGCGAAAATCACACG 
PARKIN K48A For CGTGTGATTTTCGCAGGGGCGGAGCTGAGGAATGACTG 
Rev CAGTCATTCCTCAGCTCCGCCCCTGCGAAAATCACACG 
PARKIN UBL For TGGAGAAAAGGTCAAGAAATGTAGCCAACTTTCTTGTACAAAGTTGTCCCC 
Rev GGGGACAACTTTGTACAAGAAAGTTGGCTACATTTCTTGACCTTTTCTCCA 
PARKIN R33G For GGTGGTTGCTAAGCAACAGGGGGTTCCGG 
Rev CCGGAACCCCCTGTTGCTTAGCAACCACC 
PARKIN R42P For CGGCTGACCAGTTGCCTGTGATTTTCGCAGG 
Rev CCTGCGAAAATCACAGGCAACTGGTCAGCCG 
PARKIN K161N For AGTGCAGCCGGGAAATCTCAGGGTACAGTG 
Rev CACTGTACCCTGAGATTTCCCGGCTGCACT 
PARKIN K211N For GGACTAGTGCAGAATTTTTCTTTAATTGTGGAGCACACC 
Rev GGTGTGCTCCACAATTAAAGAAAAATTCTGCACTAGTCC 
PARKIN T240R For AGTCGGAACATCACTTGCATTAGGTGCACAGACGT 
Rev ACGTCTGTGCACCTAATGCAAGTGATGTTCCGACT 
PARKIN R275W For CTGTGTGACAAGACTCAATGATTGGCAGTTTGTTCACG 
Rev CGTGAACAAACTGCCAATCATTGAGTCTTGTCACACAG 
PARKIN G328E For TGTCCTGCAGATGGAGGGCGTGTTATGCC 
Rev GGCATAACACGCCCTCCATCTGCAGGACA 
PARKIN G430D For CAGTGGAAAAAAATGGAGACTGCATGCACATGAAGTG 
Rev CACTTCATGTGCATGCAGTCTCCATTTTTTTCCACTG 
PARKIN C431F For TGGAAAAAAATGGAGGCTTCATGCACATGAAGTGTCC 
Rev GGACACTTCATGTGCATGAAGCCTCCATTTTTTTCCA 
PARKIN C431S For GTGGAAAAAAATGGAGGCAGCATGCACATGAAGTGTC 
Rev GACACTTCATGTGCATGCTGCCTCCATTTTTTTCCAC 
CLU1 1-390 For GGGGACAACTTTGTACAAAAAAGTTGGCATGCTCTTAAACGGGGACT 
Rev GGGGACAACTTTGTACAAGAAAGTTGGGGTGAAGTCGCTGTGCAC 
CLU1 390-640 For GGGGACAACTTTGTACAAAAAAGTTGGCATGACCGCGGCAGCCACCAGG 
Rev GGGGACAACTTTGTACAAGAAAGTTGGGGAGGGGGTCTCCAGCTG 
CLU1 641-975 For GGGGACAACTTTGTACAAAAAAGTTGGCATGTCCTCCCTGGAAAATGGT 
Rev GGGGACAACTTTGTACAAGAAAGTTGGGGCCTTGGGGTTGACGTG 
CLU1 975-1180 For GGGGACAACTTTGTACAAAAAAGTTGGCATGGCCTCGGATGCCTTCCATT 
Rev GGGGACAACTTTGTACAAGAAAGTTGGCAGCTGCGTCTTGTAGATGGT 
CLU1 975-1309 For GGGGACAACTTTGTACAAAAAAGTTGGCATGGCCTCGGATGCCTTCCATT 
 Rev GGGGACAACTTTGTACAAGAAAGTTGGGTATCCCTGCACGCTCGGA 
 
 
 
sonicated with 3 × 10 s pulses. We typically obtained 30–50 mg of total protein. Lysates were 
digested with trypsin as described previously with one modification (Villen and Gygi, 2008). Prior 
to trypsin digestion, lysates were diluted 1:1 with 50 mM Tris pH 8.2 to lower the urea 
concentration to 4 M and digested with 10 ng μl−1 Lys-C (Wako) for 2 h at room temperature. 
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Immunoprecipitation of diGly containing peptides 
Lyophilized peptides from 30–50 mg of digested proteins were resuspended in 1.3 ml of 
IAP buffer (50 mM MOPS pH 7.4, 10 mM Na2HPO4, 50 mM NaCl) and centrifuged at 14,000g 
for 5 min to remove any insoluble materials. The supernatant was incubated with anti-diGly 
antibody coupled to protein A agarose or acrylamide beads for 1 h at 4 °C and washed with IAP 
buffer 3 and once with PBS as described previously (Kim et al., 2011). Peptides were eluted by 
treatment with 50 μl of 5% formic acid for 10 min twice. The eluted peptides were desalted using 
C18 stage-tip method and resuspended in 5% formic acid before mass spectrometric analysis. 
Lysates were subjected to immunoprecipitation sequentially two or four times, unless otherwise 
noted in Supplementary Table 1. 
Mass spectrometry analysis of diGly peptides 
Peptides were separated on 100 μm × 20 cm C18 reversed phase (Maccel C18 3m 
200A˚ , The Nest Group) with a 165 min gradient of 6% to 27% acetonitrile in 0.125% formic 
acid (Haas et al., 2006). The twenty most intense peaks from each full mass spectrometry (MS) 
scan acquired in the Orbitrap Velos (Thermo) were selected for MS/MS (see RAW files for 
specific settings). 
Sequest-based identification using a Human UNIPROT database followed by a target 
decoy-based linear discriminant analysis was used for peptide and protein identification as 
described (Eng et al., 1994; Huttlin et al., 2010; Kim et al., 2011). Localization of diGly sites 
used a modified version of the A-score algorithm (Beausoleil et al., 2006) as described (Kim et 
al., 2011). A-scores > 13 were considered localized. SILAC-based site quantification and signal-
to-noise was performed as described previously (Kim et al., 2011) by using extracted ion 
chromatograms. The heavy- and light-labelled peptides from each search were subsequently 
combined using custom scripts. Other parameters used for database searching include: 
50 p.p.m. precursor mass tolerance; 1.0 Da product ion mass tolerance; tryptic digestion with up 
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to three missed cleavages; and variable oxidation of Met (+15.994946). For an individual 
peptide to be used for quantification of sites and proteins, it had to meet one of two conditions: 
(1) both heavy and light isotopic envelopes must be detected with signal-to-noise ratios above 
5.0; and (2) one isotopic envelope (heavy or light) must have a signal-to-noise ratio above 10.0. 
Equal mixing ratios for heavy to light cells were confirmed by calculating the mean log2(H:L) 
ratios in non-diGly non-lysine containing peptides and subtracting that from the corresponding 
log2(H:L) diGly ratios if necessary. Keratins were removed from site lists. Contributions of 
peptide identifications to various protein isoforms were condensed into a single UniProt 
descriptor using principles of parsimony. 
Interaction Proteomics 
Interaction proteomics was performed essentially as described previously, but with small 
modifications (Sowa et al., 2009). Briefly, 293T or HeLa cells were transduced with a lentiviral 
vector expressing HA–Flag–PARKIN (NP_004553.2), PINK1 (NP_115785.1), CLU1 
(NP_056044.3), or the designated PARKIN or CLU1 mutants, and stable cell lines selected in 
puromycin. Cells from 4 × 15 cm dishes at 80% confluence were treated with CCCP (10 μM) 
(Sigma Aldrich), Btz (1 μM), and/or BafA (50 nM) (Sigma Aldrich) as indicated. Btz was a gift 
from Millennium Pharmaceuticals. After the indicated time, cells were collected and lysed in 3 ml 
of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P40, and protease inhibitors. Cleared 
lysates were filtered through 0.45μm spin filters (Millipore Ultrafree-CL) and immunoprecipitated 
with 30 μl anti-HA resin (Sigma). Complexes were washed 4 with lysis buffer, exchanged into 
PBS for a further three washes, eluted with HA peptide, reductively carboxymethylated, and 
precipitated with 10% trichloroacetic acid (TCA). TCA-precipitated proteins were trypsinized, 
purified with Empore C18 extraction media (3 M), and analyzed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) with a LTQ-Velos linear ion trap mass spectrometer 
(Thermo) with an 18 cm3 125 μm (ID) C18 column and a 50 min 8–26% acetonitrile gradient. 
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All AP–MS experiments in 293T cells were performed in biological duplicates and for 
each biological experiment, complexes were analyzed twice by LC-MS to generate technical 
duplicates. AP–MS experiments in HeLa cells were performed on a single IP but with technical 
duplicates. Spectra were searched with Sequest against a target-decoy human tryptic UniProt-
based peptide database, and these results were loaded into the Comparative Proteomics 
Analysis Software Suite (CompPASS) to identify high confidence candidate interacting proteins 
(HCIPs) (Sowa et al., 2009). Here, average assembled peptide spectral matches (APSMs) for 
each identified protein were used to determine weighted and normalized DN-scores (WDN-score) 
and Z-scores in a comparative analysis using a statistics table derived from analogous AP–MS 
data for 166 unrelated proteins. The DN-score measures the reproducibility, abundance and 
frequency of individual proteins detected in each individual analysis. 
To identify PARKIN-associated proteins, we filtered proteins at a 2% false discovery rate 
for those with a WDN-score ≥ 1.0, Z-score ≥ 5, and average assembled peptide spectral 
matches (APSMs) ≥ 2 in both biological duplicates. In addition to the initially identified proteins, 
APSMs for interactors with WDN-scores greater than 1 under at least one condition examined, 
or with a Z-score greater than 10 in both biological duplicates, were plotted in heat map form 
using Multi-experiment Viewer software (MeV). Due to space limitations, a subset of proteins 
which had a WDN-score ≥ 1.0 in at least one experiment were omitted from Figures 2.12 and 
2.14 but are contained in Supplementary Tables 3 and 4. TAX1BP1 that was identified in 
PARKIN immunoprecipitates and also found to be ubiquitylated but did not pass the stringent 
cut-off for passing our scoring scheme was also displayed in the heat map. We note that 
whereas several proteins passed the WDN-score cut-off for PARKIN-associated proteins in the 
absence of depolarization in individual experiments, there was essentially no overlap within 
biological duplicates (Supplementary Table 4). In addition, for proteins with a maximum of 1–3 
spectral counts, it is possible that those proteins were missed under some conditions due to 
stochastic sampling of low abundance proteins by LC-MS (for example, CYB5R3, TOM22, and 
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RHOT1 with wild-type PARKIN at 8 h post-CCCP in the presence versus the absence of BafA, 
Figure 2.12. The following proteins were identified in only 1 biological duplicate as being 
associated with PARKIN but were included in the heat map (Figure 2.12) as they are also 
present as Class 1 diGly targets: SQSTM1, TAX1BP1, TBC1D15, MYO6, VCP, RHOT2, HK2, 
MDH2, CYB5R3 and ACSL4. 
For phosphoproteomic analysis, sequest-based identification using a Human UNIPROT 
database followed by a target decoy-based linear discriminant analysis was used for peptide 
and protein identification as described (Eng et al., 1994; Huttlin et al., 2010; Kim et al., 2011). 
Localization of phosphorylation sites used a modified version of the A-score algorithm 
(Beausoleil et al., 2006; Kim et al., 2011). A-scores/ Modscores > 13 were considered localized. 
Parameters used for database searching include: 2.0 Da product ion mass tolerance; tryptic 
digestion with up to two missed cleavages; carboxymethylation of Cys (57.021463), variable 
oxidation of Met (+15.994946), and phosphorylation of Ser, Thr, or Tyr (79.966330. 
Protein Interaction 
To validate interactions between PARKIN and candidate interacting proteins, 293T cells 
stably expressing HA–Flag–PARKIN were either left untreated or treated with CCCP (10 μM) or 
CCCP (10 μM) and Btz (1 μM) for 1 h. Extracts (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% 
Nonidet P40, and protease inhibitors) from cells were subjected to immunoprecipitation with 
anti-Flag resin (M2 agarose; Sigma), and washed complexes subjected to immunoblotting with 
the indicated antibodies. To examine MFN2 ubiquitylation, extracts from cells lysed in 
denaturing lysis buffer (8 M urea, 75 mM NaCl, 50 mM Tris (pH 8.0), and protease inhibitors) 
expressing the indicated HA–Flag–PARKIN mutant proteins were separated on a 4–12% 
gradient SDS-polyacrylamide gel (PAGE) and blotted with anti-HA or anti-MFN2. To examine 
PARKIN levels in the cell lines used, cells were lysed in denaturing lysis buffer and protease 
inhibitors and extracts subjected to SDS–PAGE and immunoblotting. To examine ubiquitylation 
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of candidate PARKIN substrates by immunoblotting, HCT116 cell lines stably expressing the 
candidate substrates C-terminally tagged with HA–Flag epitopes were transfected with either 
control siRNA or an siRNA targeting PARKIN After 72 h, cells were treated with CCCP (10 μM) 
with or without Btz to block proteasomal turnover of targets. At the indicated times, cells were 
lysed in 8 M urea and subjected to immunoblotting using anti-HA antibodies. Identical gels were 
run and probed with anti-PCNA as a loading control. 
To validate interactions between PINK1 and CLU1, the indicated proteins were 
expressed in 293T or HeLa cells and lysed in lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 0.5% Nonidet P40, and protease inhibitors) and subjected to immunoprecipitation with 
anti-Myc resin (Sigma). Washed complexes were subjected to immunoblotting with the indicated 
antibodies. 
Virus Production 
 For retroviral MSCV vectors, DNA was mixed 2:1:1 (MSCV-DEST:pCG-VSVG:pCG-
GagPol) and transfected with Transit 293 Transfection Reagent (Mirus) into 293T cells. Media 
was changed 24 hours post-transfection and virus was harvest 48 hours post-transfection. Virus 
was filtered through 0.45µM filters and added to plated cells in the presence of 8mg/ml of 
polybrene. Twenty-four hours after infection, media was changed and 48 hours after infection, 
cells were split into the appropriate selection media. 
 For lentiviral pHAGE vectors, DNA was mixed 2:0.5:0.5:0.5:0.5 (pHAGE-DEST: HDM-
Tat1b: HDM-VSVG: RC-CMV-Rev1b: HDM-Hgpm2). Virus was produced as described above. 
In vitro ubiquitylation  
Purification of PARKIN: 293T cells stably expressing N-HA-PARKIN WT or C431S were 
treated with CCCP (10 μM) or CCCP (10 μM) and Btz (1 μM) for 1 h and lysed in 50 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P40, 1uM ubiquitin aldehyde, 1mM β-
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glycerophosphate, 1mM NaF, 0.1uM Okadeic Acid, 1mM DTT, and protease inhibitors. Cleared 
lysates were filtered through 0.45μm spin filters (Millipore Ultrafree-CL) and immunoprecipitated 
with 80 μl anti-HA resin (Sigma) for 1h at 4°C followed by 4 washes with lysis buffer and 
washed into in vitro ubiquitylation buffer (500mM Tris-HCl, pH 7.4, 500mM NaCl, 10μM ZnCl2, 
1mM B-glycerophosphate, 1mM NaF, 0.1μM Okadeic Acid , protease inhibitors) twice. 
Purification of mitochondria from HeLa cells was as performed as described in (Bozidis et al., 
2007) with minor modifications including treatment with CCCP (10 μM) for 1 h. In vitro 
ubiquitylation reactions were performed using HA agarose conjugated HA-PARKIN (5μl), E1 
ubiquitin-activating enzyme (3.6μM) (Boston Biochem), UbcH7 (100μM), ubiquitin (10-50μM) 
(Boston Biochem), 1 μM ubiquitin aldehyde (Boston Biochem), energy mix (200mM creatine 
phosphate, 2μg/µl creatine phosphokinase), 1 mM dithiothreitol, 2 mM ATP, 100nM Btz, 1mM 
B-glycerophosphate, protease inhibitors, and 50-100μg purified mitochondria. Reactions were 
incubated at 32°C for 1-2 hours. 
RNAi 
 RNAimax (Invitrogen) was used for reverse siRNA transfections (20nM or 30nM as 
noted) according to the manufacturer’s instructions. siRNAs used were from Dharmacon and 
sequences are provided by the ICCB screening facility upon request. 
siRNA screen transfection and PARKIN immunofluorescence 
For the primary siRNA screen, clonal HeLa cells stably expressing N-HA-Flag-PARKIN 
were reverse transfected in Evotec 384-well, black, clear-bottom plates (Perkin Elmer) in one 
siRNA-one well format with four individual siRNAs for each gene (Thermo Fisher). The siRNA 
was dispensed in quadruplicate directly into empty 384-well plates to achieve a final 
concentration of 30 nM. A mixture of Lipofectamine RNAiMAX/OptiMEM (Invitrogen) was then 
added to the wells and the plates were briefly centrifuged; the complex was incubated at room 
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temperature for 15 min. HeLa-PARKIN cells were trypsinized, counted and 3000 cells were 
added to each well. Each plate also contained Universal Negative Control, PARKIN and PINK1 
siRNAs as negative and positive controls (Thermo Fisher). Plates were briefly centrifuged and 
incubated at 37°C for 72 hours to achieve maximum penetrance of the siRNA phenotype. 
Following incubation, media was aspirated and plates were either untreated or treated 
with either 2 hour 10µM CCCP (translocation screen) or 24 hours 10µM CCCP (mitophagy 
screen, treatment was initiated 48 hours post transfection). Cells were washed once with PBS, 
fixed in 4% paraformaldehyde/ PBS (15 min at RT), washed, and permeabilized with 0.5% 
Triton X-100 in PBS (10 min, RT). Cells were washed with PBS and then blocked in 1% BSA in 
PBS (1 hour, RT). Cells were incubated with anti-HA (Covance) and anti-TOMM20 (Santa Cruz 
Biotech) for 1 hour at RT, and then washed 3 times in wash buffer (10 mM Tris-Cl pH 7.5, 150 
mM NaCl, 1% FBS and 2 mM EDTA pH 8.0). Cells were incubated with Alexa Fluor goat anti-
mouse 488 and Alexa Fluor goat anti-rabbit 562 (Invitrogen) for 1 hour at RT and then washed 3 
times with wash buffer. Nuclei were stained with Hoechst 33342, 5 min at RT (Molecular 
Probes/Invitrogen). Cells were stained with HCS CellMask Deep Red Stain (Invitrogen) to 
delineate cell boundaries and facilitate downstream image analysis. 
Image Acquisition and Analysis 
Plates were imaged using the ImageXpress Micro (IXM) automated High Content 
epifluorescent microscope in the Institute of Chemistry and Cell Biology (ICCB) at Harvard 
Medical School. Eight fields per well were selected for image capture using a 20X lens. A 
custom MATLAB script was developed by Tiao Xie of the Image and Data Analysis Core (IDAC) 
at Harvard Medical School to aid in image analysis. For both screens, 1) the total number of 
cells, 2) mean nuclear area, 3) mean cell area were determined on a per field as well as per well 
basis. For the PARKIN translocation screen, the percent of HA-PARKIN that colocalized with 
mitochondria (TOMM20 staining) was determined. Cells that did not express PARKIN (on 
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average < 5%) were determined on a per field basis based the background staining intensity 
and discounted from the analysis. For the PARKIN translocation screen, genes were classified 
as Class 1 if depletion resulted in >=75% loss of translocation or Class 2 if depletion resulted in 
>=50% loss of translocation. Genes were further classified based on how many siRNAs out of 
four gave a positive result. 
For the Mitophagy screen, the mean mitochondrial area (based on TOMM20 staining) 
was calculated and normalized for cell thickness using the HCS CellMask staining profile. 
Residual mitochondrial staining that overlapped with nuclei was subtracted from the analysis. 
The mean mitochondrial area and the standard deviation for the quadruplicate wells were 
calculated and hits from the screen were classified based on thresholds determined by siPINK1, 
siPARKIN, and siControl experiments. Class 1 proteins, thresholded on mean mitochondrial 
area in siPINK1-treated cells showed the most drastic effect on mitophagy progression. Class 2 
proteins were thresholded on siPARKIN-treated cells and showed a milder defect. Within each 
class of proteins, genes were further classified based on how many siRNAs out of four gave a 
positive result. For measurement of increased mitophagy, mean mitochondrial area was 
compared to siControl-treated cells. Further details are contained in Supplementary Table 8. 
Immunofluorescence staining and microscopy 
To examine the localization of PARKIN and various PARKIN mutants, HeLa cells stably 
expressing HA–Flag-tagged proteins were plated on No.1 coverslips, treated with CCCP 
(10 μM, 1 h), and fixed with 4% paraformaldehyde before immunofluorescence using anti-HA to 
detect PARKIN proteins and anti-TOMM20 to detect mitochondria. All images were collected 
with a Yokogawa CSU-X1 spinning disk confocal on a Nikon Ti-E inverted microscope equipped 
with 100 Plan Apo numerical aperture 1.4 objective lens. HA–PARKIN fluorescence was 
excited with the 491 nm line (selected with an AOTF) from Spectral Applied Precision LMM-7 
solid-state laser launch. Emission was collected with a quad band pass polychroic mirror 
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(Semrock) and a Chroma ET525/50m emissions filter. TOMM20 fluorescence was excited with 
the 561 nm line from the LMM-7 launch, and emission collected with the Semrock polychroic 
and a Chroma ET620/60m emission filter. Images were acquired with a Hamamatsu ORCA-AG 
cooled CCD camera controlled with MetaMorph 7 software. Nine z-series optical sections were 
collected with a step size of 0.2 μm, using the internal Nikon Ti-E focus motor. z-series were 
deconvolved using AutoQuant blind deconvolution software, and are displayed as maximum z-
projections. Gamma and brightness were adjusted on displayed images (identically for 
compared image sets) and percent colocalization was calculated by thresholding for signal at 
least 4 standard deviations above background in a single z slice (identically for compared image 
sets) using MetaMorph 7 software (Supplementary Table 6). 
Structural analysis of ubiquitylation sites and web portal 
Using the UniProt identifier for each protein identified, the corresponding PDB file(s) (if 
available) were determined using data from the UniProt to PDB cross-reference table 
(http://www.ebi.ac.uk/pdbe/docs/sifts/quick.html). The amino acid position in the structure 
corresponding to each ubiquitylation site was calculated based on their relative position in the 
structure using the information provided by the cross reference table. Data for each experiment 
was stored in MySQL tables, which are used when accessing the data via the web portal. For 
rendering of the structural information via the web portal, Jmol: an open-source Java viewer for 
chemical structures in 3D (http://www.jmol.org/) was used. Access to the web portal is available 
at harper.hms.harvard.edu. 
Gene ontology 
Gene ontology analysis was performed using DAVID (Huang da et al., 2009a, b). 
Additional sub-cellular localization parameters as designated in Figure 2.9b were performed 
manually using MITOCARTA, Human Protein Atlas, and GenBank. 
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Fly stocks 
The following fly stocks were used: tubulin-GAL4, UAS-parkin-RNAi/TM6B, GAL80 
tubulin-GAL4, UAS-PINK1-RNAi /TM6B, Tb, GAL80, clueless [d08713]/CyO, clueless 
[f04554]/CyO, and clueless [d00713]/CyO. 
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Appendix A: Landscape of the PARKIN-dependent ubiquitylome in response to 
mitochondrial depolarization  
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